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1.1. Intellectual disability  
Intellectual disability (ID), formerly mental retardation, affects 2%-3% of the population in 
western countries and is characterized by significant limitations in both intellectual 
functioning and adaptive behavior that begin before the age of 18 years and are usually 
reflected in an IQ below 70.1,2 Severe or profound ID, reflected by an IQ below 35 or in 
simpler classifications below 50, affects 0.3% to 0.5% of the population.3 The causes for 
severe ID are highly heterogeneous. Despite an increasingly known number of underlying 
genes, the genetic etiology still remains unsolved in nearly half of the cases.4 Mild forms of 
ID are assumed to represent the lower end of normal IQ distribution and to result from the 
interaction of various genetic and other factors.2 ID disorders represent a large 
socioeconomic burden for families and an economic burden for health care.2 
 
1.2. Genetic causes of intellectual disability  
The first genetic anomalies to be detected as causative for ID were numeric chromosomal 
aberrations. Trisomy 21 as the first one was identified in 1959.5,6 In the 1970s banding 
techniques allowed the detection of cytogenetically visible structural chromosomal 
aberrations up to a resolution of 5-10 Mb in a diagnostic setting. With the development of 
techniques such as FISH (fluorescence in situ hybridization) in 1988,7 MLPA (Multiplex 
Ligation-dependent Probe Amplification) in 2002,8 and molecular karyotyping around 2000,9-
11 submicroscopic aberrations below 5 Mb and up to a resolution of several kb became 
stepwise detectable. Additionally, with the identification of single ID associated genes in the 
1990s,12 screening for point mutations with Sanger sequencing become more and more 
important. However, this allowed only analyses of single or a limited number of genes. Now, 
next generation sequencing (NGS) techniques are being established to identify point 
mutations by screening nearly the complete exome.13 Progress in technology has thus 
stepwise increased our knowledge on the (different types of) genetic causes of diseases in 
general, and of ID specifically. 
 
1.2.1. Chromosomal aberrations 
Cytogenetically visible chromosomal aberrations can be found in ca. 16% of ID patients, with 
trisomy 21 still being the most frequent one.14 With conventional karyotyping only numeric 
aberrations or structural aberrations larger than 5-10 Mb are detectable.  
For many years FISH-analysis and more recently MLPA-analysis were used to detect 
smaller chromosomal aberrations. With these, common microdeletions or subtelomeric 
rearrangements could be identified in ca. 5% and 1.3% of patients, respectively.14 However, 
FISH- and MLPA-probes are limited to specific chromosomal regions like subtelomeric 
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regions or previously known microdeletion regions. The development of molecular 
karyotyping by arrayCGH or SNP arrays allowed genome-wide screening and a resolution of 
currently 100 kb in a diagnostic setting.15 It therefore increased the diagnostic yield of 
chromosomal aberrations in patients with ID and previously normal karyotype to ca. 10-15%. 
The detection rates range between 5.5 - 35%, depending on the resolution of the used array 
and the pre-selection of patients.16  
Chromosomal aberrations can occur as deletions or duplications with variable 
breakpoints and sizes. This is observed in many rare, individual aberrations or in the more 
common 4p- or Wolf-Hirschhorn syndrome17 and the 1p36 microdeletion syndrome.18 
Furthermore, they can occur as common microdeletions with identical and recurrent sizes 
and breakpoints, usually mediated by low copy repeats resulting in non-allelic homologous 
recombination.19,20 This applies for example to DiGeorge syndrome, caused by a typical 
deletion in 22q11.221 or to Williams-Beuren syndrome, caused by a recurrent 1.55 (95%) or 
1.84 Mb (5% ) deletion in 7q11.23.22 
Molecular karyotyping not only increased the findings of individual small chromosomal 
aberrations but also resulted in the identification of novel, relatively common microaberration 
syndromes like the 17q21.31 microdeletion syndrome23-25 or the 16p11.2 
microdeletion/duplication syndrome,26 thus adding to the number of previously known 
common microaberration syndromes such as Di George syndrome, Williams-Beuren 
syndrome, and Smith-Magenis syndrome. 
Microdeletions or –duplications can act as contiguous gene syndromes with several 
deleted/duplicated genes contributing to the phenotype. This applies e.g. for Williams-Beuren 
syndrome or monosomy 1p36.18,27 For other microdeletion syndromes, responsibility of a 
single deleted, dosage sensitive gene, was identified. Regarding the phenotype of 
monosomy 22q11.2, TBX1 is considered as the most promising candidate gene,28 and for the 
9q23 subtelomeric microdeletion, EHMT1 was identified as the phenocritical gene.29 In both 
genes point mutations were shown to result in a similar phenotype as the deletions.29-31 
The vast majority of larger chromosomal aberrations and copy number variants 
(CNVs) occurs de novo as reproduction of (severely) affected patients is usually limited. 
However, microaberrations that are associated with mild forms of ID are often found 
segregating in families, e.g. monosomy 22q11.232 and deletions or duplications of 16p11.2.33 
 
1.2.2. Monogenic causes 
To date, about 518 genes are reliably implicated in ID. Ca. 59% harbor autosomal recessive 
and ca. 24% harbor autosomal dominant mutations. Further 20% are located on the X-
chromosome and 1.7% in the mitochondrial genome (status May 2013, see chapter 6 of this 
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thesis). Two years ago the total number was still estimated to run into the thousands.2 
However, as recent studies in patients with unspecific severe ID showed a mutation 
detection rate of 13-30% in previously known ID genes,34-36 the final number might be not as 
large as proposed.  
Fragile X syndrome is considered to be the first identified ID syndrome caused by a 
genetic defect in a single gene.37 It is also the most frequent cause for monogenic ID.38 With 
more than 90, a relatively large number of X-linked ID genes is known to date. Gene 
identification for X-linked recessive ID has been facilitated by the inheritance pattern. This is 
often characterized by several affected males and unaffected carrier women, thus allowing 
linkage analysis.39 Due to the limited number of genes on the X-chromosome, also large-
scale systematic re-sequencing of all coding exons could be performed.40 In total, genetic 
defects on the X-chromosome are supposed  to underlie ID in 8-12% of affected males.41 In 
addition, as for example regarding Rett syndrome, some X-linked dominant mutations are 
known. These are usually de novo, accompanied by a phenotype in females and assumed to 
be lethal in males.       
This leaves a large number of supposedly autosomal genetic defects. Gene 
identification for autosomal recessive disorders was until recently easier than for mostly 
sporadic, dominant disorders. Many recessive metabolic disorders show specific 
phenotypes, and gene identifying methods such as linkage analysis only work in inherited 
disorders. How many genetic defects underlying ID will in the end be autosomal recessively 
inherited or will be sporadic dominant de novo mutations, is therefore difficult to estimate. 
However, recent studies indicate that recessive mutations in outbred populations seem to be 
rather rare in contrast to de novo mutations.34,35,42 
In disorders with severe ID and therefore limited reproduction, the causative 
autosomal dominant or also X-linked dominant mutations are usually found to have occurred 
de novo. In contrast, dominant mutations that are associated with rather mild or low 
penetrant cognitive defects can be observed to be inherited in families. This applies for 
example to Noonan syndrome.43 
Mutations in mitochondrially encoded genes can also be associated with ID in the 
context of mitochondrial disorders, however, compared to X-linked and autosomal dominant 
causes of ID they are rare. Mutations in the mitochondrial genome either occur de novo or 
are transmitted by the mother.44  
 
1.2.3. Others 
In mild cases of ID or in autism spectrum disorders (ASD), which are usually accompanied 
by rather mild cognitive impairment, the underlying genetic defect might be more complex. 
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This means that a single mutation or CNV represents a risk factor which is only pathogenic in 
combination with one or more additional “hits”. This has been shown for the 16p12.1 
microdeletion,45,46 but is also discussed for defects in single genes such as SHANK346 or 
FOXP1.47 For some disorders such as Bardet-Biedl syndrome, a di- or even trigenic 
inheritance has been reported.48 In general, the understanding which combination of multiple 
hits underlie certain neuropsychiatric disorders and how they mutually interact is currently 
still at the beginning and significantly more difficult than for monogenic disorders. 
Some forms of mutation do not affect genes themselves, but their regulation. This is 
the case in imprinting disorders. Deregulation of imprinted genes can for example result in 
Angelman- or Prader-Willi syndromes, depending on, whether the maternal or paternal copy 
is lacking or inactive.49 
Very little has been known about mutations or other aberrations in regulatory 
elements of the genome so far. While CNVs in non-transcribed regions are reported in 
several limb malformation syndromes (reviewed by Klopocki and Mundlos50), their relevance 
for ID disorders is only known for single cases so far. For example, an intronic deletion in the 
PLP gene can lead to an abnormal presentation of Pelizaeus-Merzbacher disease,51 and a 
non-coding mutation regulates HCFC1 expression in non-syndromic ID.52 Aberrations in non-
coding elements and their pathomechanisms represent a level of complexity whose extent is 
currently difficult to foresee. 
 
Figure 1  Distribution of the inheritance pattern of 518 genes reliably implicated in ID.  
(status May 2013, see chapter 6 of this thesis). Percentages refer to the proportion of genes. Mito, 
mitochondrially encoded. 
 
1.3. Identification of novel ID genes 
Dependent on the occurrence of ID in several members of a family or sporadically due to a 
de novo event, different strategies for gene identification can be used. While methods such 
as linkage analysis or breakpoint mapping have in principle been available for more than two 
decades, they developed their real power only during the last decade. SNP arrays and the 
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evolution of sequencing technologies allowed high resolution homozygosity mapping and an 
increased screening throughput of candidate genes, respectively. As to familial ID, a 
combination of mapping methods with targeted re-sequencing of candidate regions by 
recently developed NGS technologies can be considered as the optimization of previously 
available strategies. Regarding sporadic ID, NGS can be considered as the big, revolutionary 
step forward. For the first time a systematic approach to unravel its underlying genetics can 
be undertaken.     
 
1.3.1. Linkage analysis 
Linkage analysis can be used when an ID disorder segregates within a family and when 
several affected and unaffected individuals are available for testing. Through positional 
cloning, genes following mendelian traits can be identified based only on the knowledge that 
the phenotype is inherited. Further information on the biology of the disease or its cause is 
not necessary.53 Linkage analysis uses Linkage Disequilibrium (LD) within families with a 
segregating phenotype to identify co-segregating haplotype blocks. To achieve this, DNA 
polymorphisms like previously microsatellite markers and now single nucleotide 
polymorphisms (SNPs) contained on microarrays53,54 are utilized. To obtain sufficient LOD 
scores, reflecting the likelihood of linkage between two genetic traits, large families or several 
smaller families with the same phenotype and overlapping candidate regions are required. 
Until recently, this was the bottleneck in disease gene identification as time and cost 
consuming Sanger sequencing allowed screening only of a limited number of candidate 
genes. With (targeted) NGS larger regions containing a higher number of genes can be 
screened.  
Linkage analysis has been successfully applied to autosomal dominant ID associated 
disorders such as Neurofibromatosis type I,55,56 to autosomal recessive ID syndromes like 
Cohen syndrome,57 and to X-linked recessive ID caused for example by mutations in the 
oligophrenin gene.39 
 
1.3.2. Homozygosity mapping 
Homozygosity mapping works only for recessive disorders in consanguineous families and is 
based on the assumption that the phenotype is caused by a true homozygous mutation. A 
single heterozygous variant for a recessive disease has a very high chance of becoming 
homozygous and therefore disease causing in the offspring of consanguineous parents.58 
Similar to linkage analysis, mutational screening in candidate genes within homozygous 
regions is performed. Systematic studies using homozygosity mapping require populations 
with a high degree of parental consanguinity and large family sizes accompanied by a high 
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frequency of ID and congenital anomalies. Such conditions are typically found in Arab 
countries, Turkey, Iran, Pakistan, and some parts of India.59,60 Large studies in families from 
Iran or Syria using DNA array-based SNP typing revealed various novel loci for non-
syndromic autosomal recessive ID.61,62 In the biggest study with 136 families this approach 
led to the identification of mutations in 23 genes previously implicated in ID or related 
neurological disorders. Probably disease-causing variants were additionally identified in 50 
novel candidate genes.63 These studies therefore emphasize the extreme heterogeneity of 
autosomal recessive ID. 
 
1.3.3. Chromosomal translocations 
De novo balanced chromosomal translocations can be identified by conventional karyotyping 
and occur with an incidence of 1 in 2000.64 Six percent of them are associated with ID with or 
without further anomalies.60 Exact breakpoint mapping of such translocations can therefore 
elucidate candidate genes for ID.65 Subsequent confirmation can be achieved by identifying 
mutations in the same gene in other patients with a similar phenotype. This approach has 
been successful for autosomal genes like ZEB2, mutations in which underlie Mowat-Wilson 
syndrome,66 or for GRIN2A and GRIN2B, mutations in which cause variable ID with or 
without epilepsy.67 Furthermore, this approach was also successful for the X-linked dominant 
CDKL5 gene.68,69 
Breakpoint mapping cannot be pursued systematically but depends on the finding of 
apparently balanced chromosomal translocations. 
 
1.3.4. Molecular karyotyping by arrayCGH and SNP arrays 
Apart from an increasing diagnostic outcome in patients with ID harboring individual small 
chromosomal aberrations70,71 or by identifying novel common microdeletions syndromes 
(reviewed by Slavotinek72), molecular karyotyping by arrayCGH or SNP arrays has been 
proven to be a suitable method to identify novel disease causing genes. After initial 
identification of small aberrations affecting only one or few genes, subsequently mutations in 
the respective candidate gene in further patients without copy number variants can be 
uncovered. This applied to well-known syndromic disorders such as autosomal-dominant 
CHARGE syndrome36 or autosomal recessive Peters Plus syndrome.73 Further examples are 
the identification of causative genes for an epileptic encephalopathy74 or for non-specific 
moderate to severe ID.75,76 
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1.3.5. Sequencing of functional candidate genes 
Targeted screening for mutations in a particular gene by conventional Sanger sequencing is 
often the method of choice if this gene is considered to be a good ID candidate gene. This 
can for example be due to its known function or due to an interaction with known disease 
causing genes/proteins. 
Selecting a functional convincing candidate gene can be done in combination with 
linkage analysis and homozygosity mapping (see above), where it can be picked from a 
larger but still limited number of genes. Furthermore, several studies proved the feasibility of 
selecting and screening a candidate gene purely on its function without additional genetic 
information. Within the framework of the Canadian Synapse to Disease consortium, Hamdan 
et al. found de novo protein-truncating mutations in SYNGAP177 in patients with non-
syndromic ID as well as in other synaptic genes associated with glutamatergic systems.78 
SYNGAP1 had been known to be involved in pathways regulated by NMDA receptors, and 
mice with heterozygous Syngap1 mutations had been found to have cognitive dysfunction.77 
Mutation screening for RPGRIP1L was performed because of its interaction with 
ciliary and basal body proteins involved in Joubert syndrome and indeed led to the 
identification of mutations in patients with a typical Joubert syndrome phenotype.79  
 
1.3.6. Next generation sequencing 
Sanger sequencing allows only screening of a limited number of genes, e.g. single genes or 
genes from linkage or homozygosity mapping regions or, in an exceptional large scale 
attempt, of all coding exons of the X-chromosome.40 During the last few years NGS 
technology has evolved as the key to overcome these limitations.80  
For the identification of the underlying mutations in monogenic disorders like many 
forms of ID, currently mainly whole exome sequencing is used. As only about 1% of the 
whole genome is protein coding, massive parallel sequencing of those regions has been 
become a relatively rapid and cost efficient method. Exome sequencing starts with enriching 
exonic sequences using different array-based or solution based capturing methods.26 This is 
followed by massive parallel sequencing and a bioinformatics pipeline that filters the 
identified changes to distinguish pathogenic mutations from common variants or technical 
errors.34 
Whole exome sequencing can be utilized for disease gene identification based on 
different hypotheses. In index patients of consanguineous families screening for recessive 
mutations in homozygous regions can be performed much more extensive than before with 
Sanger sequencing and resulted in the identification of several new ID related genes or 
candidate genes.63,81,82 This also applies to families with X-linked ID and targeted NGS for 
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genes on the X-chromosome (Kalscheuer et al., Next-generation sequencing in 248 families 
with X-linked intellectual disability; Abstract #84, Presented at the 12th International 
Congress of Human Genetics/61st Annual Meeting of The American Society of Human 
Genetics, October 13th, 2011, Montreal, Canada). 
The largest progress was made regarding sporadic de novo mutations. The first two 
ID syndromes solved by this method were Kabuki syndrome83 and Schinzel-Giedion 
syndrome.84 Several patients with a similar clinical phenotype were tested simultaneously 
and subsequently screened for mutations in the same gene. This approach relies on 
syndromic forms of ID where several patients with a recognizable similar phenotype are 
available. In non-syndromic ID the so called trio approach has been successfully used by 
testing patient and parents simultaneously and looking for de novo mutations in previously 
known or functionally convincing genes.34,35,42 
Table 1  Strategies for disease gene identification 
Strategy  Suitable for the indicated 
inheritance patterns  
Specifics 
linkage analysis familial x-linked, autosomal recessive 
and dominant 
currently NGS used for candidate gene 
screening in linkage regions  
homozygosity 
mapping 
autosomal recessive mainly for consanguineous families 
chromosomal 
translocations 
sporadic, dominant; (familial dominant) based on “incidental” findings, no 
systematic approach 
molecular 
karyotyping 
sporadic, dominant CNVs of one or few genes of which 
candidate gene has to be selected 
functional 
candidate genes 
independent from inheritance pattern based on function rather than on 
genetics 
NGS all systematic, can be used unbiased 
 
1.4. The clinical faces of ID  
ID comes in many facets. It is defined as a significant limitation in both intellectual functioning 
and adaptive behavior starting before the age of 18 years (see 1.1.). This definition includes 
primary cognitive impairment that is often initially noted by delay of developmental 
milestones as well as disorders that are accompanied by no development at all, by early 
neurodegeneration and regression, and sometimes even by lethality. 
Not only the cognitive and neurological performance in ID disorders can be highly 
variable, but also the accompanying phenotypes. Classically, ID is clinically distinguished 
into syndromic and non-syndromic forms. While non-syndromic ID disorders are not marked 
by any specific phenotypic aspect, characteristic features co-occurring with ID in syndromic 
disorders can be very variable.  
Cornelia-de Lange syndrome and lissencephaly, for example, are characterized by a 
whole spectrum of distinct dysmorphism and malformations of extremities and organs in case 
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of the first and specific brain malformations in case of the latter.85,86 Such structural 
malformations can be noted by external clinical examination of the patient, by ultrasound 
examination of the organs, and by MRI (magnetic resonance imaging) examination of the 
brain. Physical examinations are therefore an important first step in the diagnosis of 
syndromic ID as they can provide a clue on the disorder and prompt specific molecular 
testing. 
Other disorders like Down syndrome, Williams-Beuren syndrome87 or Mowat-Wilson 
syndrome88 are associated with a specific facial gestalt that alone is sufficient to allow clinical 
diagnosis in most of the patients. 
In some ID disorders the disease course over several months or years can be the 
main contributing factor for the clinical diagnosis. Typical Rett syndrome, for instance, is 
characterized by the sequence of normal development, stagnation, regression, and then 
long-term stability.89  
Many of the metabolic ID syndromes are not characterized by any physical anomalies 
but by specific enzymatic, metabolic or biochemical alterations in blood, urine or liquor. Some 
of them can also lead to specific non-malformation anomalies detected with brain MRIs like 
for example in lipid storage disorders such as X-linked adrenoleukodystrophy.90 Only few 
inherited metabolic diseases cause isolated stable ID. Additional neurological signs such as 
regression, ataxia, seizures, movement disorders or behavioral problems are more 
commonly found.91 
Furthermore, there are disorders that can be accompanied by ID but without ID being 
a major aspect. This applies for example to Neurofibromatosis Type I, which is mainly 
characterized by skin features such as Café-au-lait macules and neurofibromas. But it is also 
associated with learning disabilities in 50 to 75% of patients.92 
Some forms of ID were initially considered as non-syndromic and later re-classified to 
syndromic ID after the underlying cause was identified or after patients were analyzed in 
more detail. This happened for example with the AP4 syndrome. Specific features like shy 
personality and spasticity of the lower extremities were commonly recognized in several 
individuals carrying defects in the same gene or genes from the same complex.82  
For the past years the prevalence of diagnosed autism spectrum disorders (ASD) has 
rapidly increased.93 This is probably not only due to a real increase in co-morbidity but rather 
due to softening borders of terminology and by including ID patients into ASD studies, based 
on phenotypic overlap. The mixing of ID with neuropsychiatric disorders such as autism is 
reflected in the estimation that approximately 10% of children with ID have autistic symptoms 
and that 70% of individuals with autism also have ID.94,95 This clinical overlap is probably at 
least partly based on a molecular overlap of ID and autism related molecular pathways,96 but 
might also be influenced by changing diagnostic criteria and societal biases.93 
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1.5. The molecular faces of ID 
Genetic defects can be pathogenic due a variety of molecular consequences. In principle, a 
genetic alteration can by several mechanisms result in loss of function or gain of function of 
the encoded protein, respectively. 
 
1.5.1. Dosage sensitivity 
The phenotype of trisomy 21 (Down syndrome) is assumed to result from an increased 
dosage of one or more of the ~310 genes present on this chromosome.97 Several dosage 
sensitive genes have been identified that might play a role in the pathogenesis of Down 
syndrome, amongst them DYRK1A. Overexpression of DYRK1A results in severe learning 
deficits in mice,97 and deletions are reported in association with ID and primary 
microcephaly.98 
Also for TBX1, a gene contained in the 22q11.2 microdeletion and –duplication 
region, and in which point mutations were shown to cause the monosomy 22q11.2 
phenotype, a time and tissue dependent dosage effect is discussed.99 The RAI1 gene is 
assumed to be the dosage sensitive gene in clinically distinct Smith-Magenis and Potocki-
Lupski syndromes, caused by reciprocal microdeletions and –duplications in 17p11.2, 
respectively.100-102  
 
1.5.2. Loss of function 
Loss of function can be caused by different mechanisms that all result in inactivation of the 
affected gene/protein. Nonsense mutations, frameshift mutations, splice mutations and out-
of-frame intragenic deletions or duplications can lead to premature termination codons. This 
can result in truncation of the protein with loss of important C-terminal domains as for 
example assumed for KAT6B mutations in Genitopatellar syndrome103,104 and distinct Say-
Barber-Biesecker Variant of Ohdo Syndrome.105 It is suggested that loss-of-function, either 
by haploinsufficiency or loss of the c-terminal region, results in overlapping features between 
the two syndromes, whereas an additional dominant-negative or gain-of-function effect is 
responsible for the more specific symptoms.104,106 
More commonly, aberrant mRNAs are subject to nonsense mediated mRNA decay,107 
leading to a reduction of mRNA and subsequently protein. Heterozygous loss-of-function 
mutations often result in haploinsufficiency (see 1.5.3.), while biallelic loss of function often 
affects enzymes, whose complete or nearly complete loss is often found in metabolic 
diseases. 
Additionally, also missense mutations within important functional domains can cause 
loss of function as shown for example for MeCP2.108 
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1.5.3. Haploinsufficiency 
Haploinsufficiency occurs, when a single functional allele is not sufficient to produce a normal 
phenotype. This mechanism typically underlies dominant heterozygous loss-of-function 
defects or the loss of dosage-sensitive genes, both described above. 
Haploinsufficiency of a specific gene can be assumed, when larger deletions of a 
gene and point mutations within this particular gene are found to result in the same 
phenotype. This was, for instance, shown for Kleefstra syndrome that is either caused by a 
microdeletion of 9q34.3 containing the EHMT1 gene or by mutations in the EHMT1 gene 
itself.29 Also larger deletions in 5q as well as point mutations – both stop mutations and 
missense mutations- in the MEF2C gene cause an identical phenotype of severe ID with 
epilepsy.75 
 
1.5.4. Gain of function 
Gain-of-function mutations result in increased or abnormal function of the gene product. 
Therefore gain of function can lead to more specific consequences compared to loss of 
function.  
Noonan syndrome and related Rasopathies are caused by deregulation of the RAS-
MAPK signaling pathway. For many mutations that were identified in positive regulators of 
the pathway (SHP2, SOS1, KRAS, HRAS, BRAF, MEK1, MEK2), a gain-of-function effect 
could be experimentally shown.109 Most of these mutations are missense changes, and a few 
are deletions of single amino acids in particular functional domains of the respective 
protein.109  
Also missense mutations in SETBP1, causing Schinzel-Giedion syndrome, and 
clustering in a highly conserved 11 bp region, are supposed to act in a gain-of-function 
manner.84 Schinzel-Giedion syndrome is characterized by severe ID, distinctive facial 
features, multiple congenital malformations, and lethality within the first decade.84 The 
specific effect of the supposed gain-of-function mutations in SETBP1 in those patients is 
confirmed by the finding of SETBP1 haploinsufficiency in patients with a different phenotype 
of mild ID and expressive language impairment.110 
 
The heritability of intelligence: gain of function versus loss of function? 
Though the heritability of intelligence is high, only very few genetic factors have been 
identified so far. Due to their number, the effect of each single factor is probably low.111 It is 
suggested that genes associated with intelligence might also be of importance to ID. This 
means that variants in the same gene can contribute to both upper (normal or high 
Chapter 1  
22 
 
intelligence) and lower (ID) extremes of intelligence as a normally distributed trait.112,113 
One might hypothesize a rather high proportion of loss-of-function defects in ID compared to 
gain-of-function variants which might contribute to normal or high intelligence. This idea is 
supported by a larger number of ID associated recurrent chromosomal deletions than 
duplications (15 versus 8, Vissers et al.,114). However, strategies in the pre-NGS era have 
been biased towards loss-of-function defects due to a high fraction of metabolic diseases 
and due to genes identified by chromosomal aberrations which mostly are deletions or 
gene-disrupting translocations.   
Interestingly, for an increasing number of genes, gain-of-function as well as loss-of-function 
mutations have been implicated in ID. These can result in distinguishable phenotypes, 
respectively. This applies to SETBP1 as described above84 as well as to SCN2A. Missense 
mutations in this gene cause an early onset epileptic encephalopathy and were shown to 
have a gain-of–function effect.115 In contrast, truncating mutations were recently identified in 
individuals with unspecific ID and autism without epilepsy.34,35,116 It might therefore be 
suggested that gain-of-function mutations lead to a more complex and syndromic phenotype 
than loss-of-function mutations. The increasing findings of different phenotypes caused by 
mutations in the same gene might also implicate that at least ID associated with sporadic de 
novo mutations might be genetically less heterogeneous than proposed before. 
 
1.5.5. Dominant negative effects 
A dominant negative effect occurs when a mutant protein interferes with the function of the 
normal second allele in a heterozygous person. 
Such an effect is discussed for mutations identified in the SMARCA2 gene in patients 
with Nicolaides-Baraitser syndrome. All point mutations found so far have been missense 
mutations within the SNF2_N and HELICASE_C ATPase domains. Additionally, one deletion 
encompassing the C-terminal helicase domain was observed.117,118 These findings, together 
with data from yeast, support a dominant-negative model in which dysfunctional but 
structurally undamaged SMARCA2 generates a complex that is intact with respect to its 
composition and occupies its appropriate chromatin domains but is nonetheless functionally 
inactive.117  
 
1.5.6. Dynamic mutations 
Fragile X syndrome, the most common cause of monogenic ID, is caused by an expanded 
CGG repeat in the promoter of the FMR1 gene, leading to hypermethylation and therefore 
inactivation of the protein.37 
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Another example is the congenital form of myotonic dystrophy type I which is often 
accompanied by ID. This disorder is caused by a trinucleotide expansion in the non-coding 
region of the DM1 protein kinase gene, DMPK,119 resulting in accumulating and thus possibly 
toxic RNA molecules.120,121 
 
1.5.7. Imprinting defects 
Genomic imprinting describes the preferential or exclusive expression of a gene on either the 
maternal or paternal allele. The allele-specific expression of imprinted genes is mediated by 
allele-specific epigenetic modifications such as DNA-cytosine methylation, histone 
acetylation, and other modifications.49 Abnormalities in imprinted inheritance occur in several 
well-known developmental and neurobehavioral disorders, including Albright’s hereditary 
osteodystrophy or Beckwith-Wiedemann syndrome.122 Loss of a functional paternal or 
maternal allele in chromosomal region 15q11-q13 due to deletion, uniparental disomy, or 
mutations in imprinting centers, results in the clinically distinct phenotypes of Prader-Willi or 
Angelman syndromes, respectively.122  
 
1.6. Common themes among ID disorders 
Many of the genes and proteins implicated in ID can be assigned to different categories 
according to their function as enzymes, mediators of signal transduction, transcriptional 
regulators, etc. or according to their biological function in processes like nuclear organization, 
metabolic and signaling pathways, organization of cytosceleton.4 Defects are suggested, 
apart from potential functions outside the nervous system, to lead to two major common 
groups of phenotypic outcomes: 1. dysfunctional neurodevelopment and brain malformation 
and 2. alterations in molecular mechanisms underlying synaptic organization and plasticity.4 
However, a complete summary as well as a comprehensive overview on all ID-related genes 
is still lacking. Several examples of genotypic and/or phenotypic entities are given here. 
However, they often show considerable overlap between each other and are by far not 
complete. 
 
1.6.1. Inborn errors of metabolism 
For many inborn errors of metabolism the underlying biochemical defect, often integrated in 
larger pathways, is well known. However, the exact mechanisms of brain damage and 
dysfunction are still poorly understood.91,123 
Lysosomal storage disorders are characterized by deficient intracellular transport or 
metabolism resulting in progressive accumulation of un-degraded catabolites. This occurs 
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particularly in the reticuloendothelial system and the nervous system, thus often leading to 
progressive central nervous system damage by disturbance of myelin formation and 
function.123,124  
Also phenylketonuria seems to result in white matter anomalies and dysmyelination 
by direct neurotoxic effects. These are discussed to result from elevated phenylalanine levels 
leading to disturbed amino acid transport into the brain and alterations in neurotransmitter 
levels.123,125 Aberrant neurotransmission is also observed in glycine or serine disorders.123 
Furthermore, deficiencies in energy availability as seen in creatine deficiency as well 
as defects in energy production caused by mitochondrial disorders can underlie cognitive 
impairment.123 The respiratory (or electron transport) chain in mitochondria consists of 4 
complexes comprising ca. 90 subunits which are mainly encoded by nuclear genes. It is the 
core machinery for oxidative phosphorylation and a hub in the cellular metabolism network. 
Disruptions can lead to a broad spectrum of phenotypes ranging from highly tissue-specific 
to multisystemic symptoms.44 
 
1.6.2. Neurogenesis 
The first and critical step of cortex development is the generation and proliferation of 
neuronal precursor cells. Various neurological conditions are associated with alterations in 
mechanisms of cell proliferation, cell fate determination or programmed cell death, thus 
leading to an abnormal number of neurons.4 The resulting abnormalities in brain size are 
characteristic for primary microcephaly disorders. These are caused by mutations in genes 
like MCPH1,126 ASPM,127 or CENPJ,128 which are involved in centrosome function and DNA 
repair response pathways.4 
 
1.6.3. Neuronal migration 
Neuronal migration disorders involve disruptions of various stages of the migration process, 
including the onset of migration, migration movements, the penetration into the preplate, and 
the arrest of migration.4 Depending on the time, type and localization of migration defects, 
different brain malformation phenotypes can manifest. These comprise lissencephaly, 
heterotopias, polymicrogyria and schizencephaly.129 Examples are mutations in LIS1, DCX, 
and TUBA1A in classical lissencephaly, mutations in POMT1, POMT2, FKTN etc. in 
cobblestone lissencephaly, mutations in FLNA or ARFGEF2 in periventricular heterotopias, 
mutations in GPR56 in polymicrogyria, and mutations in EMX2 in schizencephaly 
(summarized and reviewed by Verrotti et al.129). 
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1.6.4. Synapse formation and plasticity  
The formation, maintenance and modification of synapses are fundamental to learning, 
memory, and other cognitive processes. Mutations in the “synaptome” can result in a broad 
spectrum of neurodevelopmental and cognitive disorders.130 However, despite being a major 
theme in ID the degree of its contribution is still debated.63 
Synaptic plasticity is reflected by experience- or activity-induced changes in molecular 
composition and morphology of synapses and dendritic spines, the main sites of excitatory 
synaptic input. It is assumed as a correlate for learning and memory.3 Various defects in 
presynaptic pathways, in postsynaptic protein complexes, or in the cytoskeleton can lead to 
impaired synaptic plasticity and therefore to cognitive dysfunction.3,4  
ID genes with a role in presynaptic vesicle recycling are for example STXBP1,74 
GDI1,131 and RAB39B.132 Presynaptic CASK has an important role in trans-synaptic protein 
interaction and is implicated in severe ID with brain malformations.133 
 
Figure 2  Schematic drawing of a synapse with some pre- and postsynaptic networks and 
pathways, involved in various processes.  
Shaded proteins are encoded by known ID genes. Adapted from Van Bokhoven, 20113. G., GTPase; 
Syntax.1, Syntaxin-1; Rabph.3A, Rabphilin 3A, RTK, receptor tyrosin kinase 
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ID associated genes involved in postsynaptic complexes are for instance GRIA1, encoding 
an AMPA receptor subunit,134 or GRIN2A and GRIN2B, coding for NMDA receptor subunits.67 
Other proteins involved in postsynaptic density complexes are SYNGAP77 and the scaffolding  
proteins SHANK1-3.135-137 Also local regulation of postsynaptic protein levels seems to be 
critical for normal learning and memory processes.3 This is demonstrated by mutations in the 
Fragile X syndrome gene FMR1, which encodes a regulator of local synaptic protein 
snythesis.138 Another example are mutations in the Angelman syndrome gene UBE3A, which 
is involved in ubiquitin-proteasome system-dependent protein degradation.139,140 
Members of RhoGTPase signaling pathways are important regulators of dendritic 
spine morphology and synaptic acitivity.49 Deficits in the regulation of the dendritic 
cytoskeleton affect both the structure and function of dendrites and synapses, common 
features in patients with ID.141 The RhoGTPase pathway includes ID genes such as 
OPHN1,39 PAK3,142 ARHGEF6,143 and FGD1.144 
Another well-known example for a cellular signaling cascade implicated in ID is the 
RAS-ERK signaling pathway with both presynaptic and postsynaptic roles.3,145 It is involved 
in Noonan syndrome and related disorders and comprises the Ras GTPases HRAS and 
KRAS146 as well as the downstream effectors RAF1, BRAF, MEK1, MEK2 and RSK2, and 
regulators of the Ras-MAPK pathway such as SHP2, SOS, NF1, SPRED1, and SHOC 
(reviewed  by Tartaglia et al.147), thus highlighting a nearly complete molecular pathway. The 
associated disorders of the Noonan/CFC/Costello syndrome spectrum are often 
accompanied by cognitive deficits of variable severity, which seems to be at least partially 
correlating with the affected gene and the type of mutation.148  
 
1.6.5. Transcriptional regulation 
Transcription is, amongst other processes, a molecular prerequisite for long-term synaptic 
plasticity and long-term memory function.149 It is controlled by transcription factors and co-
factors, by signal transduction cascades, and by chromatin-remodeling proteins.49 
Transcription factors bind to particular cognate sequences in promoter regions of their 
target genes and regulate their expression. Examples for transcription factors implicated in 
ID syndromes are ZEB2 in Mowat-Wilson syndrome,150,151 MEF2C in severe Rett-like ID,75,152 
or SOX3 in X-linked ID with growth hormone deficiency153 and SOX10 in the neurologic 
variant of Waardenburg-Shah syndrome.154 
Furthermore, transcription is regulated by epigenetic modulation of chromatin 
structure. This includes mechanisms like DNA methylation, modification of histone proteins, 
and ATP-dependent chromatin remodeling.155 The Rett syndrome gene MECP2 encodes the 
methyl-CpG binding protein 2. It binds to methylated CpG dimer pairs in DNA and recruits 
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certain transcriptional co-factors like histone deacetylases. This subsequently leads to 
chromatin condensation and repression of target gene expression.156,157 Mutations in MLL2 
and EHMT1, both encoding histone methyltransferases, were identified in Kabuki syndrome 
and Kleefstra syndrome, respectively.29,83 The histone acetyltransferases CREBBP and 
EP300 are implicated in Rubinstein-Taybi syndrome.158,159 CREBBP is regulated by the 
ERK/CREB pathway, which is connected to the above mentioned Ras-MAP kinase pathway 
by the ribosomal protein S6 serine/threonine kinase RPS6KA3. Mutations in this gene cause 
Coffin-Lowry syndrome.160 Only recently, mutations in several components of the SWI/SNF 
ATP-dependent chromatin remodeling complex were identified in Coffin-Siris syndrome, 
Nicolaides-Baraitser syndrome, and unspecific ID.76,117,161-164 This complex regulates gene 
expression by using energy of ATP hydrolysis to alter chromatin structure around its target 
genes in order to facilitate access of other transcription factors.165 Other chromatin 
remodeling ATPases/helicases are for example ATRX in X-linked mental retardation with 
alpha-thalassemia166 and CHD7 in CHARGE syndrome.36 
 
1.6.6. Cytoskeleton 
Proper regulation of the actin and microtubule cytoskeleton is important for dendritic spine 
morphology and synaptic activity.4 Recently, mutations in the cytoplasmic actin genes ACTB 
and ACTG1 were identified in patients with Baraitser-Winter syndrome.167 
 
1.6.7. Channelopathies 
Most of the so far known channelopathies are implicated in idiopathic epilepsy or epilepsy 
syndromes.168 Many of them are associated with developmental and cognitive anomalies. 
Mutations in sodium channel genes like SCN1A and SCN2A as well as in the potassium 
channel gene PCDH19 cause a broad range of epileptic and neurodevelopmental disorders 
ranging from familial febrile seizures169 to severe and early-onset epileptic encephalopathies 
including Dravet syndrome.170,171 
 
1.6.8. Ciliopathies 
Cilia are complex sensory organelles. They play a role in the regulation and control of 
various cellular signaling pathways. Ciliopathies are a heterogeneous group of disorders 
which are caused by mutations in genes/proteins that localize to the cilium-centrosome 
complex.172 Apart from renal disease and retinal blindness, ciliopathies comprise also 
Joubert and Bardet-Biedl syndromes. Both disorders are accompanied by brain 
malformations, neurological symptoms and cognitive impairment. Therefore, a role of the 
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primary cilium and of the many genes involved in its regulation is assumed for the modulation 
of neurogenesis, neuronal migration, cell polarity, axonal guidance, and possibly adult 
neuronal function.173,174 Both Joubert syndrome and Bardet-Biedl syndrome are genetically 
heterogeneous disorders with mutations in several ciliary genes resulting in an highly similar 
phenotype, respectively.175,176 
 
1.7. Modules and networks  
On one hand a distinct ID disorder can be caused by mutations in different genes, whereas 
on the other hand mutations in one particular gene can result in several clinically distinct 
phenotypes. This general complexity in disease genetics has for a long time being reflected 
in the so called “lumping” and “splitting” debate of phenotypes.177 Together with the growing 
number of identified ID related genes, the awareness of functional connection between those 
is increasing. It has been observed that similar phenotypes are often caused by defects in 
functionally related genes.178 The so far best studied “module” are the above already 
mentioned “Rasopathies”, comprising the Noonan/CFC/Costello syndrome spectrum and 
being caused by defects in several proteins of the Ras-MAPK pathway.179 Also other 
correlations between similar clinical phenotypes and their underlying molecular modules are 
reflected in comprehensive terms such as “ciliopathies”, including ID disorders like Joubert 
and Bardet-Biedl syndromes, “cohesinopathies”, comprising Cornelia-de-Lange syndrome 
and related disorders, and “channelopathies”.180  
These terms are based on the attempt to express molecular themes behind clinical 
phenotypes. This is accomplished on different levels, emphasizing organelles, processes, 
pathways or complexes. 
Establishing modules and networks is considered to be an important step to be able 
to cope with the large amount of data that will result from NGS, hence for evaluating and 
prioritizing variants found in a large number of candidate genes.96,180 It is also considered to 
be the starting point for the development of therapies in ID disorders as intervention into a 
central point of a larger complex or pathway is the only feasible approach compared to 
targeting every single rare genetic defect. Modules, networks and common themes in ID are 
subject of chapter 6 of this thesis. 
Large scale approaches to establish both clinical and functional networks are 
currently mainly based on bioinformatic analyses. These can link up information such as 
protein-protein interaction, known associations with pathways, and phenotype ontology 
databases.96,178,181 First approaches in this direction were recently undertaken for autism, 
autism spectrum disorders, and ID. They indeed showed common pathways of overlapping 
synaptic regulatory subnetworks, beta-catenin/chromatin remodeling networks, or enrichment 
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of neurophenotypes.47,96,182 However, these bioinformatic analyses are hypothetical and rely 
on the existence, extent and availability of molecular and functional data of the genes and 
proteins of interest. 
 
 
 
Figure 3 Schematic drawing of the RAS-MAPK signal transduction pathway, one of the best 
characterized disease-associated pathways.  
Dimerized cell surface receptors are activated by ligands, and signals are conducted via the pathway 
to the nucleus. Shaded ovals represent genes/proteins associated with disorders from the neuro-
cardio-facial-cutaneous syndrome family. Light grey boxes name the disorders linked to mutations in 
the particular gene. NS, Noonan syndrome; CS, Costello syndrome; LS, LEOPARD syndrome; CFCS, 
cardio-facio-cutaneous syndrome; NF1, neurofibromatosis type 1; NFLS, neurofibromatosis type 1-like 
syndrome (Legius syndrome); NFNS, neurofibromatosis-Noonan syndrome; NS/LAH, Noonan-like 
syndrome with loose anagen hair. The figure is adapted from Tartaglia et al..183 
 
1.8. Taking the next step: functional analyses 
1.8.5. Aims 
Functional analyses of ID related genes or proteins are done for different reasons and with 
different aims. These include: 1) To prove pathogenicity of a specific mutation. This might be 
either the first one in a newly identified candidate gene and therefore lacking affirmation 
through a larger number of patients. Or it might be found in a known disease gene but is in 
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its nature or localization different from previously known mutations. 2) To delineate genotype 
phenotype correlations. Understanding specific effects of specific genetic aberrations helps 
to appreciate the complex genetic and phenotypic interactions. 3) To find out more about the 
gene/protein of interest and its function, in order to confirm its role in disease-relevant 
phenotypes and to generate fundamental knowledge about it. 4) To establish the position 
and role of a particular gene or protein in a larger complex or pathway. This might help to 
identify new candidate genes for cognitive function and dysfunction due to their functional 
and interactive role. Furthermore, it is also an important prerequisite for the establishment of 
therapeutic approaches that can target a pathway or complex rather than each of its single 
components. 
 
1.8.6. Sources and approaches to investigate gene/protein function 
Depending on the nature of the investigated gene or protein, on the nature of the identified 
defect, and depending on available patient material, a large variety of functional analyses 
can be exploited to investigate the general function of a gene/protein and/or to test a more 
specific outcome of single mutations. Some examples are given below. 
a) Human samples 
Human samples are usually limited to easily accessible materials like cells from peripheral 
blood (lymphocytes or cells from EBV-transformed lymphoblastoid cell lines) or fibroblasts. 
Rarely, brain specimens are available from autopsies or after brain surgery of patients.184 
Usually, these allow only static biochemical or morphological examinations.185 
Analyses done on peripheral cells from blood or skin do not necessarily reflect the 
processes happening in brain, and they do not allow investigations on specific neuronal cell 
types. Therefore, scientists are trying to overcome these limitations by using stem cells that 
can be differentiated into various subsets of neurons. Utilizing human embryonic stem cells 
as done for example to model chromosomal disorders186 was in that case limited to the 
availability due to spontaneous abortion of aneuploid embryos. It is in general under ethical 
discussion and prohibited in many countries. However, the derivation of induced pluripotent 
stem cells (iPS cells) from somatic tissues such as fibroblasts can provide a good source of 
patient-specific stem cells. It is a very promising perspective for disease research that allows 
cellular modeling of disease processes,187 and has already been used successfully in 
research into Rett syndrome and related disorders.188,189 However, to what extent these cells 
mirror the state of (specific) brain neurons still has to be elucidated in more detail. 
b) Cell system based analyses 
If no suitable patient material is available or if more basic processes are to be investigated, 
standard cell lines such as HEK (human embryonic kidney) or HELA (cervical cancer) can be 
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exploited to investigate disease gene function. Overexpression or knockdown of a gene of 
interest can be induced, respectively. Also a large number of more specific assays are 
possible when transfecting cell lines with wild type or mutant constructs. Subsequently, 
intracellular changes of localization can be determined, or transcriptional activity and cellular 
processes can be measured by image-based approaches or in cell extracts. The latter is 
described below in more detail. 
c) Animal models 
Animal models can be used to model pathologies leading to ID and to investigate the role of 
specific alterations more detailed than usually possible in humans or in human samples. 
They allow phenotyping on many different levels, thus connecting molecular, morphological, 
and functional phenotypes with system properties such as changes in learning, memory, and 
behavior.  
Genetically modified mice are currently most commonly used. Mice are, among 
mammals, the most amenable to genetic manipulation. Furthermore, an extensive 
knowledge of the murine genome, physiology, and behavior facilitates interpretation of 
effects.190 Standardized procedures such as knocking out genes by homologous 
recombination or random insertion of wild-type or mutant transgenes are used. These may 
induce pathological events that mimic the human disorder and can therefore provide a basis 
to study the molecular basis of specific pathologies. Once validated, they can also be used to 
test potential therapeutic interventions.190    
Another powerful animal model for neurodevelopmental disorders is Drosophila 
melanogaster due to its rapid generation time, comparatively low cost, and vast arsenal of 
genetic and transgenic capabilities.191 Despite the evolutionary and neuro-anatomical 
divergence between flies and humans, a large number of genes known to be involved in ID 
have orthologs in Drosophila. This, and much other evidence indicate a conservation of 
molecular mechanisms underlying learning and memory.192-195  
In addition to generating information on specific gene function and associated 
pathologies for several ID disorders,191,192 Drosophila allowed a first pharmacological rescue 
of certain Fragile X- associated cognitive phenotypes in flies.196 This resulted in further 
studies in the Fragile X mouse model and triggered ongoing clinical trials in human 
patients.197,198 
While the generation of knockout mutants can be quite time consuming for Drosophila 
and even more for mice, the UAS-GAL4 system in Drosophila allows rapid and tissue 
specific knockdown or overexpression of any gene of interest and therefore provides a 
suitable foundation for many subsequent experiments.199,200 
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Figure 4  Schematic drawing of RNA interference201 via the UAS-Gal4 system.  
Female, non-mated flies carrying a promoter (prom)-GAL4 insert, are crossed with male flies carrying 
a UAS-RNAi transgene. In the progenies, GAL4, a transcriptional activator, is generated in specific 
tissues and binds to the upstream activating sequence (UAS). This activates the RNAi insert to 
express short hairpin RNAs. These are cleaved by the enzyme Dicer into short interference RNAs 
(siRNAs), which assemble with the target mRNA via the RNA-induced silencing complex (RISC). The 
subsequently cleaved mRNA cannot be translated anymore, and therefore a downregulation of the 
gene of interest is induced.  
 
1.8.7. Methods to investigate gene/protein function 
a) In silico analyses 
When trying to evaluate the pathogenic potential of an unknown variant, software tools that 
consider effects on splicing, conservation, or nature of the amino acid change are often used. 
These provide a first step of evaluation and can be of great assistance in prioritizing genetic 
variants. However, those in silico tools are limited to a theoretical assessment of the variant 
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based on several parameters. They lack biological evidence that can only be obtained by 
experimental analyses. 
b) RNA 
If a genetic defect is assumed to affect a dosage sensitive gene, the expression level of this 
gene in RNA from the patient can be tested. In order to confirm dosage loss due to a 
disruption of the gene, expression levels can be determined by quantitative real time-PCR 
approaches.202 Quantitative RT-PCR can also be used to investigate effects of a mutation on 
the expression level of a small number of suspected target genes.75 
Additionally, individual genetic defects can contribute to the understanding of gene 
and protein function on a more general level. With the evolving technologies of microarray 
analysis and transcriptome mRNA sequencing (RNA-Seq) it is now possible to reveal effects 
of mutations or gene dosage on the whole transcriptome. This facilitates the identification of 
pathways and networks that are connected with ID disorders or even with sub-phenotypes as 
shown for example for Rett- and Williams-Beuren syndromes.203,204 
While the availability of patient material is a prerequisite for such analyses, RNA 
interference using siRNA (small interfering RNA) or shRNA (short hairpin RNA) permits 
knockdown of gene expression in cellular systems with subsequent transcriptome profiling as 
done for example for MYST4 in HEK and HELA cells205 or for Sox2 and Chd7 in murine 
neuronal stem cells.206 
c) Protein 
Provided that a suitable antibody is available or can be generated, and depending on its 
binding sequence, protein truncation and reduction or lack of protein level can be detected by 
western blot analysis.207 Both wild type and mutant protein localization and co-localization as 
well as cellular morphology can be investigated by immunofluorescence on patient/control 
cells or after transfecting cell lines with expression constructs. For example, aberrant actin 
organization was shown for ACTB and ACTG1 mutations in cell lines of patients with 
Baraitser-Winter syndrome.167 
Effects of mutations in enzymes can be tested by specific activity assays as for 
example done for the serine/threonine kinase RPS6KA3, which is mutated in Coffin-Lowry 
syndrome.207 
The effect of mutations in ion channel encoding genes such as SCN1A or SCN2A can be 
tested by using patch clamp techniques in transfected cell lines or xenopus oocytes.208,209 
d) Protein-DNA binding 
Transcription factors regulate transcription of target genes by binding to specific sequences 
in promoter regions and by activating or repressing mechanisms.  
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Figure 5  Schematic illustration of an indirect dual luciferase assay.  
A cell line is co-transfected with: 1. An expression vector containing wild type or mutant cDNA of the 
transcription factor (TF) of interest, which is cloned behind an endogenously active promoter. 2. A 
reporter construct containing cDNA of firefly luciferase (FF luc) and a promoter with specific binding 
sites of the transcription factor of interest. 3. A construct containing renilla luciferase together with an 
endogenously active promoter. The transcription factor activates expression of firefly luciferase which 
is stimulated to produce luminescence by substrate 1. The luminescence is measured and normalized 
to luminescence intensity of an endogenously active renilla luciferase, in order to even out differences 
in transfection efficiciency. 
 
Indirect Luciferase assays provide the possibility to test transcriptional activity of a 
protein by co-transfecting it with a reporter construct. The latter contains the specific binding 
site of the transcription factor together with a promoter element that activates transcription of 
luciferase, whose activity can then be determined.210  
While Luciferase assays allow more complex determination of transcriptional activity, 
electro mobility shift assays (EMSA) are focusing rather strictly on the pure DNA-binding 
capacities of a transcription factor. They determine the shift caused by the binding of a 
protein to a DNA nucleotide during gel electrophoresis.211 Often both methods are used 
together in a complementary fashion.212 
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Also chromatin remodeling factors play a role in transcriptional regulation by different 
mechanisms which regulate chromatin structure and status.213 The methodology of chromatin 
immunoprecipitation (ChIP) involves shearing of protein-associated chromatin into smaller 
fragments followed by immunoprecipitation of the DNA-protein complex with a protein-
specific antibody. The isolated DNA-protein complexes can then be dissociated and the 
specifically enriched DNA segment can be analyzed using PCR amplification methods.211 
ChIP can be combined with subsequent microarrays (ChIP-ChIP) or DNA sequencing (ChIP-
Seq), thus allowing generation of genome-wide profiles of binding sites for transcription 
regulators. Such experiments were done for MYST4 in patient lymphoblastoid cell lines,205 for 
Ehmt1 in fly larvae,213 or for Sox2 and Chd7 in murine neural stem cells.206  
e) Protein-Protein binding 
Co-immunoprecipitation can be used to confirm interaction of a particular protein with the 
protein of interest by western blot214 but also to investigate the effect of a mutation on the 
interaction.215 
A large number of methods, including co-immunoprecipitation, co-purification, or 
affinity purification of protein complexes, can be used to identify new interaction partners of 
the protein of interest. This can be achieved by separating bound proteins on a 
polyacrylamide gel and by subsequently analyzing them with mass spectrometry.216 For 
example, FLAG- affinity based protocols and mass spectrometry were used to identify factors 
of the nucleosome remodeling and deacetylation (NuRD) complex as interaction partners of 
Sox 2206 or of PHF6.217 
While these methods require generation of homogenized protein extracts, the yeast two-
hybrid technique allows detection of interacting proteins in living yeast cells.216 The classical 
cDNA-library screen searches for pairwise interactions between the defined proteins of 
interest (bait) and their interaction partners (preys), present in cDNA libraries or sub-pools of 
libraries. Interaction between two proteins activates reporter genes that enable growth on 
specific media or a color reaction.216 Yeast two-hybrid approaches were for example used to 
identify or confirm interaction partners of Fragile X syndrome protein FMR1,218 of CASK, 
which is implicated in X-linked ID,219 or for Joubert syndrome related proteins within the 
ciliary network.220 
f) Phenotyping in animal models  
Over the last years, model organisms such as mouse and Drosophila have contributed to a 
broader understanding of the underlying molecular and functional mechanisms in a large 
number of ID disorders. Examples are Down syndrome, Angelman syndrome, Rett 
syndrome, and Fragile X syndrome.190-192 
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Basic investigation of expression patterns of a gene of interest during different stages 
of embryonic and adult development can be investigated with whole mount in situ 
hybridization in both mouse221 or Drosophila.222 
The nervous system of knockout or knockdown models allows various investigations 
such as detection of expression levels, investigation of morphology of neuronal and glial 
cells, or testing synaptic function. 
For example, the αPix/Arhgef6 mouse model for X-linked ID allowed to determine 
expression of the gene in certain areas of the brain and to detect altered expression of Rho 
GTPases in the hippocampus. Furthermore, changes in dendritic morphology and linear 
spine density as well as altered synaptic plasticity as measured by long-term potentiation and 
repression, were observed.223 Similarly, the Ehmt1 knockout fly allowed delineation of 
expression patterns in the brain and detection of altered dendrite development in 
multidendrite neurons.213  
Additionally, deficits in navigation, object exploration and complex positional learning 
were observed in the αPix/Arhgef6 knockout mouse.223 In the Ehmt1 knockout mouse model, 
reduced activity and exploration increased anxiety, diminished social playing, and a delayed 
or absent response to social novelty were demonstrated.224 The Ehmt1 mutant fly showed 
deficiencies in larval locomotor behavior, habituation and courtship memory.213  
Using the UAS-GAL4 system the consequences of a knockdown in specific tissues 
can be tested. This was done for climbing behavior in the Drosophila model of CHARGE 
syndrome after inducing knockdown of kismet/CHD7 in different subsets of neurons and 
muscle cells.225 Courtship memory defects in EHMT1 flies have been show to reside in 
mushroom bodies.213 
These examples illustrate that a vast number of behavioral tests in mice and 
Drosophila exist. Mouse models can mirror human disease symptoms like autistic traits quite 
well in behavioral assays, which test impaired social interaction, communication deficits, and 
repetitive behaviors.226 However, in general no one-to-one equivalency of human behavioral 
phenotypes to animal models can be expected. Modeling of human-like symptoms in animals 
should therefore not test if the animal would show a given cognitive impairment but rather, 
how a cognitive impairment would manifest in the animal.185  
 
1.9. Outline and aim of this thesis 
The aim of this thesis was to contribute to the genetic, clinical and functional characterization 
of ID disorders, with a particular focus on Pitt-Hopkins (PTHS) and Pitt-Hopkins-like 
syndromes. 
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Work described in this thesis covers the identification of TCF4 haploinsufficiency as 
the underlying genetic defect for Pitt-Hopkins syndrome, a distinct, but previously 
unrecognized syndrome that is characterized by severe ID, distinct facial features, and 
breathing anomalies. Consequences of TCF4 mutations on interaction with ASCL1 from the 
ASCL1-PHOX2B-Ret pathway were investigated with a transcriptional reporter assay as 
those might explain some of the characteristic PTHS symptoms (chapter 2). 
Following the identification of the underlying genetic defect, a larger number of 
patients with Pitt-Hopkins syndrome and TCF4 mutation were collected in order to further 
delineate the clinical and genetic characteristics of this syndrome (chapter 3).     
As in many patients with a relatively homogenous PTHS-like phenotype no TCF4 
mutation was identified, we performed molecular karyotyping in order to identify further 
defects responsible for PTHS or related disorders. We found a homozygous deletion in 
CNTNAP2 in a pair of siblings and a compound heterozygous deletion and splice site 
mutation in NRXN1 in a sporadic patient. Subsequently, Drosophila melanogaster was used 
as a model organism to investigate a possible interaction between Nrx-IV and Nrx-I that 
could provide an explanation for the similar phenotypes caused by the newly identified 
recessive defects in their human homologues CNTNAP2 and NRXN1 (chapter 4). 
To further characterize the phenotype associated with defects in CNTNAP2 and 
NRXN1 and to further confirm their role in severe ID, we identified a larger number of 
patients with CNVs or mutations in either gene and described their genotypic and phenotypic 
characteristics (chapter 5). 
Beyond these focused studies, this thesis also aimed at the contribution to a more 
global understanding of the molecular pathology of ID disorders. In order to pave the way to 
large-scale functional studies, a systematic inventory of all ID-related genes and their 
associated phenotypes was established. We also classified ID disorders according to their 
clinical phenotypes and attempted to establish correlations between clinical and 
molecular/functional aspects (chapter 6). 
A general discussion of the findings in this thesis and their implications in the broader 
field of ID genetics is provided in chapter 7. 
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Chapter 2 
 
Haploinsufficiency of TCF4 causes syndromal 
mental retardation with intermittent 
hyperventilation (Pitt-Hopkins syndrome). 
 
Zweier C, Peippo MM, Hoyer J, Sousa S, Bottani A, Clayton-Smith J, Reardon W, Saraiva J, 
Cabral A, Goehring I, Devriendt K, de Ravel T, Bijlsma EK, Hennekam RC, Orrico A, Cohen 
M, Dreweke A, Reis A, Nürnberg P, Rauch A.  
 
 
Am J Hum Genet. 2007 May;80(5):994-1001 
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Pitt-Hopkins syndrome is a rarely reported syndrome of so-far-unknown etiology 
characterized by mental retardation, wide mouth, and intermittent hyperventilation. By 
molecular karyotyping with GeneChip Human Mapping 100K SNP arrays, we detected 
a 1.2-Mb deletion on 18q21.2 in one patient. Sequencing of the TCF4 transcription 
factor gene, which is contained in the deletion region, in 30 patients with significant 
phenotypic overlap revealed heterozygous stop, splice, and missense mutations in 
five further patients with severe mental retardation and remarkable facial 
resemblance. Thus, we establish the Pitt-Hopkins syndrome as a distinct but probably 
heterogeneous entity caused by autosomal dominant de novo mutations in TCF4. 
Because of its phenotypic overlap, Pitt-Hopkins syndrome evolves as an important 
differential diagnosis to Angelman and Rett syndromes. Both null and missense 
mutations impaired the interaction of TCF4 with ASCL1 from the PHOX-RET pathway 
in transactivating an E box–containing reporter construct; therefore, hyperventilation 
and Hirschsprung disease in patients with Pitt-Hopkins syndrome might be explained 
by altered development of noradrenergic derivatives. 
 
In 1978, Pitt and Hopkins described two patients with sporadic “mental retardation, wide 
mouth and intermittent overbreathing”227 Since then, only four other sporadic cases with a 
similar phenotype and one sib pair with possible Pitt-Hopkins syndrome (PHS) have been 
published, but there is no MIM entry for this entity.228-231 Breathing abnormalities in these 
published patients with PHS appeared in midchildhood, were present only when they were 
awake, and consisted of abrupt paroxysms of tachypnea followed by breath holding and 
even overt cyanosis. Other common findings were epilepsy with severe grand mal seizures, 
short stature, microcephaly, severe motor and mental retardation, and minor brain 
abnormalities such as cerebellar and vermis hypoplasia, hypoplasia of the corpus callosum, 
small hippocampus, and bulging caudate nuclei. Facial features were characterized by heavy 
supraorbital regions, a broad and beaked nose with a high bridge and flaring nostrils, a wide 
mouth, broad palate, and a bowshaped upper lip.229  
Since extensive metabolic studies and conventional karyotyping did not reveal any 
clues regarding the etiology, we performed molecular karyotyping10 using GeneChip Human 
Mapping 100K SNP arrays (Affymetrix) in the two sporadic cases published by Peippo et 
al.229 This work was performed as part of our research study addressing the genetics of 
mental retardation, which was approved by the Research Ethics Committee of the Medical 
Faculty of the University of Erlangen-Nuremberg. For molecular karyotyping, DNA samples 
were hybridized to GeneChip Human Mapping 50K Xba240 and Hind240 arrays, and images 
were obtained using an Affymetrix GeneChip Scanner 3000. Raw data were analyzed with 
the Affymetrix copy-number analysis tool (CNAT 2.0.0.9), with 0.5-Mb sliding windows for the  
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Figure 1 Results of molecular karyotyping with Affymetrix GeneChip Human Mapping 100K 
SNP array in patient 2.  
A) Plot of ±log10 GSA P values for SNPs covering chromosome 18, with use of a Gnuplot program. 
The 1.2-Mb deletion in 18q21.2 is visible through a cluster of SNPs with GSA P values < -2.5. The 63 
SNPs indicating a deletion are flanked by SNP_A-1695165 (rs4800947; 50,552,638 Mb) and SNP_A-
1724163 (rs784395; 51,742,365 Mb). Genotypes of individual SNPs are indicated by colored bars at 
the bottom (magenta=homozygous; blue=heterozygous; brown=no call). Note the magenta stretch of 
homozygosity corresponding to the deleted region. B) Representative results of two-color FISH 
analyses, with the RP11-7L24 probe labeled with Cy3 (pink) in combination with a FluoroX-labeled 
(green) subtelomeric 18p control probe, for patient 2 and his parents. Whereas the RP11-7L24 probe 
is lacking on one chromosome 18 homologue in the patient, it is present on both homologues in the 
parents, demonstrating de novo origin of the deletion in patient 2. 
 
genomic smoothing algorithm (GSA). Copy-number values calculated by the CNAT were 
filtered for clusters of SNPs with high GSA P values with use of a self-programmed software 
tool that we named “CNVFinder” (J. Hoyer, A. Dreweke, C. Becker, I. Göhring, C. Thiel, M. 
M. Peippo, R. Rauch, M. Hofbeck, U. Trautmann, C. Zweier, M. Zenker, U. Hüffmeier, C. 
Kraus, A. Ekici, F. Rüschendorf, P. Nürnberg, A. Reis, and A. Rauch, unpublished material). 
In one of the two patients analyzed, molecular karyotyping revealed a 1.2-Mb deletion on 
18q21.2 (fig. 1A). The deletion was confirmed by FISH analysis with 18q21.2 BACs RP11-
99A1 (RAB27B; 50.5–50.7 Mb), RP11-839G9 (CCDC68; 50.7–50.9 Mb), and RP11-7L24 
(TCF4 [GenBank accession number NM_003199.1]; 51.1–51.24 Mb), all of which lacked the 
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specific signal on one chromosome 18 homologue (GenBank accession number 
NT_025028.13) (fig. 1B). All three BACs gave normal FISH results in both parents, thus 
confirming de novo origin of the deletion in the patient. This deletion contained three known 
genes: RAB27B (a member of the RAS oncogene family), CCDC68 (coiled-coil domain 
containing 68), and TCF4 (transcription factor 4). Since, according to the UCSC Genome 
Browser database, only TCF4 is highly expressed in fetal and adult brain, we considered it 
the most likely candidate gene for the PHS phenotype. Sequence analysis of coding exons 
2–19 and intronic flanking regions of TCF4 in the second patient published by Peippo et al.229 
revealed the missense mutation R576/580W within exon 18, which codes for the helix-loop-
helix (HLH) domain of TCF4. Sequencing was performed bidirectionally on an ABI 3730 
capillary sequencer (Applied Biosystems) (detailed conditions and primer sequences are 
available on request). De novo origin of the missense mutation was proven by its exclusion in 
both parents. Paternity was verified, and mistake of probes was excluded by genotyping 14 
polymorphic microsatellite markers in the child and both parents (PowerPlex 16 System 
[Promega]).  
Because of phenotypic overlap with the Mowat-Wilson syndrome (MIM 235730), both 
patients had been tested for mutations in the ZFHX1B gene before this study.229,232 We 
therefore screened 87 patients for TCF4 mutations in whom ZFHX1B testing had revealed 
normal results. None of these patients with mental retardation and variable features of the 
Mowat-Wilson syndrome spectrum, including constipation and Hirschsprung disease (HSCR 
[MIM 142623]), showed a TCF4 mutation.  
We then sequenced 29 further patients with a more specific phenotypic overlap with 
PHS—that is, with at least two of the following features: severe mental retardation, breathing 
anomalies, and PHS-like facial dysmorphism. These patients also included a sib pair and a 
sporadic case formerly published as having PHS or possible PHS.228,229,231 The original cases 
published by Pitt and Hopkins227 were not available, because one patient died and the other 
was lost to follow-up (D. Pitt, personal communication). The case published by Singh230 could 
not be tracked either. TCF4 mutational analysis revealed three heterozygous stop mutations 
and a splice-site mutation in four of the unpublished patients (fig. 2 and table 1). De novo 
origin was proven in two patients (3 and 4), whereas parents of patients 5 and 6 were not 
available for testing. We therefore excluded both the R385X and IVS9-1G>C mutations of the 
latter patients in a total of 180 healthy European control individuals. 
Since most of our patients have a deletion or stop or splice-site mutations, 
haploinsufficiency of TCF4 is likely to be causative of PHS. The only observed missense 
mutation affects an evolutionarily conserved amino acid and is located within the basic HLH 
(bHLH) domain of TCF4, thus likely impairing the binding capacity of the only functional 
domain known so far.  
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Figure 2  Schematic drawing of the 1.2-Mb deletion region in patient 2 and location and 
electropherograms of TCF4 mutations in patients 1, 3, 4, 5, and 6 within a schematic drawing of 
exon-intron structure of TCF4.  
Noncoding exons are light gray, and the exon coding for the functional domain is black. Blue bars 
representing BAC clones and blue squares representing SNPs indicate deletion of respective probes, 
whereas nondeleted SNPs are depicted as black squares. 
 
TCF4 (also called “ITF2,” “E2-2,” and “SEF2”) consists of 20 exons (exons 1 and 20 are 
noncoding), spans 360 kb, and encodes at least two isoforms of the transcription factor 4 
protein, differing in the presence of 4 aa (RSRS) 17 residues before the HLH domain. TCF4 
belongs to the class A subfamily of bHLH transcriptional regulators—also called “E proteins,” 
since their basic domain binds to the E-box motifs 5’-ACANNTGT-3’ or 5’-CCANNTGG-3’.233 
E proteins are characterized by a broad expression pattern and the ability to form both homo- 
and heterodimers with other classes of HLH proteins that are tissue specific or lack the basic 
DNA-binding domain.234,235  
Homozygous Tcf4 deletions in mice lead to early lethality of unknown reason and a 
slight decrease in pro-B cell numbers.235 In contrast to the apparently normal single 
heterozygous Tcf4-knockout mice, transheterozygous knockout combinations of any two of 
the E proteins Tcf4, E2a, and Heb generate significantly reduced numbers of pro-B cells, and 
mice conditionally mutated in Tcf4 show a partial block in both B and T lymphocyte 
development.234,235 Accordingly, none of our patients with heterozygous TCF4 mutations 
showed clinical evidence of immunodeficiency, and lymphocyte and Ig counts in patient 3 
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showed normal results. Nevertheless, patient 6 developed a Hodgkin lymphoma at age 29 
years, which might indicate some kind of regulatory influence of TCF4 on lymphocyte growth. 
The diversified phenotypes observed with E-protein deficiencies are consistent with the idea 
that E proteins are involved in dimeric interactions with many different tissue-specific HLH 
proteins.235 Ascl1, the mouse homologue of one of these tissue-specific proteins, is highly 
expressed in specific regions of the developing CNS and in sympathetic and enteric 
precursor cells, and Ascl1-null mice die at birth.236 ASCL1 was shown to form complexes with 
TCF4 that have the ability to bind an E-box.236 The interaction between TCF4 and ASCL1 is 
an interesting observation, since mutations in ASCL1 have been shown to impair the 
noradrenergic neuronal development in brain stem, causing some cases of congenital central 
hypoventilation syndrome (CCHS, or Ondine curse [MIM 209880]).237 In Ascl1-knockout 
mice, an impaired c-RET expression in brain-stem noradrenergic neurons and an increased 
baseline breathing frequency were reported.238 The major gene that causes CCHS, 
PHOX2B, also belongs to the RET-signaling pathway, which, in mice, involves the sequential 
expression of the Ascl1, Phox, Ret, and TH genes that are responsible for the development 
of all transient or permanent noradrenergic derivatives.237 
 
 
Figure 3  Transcriptional reporter assay showing impaired interaction of TCF4/TCF4+ mutants 
with ASCL1.  
JEG-3 cells were transiently transfected with a luciferase reporter construct with a herpes simplex 
thymidine kinase promoter either without binding sites (tkGL2) or with four E boxes (4xEtkGL2) located 
within the pTa enhancer. Co-transfection was performed with an empty CMV-expression vector (white) 
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or CMV-expression vectors containing the complete cDNA of either ASCL1 (red), TCF4 (pale yellow), 
its splice variant TCF4+ (including amino acid RSRS) (bright yellow), as well as wild-type or three 
different mutants of TCF4 and TCF4+, transfected in combination with ASCL1 (different shades of 
orange). Results were normalized for transfection efficiency to a cotransfected renilla luciferase vector 
and were expressed as mean values with SD of three independent transfections. Probably because of 
endogenous E proteins, cells transfected with the empty CMV vector alone already showed a slight 
transactivation of the luciferase vector containing the four E boxes (4xEtkGL2), in comparison with the 
reporter vector without E boxes (tkGL2). TCF4 and TCF4+ alone did not increase the activation of the 
reporter construct but enhanced the observed activation by ASCL1 when cotransfected with the latter. 
In contrast, TCF4 and TCF4+ mutants containing the mutation p.G232fsX256, R385X, or R576/580W 
did not enhance the activation by ASCL1. Differences in activation levels showed significant P values 
obtained by the Student t test. 
 
To investigate this interaction between TCF4 mutants and ASCL1, we established a 
transcriptional reporter assay using a luciferase reporter construct with a herpes simplex 
thymidine kinase promoter, either without binding sites (tkGL2) or with four E boxes 
(4xEtkGL2) located within the pTa enhancer, which interacts with several E proteins.239 JEG-
3 cells (derived from human choriocarcinoma, American-type culture collection cell line HTB-
36) were transiently cotransfected with a cytomegalovirus (CMV)–expression vector 
containing ASCL1, TCF4, its splice variant TCF4+ (including amino acid RSRS), either alone 
or in combination, and three different mutants of TCF4 and TCF4+ in combination with 
ASCL1 (fig. 3). Results were normalized, for transfection efficiency, to a cotransfected renilla 
luciferase vector. 
In accordance with the results observed by Persson et al.,236 who used a 
transcriptional reporter construct containing four E boxes from the muscle creatine kinase 
enhancer, in our assay, TCF4 and TCF4+ alone did not increase the activation of the 
reporter construct but enhanced the observed activation by ASCL1 when cotransfected with 
the latter. In contrast, TCF4 and TCF4+ mutants containing the mutations p.G232fsX256, 
R385X, or R576/580W did not enhance the activation by ASCL1 (fig. 3). Therefore, breathing 
anomalies in patients with PHS may also be caused by impaired noradrenergic neuronal 
development through defective TCF4 interaction with the ASCL1-PHOX-RET pathway. This 
interaction might also explain the occurrence of HSCR and constipation in patients 1, 2, and 
5, since RET is the major gene for isolated HSCR240 and since patients with CCHS show an 
increased incidence of HSCR (20%).241 However, no obvious defect in the sympathetic 
nervous system in Tcf4-knockout mice was observed that could be attributed to a functional 
interaction with Ascl1.236 In contrast to patients with CCHS, who are intellectually not 
impaired, patients with PHS are severely mentally retarded, which may indicate TCF4 
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involvement in other pathways important for brain development and function corresponding 
to its high expression in brain.242 
 
 
Figure 4  Facial phenotype of patients with TCF4 mutations. 
A–C) Patient 1 at ages 6 mo (A), 18 mo (B), and 14 years (C). D and H) Patient 6 at age 29 years. E–
G) Patient 2 at ages 6 mo (E and F) and 11 years (G). I–K) Patient 3 at ages 3 years (I), 6 years (J), 
and 8.75 years (K). L and M) Patient 4 at age 12.5 years. Note deep-set eyes; broad and beaked 
nasal bridge with down-turned, pointed nasal tip and flaring nostrils; wide mouth with widely spaced 
teeth, and Cupid-bowed upper lip and everted lower lip; mildly cupshaped, fleshy ears; as well as 
increased coarsening of facial features with age. 
 
All six patients with TCF4 mutations showed severe mental retardation and striking facial 
resemblance, at least to patient 1 initially reported by Pitt and Hopkins,227 consisting of deep-
set eyes; broad and beaked nasal bridge with down-turned, pointed nasal tip and flaring 
nostrils; wide mouth with widely spaced teeth, Cupid-bowed upper lip, and everted lower lip; 
and mildly cup-shaped, fleshy ears (fig. 4). Further findings were variable, including breathing 
abnormalities, which were not yet obvious in patient 3 at age 8 years (table 1). Other 
common signs were magnetic resonance imaging (MRI) anomalies such as hypoplastic 
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corpus callosum and bulging caudate nuclei, happy disposition or unmotivated laughter 
episodes, muscular hypotonia, severe constipation or HSCR, single palmar creases, and 
supernumerary digital flexion creases. The manifestation of a lymphoma in one of the oldest 
patients may be attributed to the role of TCF4 in lymphocyte development,234,235 but further 
observations and TCF4 studies in lymphoma tissues are necessary to address this question. 
Since most of the patients in whom TCF4 mutations were identified had previous 
testing for Angelman syndrome (MIM 105830) because of facial and behavioral resemblance 
and for Rett syndrome (MIM 312750) because of late-onset ventilation anomalies and severe 
mental retardation, PHS might be an important differential diagnosis for these disorders. 
Interestingly, one patient with severe mental retardation and attacks of deep sighing and 
hyperventilation who carries an interstitial deletion (18)-(q21.1q22.3) was reported as a case 
of “atypical Rett syndrome.”243 In contrast, Joubert syndrome (MIM 213300, 608091, 609583, 
608629, 610688, and 610188) was never considered in any of these patients, because its 
characteristic intermittent hyperventilation-apnea anomaly manifests in the newborn. 
Although most of the patients showed more or less overlapping features, we were unable to 
demonstrate a mutation in the remaining 24 patients, including the sporadic case published 
by Van Balkom et al.231 and the sib pair described by Orrico et al.228 Although larger gene 
deletions were excluded by the presence of heterozygous SNPs in all but 2 of the 24 
patients, we cannot exclude atypical intronic mutations or single-exon deletions in the 24 
mutation-negative patients. Nevertheless, the large number of mutation-negative patients 
with more or less similar phenotype might indicate the involvement of further genes that 
possibly interact with TCF4. 
Our study shows that molecular karyotyping10,244,245 (genomewide copy-number 
profiling) is able not only to disclose novel microdeletion syndromes23-25—as well as the 
underlying gene defect in well-known disorders, as recently shown for the autosomal 
dominant CHARGE (coloboma, heart anomaly, choanal atresia, retardation, genital and ear 
anomalies) syndrome (MIM 214800)36 and the autosomal recessive Peters-Plus syndrome 
(MIM 261540)73—but also to resolve the etiology in very rarely reported phenotypes. 
However, our findings suggest that PHS is widely underdiagnosed, just as the now clinically 
recognizable Mowat-Wilson syndrome was until the identification of the underlying gene 
defect, in 2001.150,232,246 Notably, PHS is, to our knowledge, the first constitutive phenotype in 
which the etiology was identified by molecular karyotyping with use of genomewide SNP 
arrays. 
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ABSTRACT 
Background: Haploinsufficiency of the gene encoding for transcription factor 4 (TCF4) was 
recently identified as the underlying cause of Pitt–Hopkins syndrome (PTHS), an 
underdiagnosed mental-retardation syndrome characterized by a distinct facial gestalt, 
breathing anomalies and severe mental retardation. 
Methods: TCF4 mutational analysis was performed in 117 patients with PTHS-like features. 
Results: In total, 16 novel mutations were identified. All of these proven patients were 
severely mentally retarded and showed a distinct facial gestalt. In addition, 56% had 
breathing anomalies, 56% had microcephaly, 38% had seizures and 44% had MRI 
anomalies. 
Conclusion: This study provides further evidence of the mutational and clinical spectrum of 
PTHS and confirms its important role in the differential diagnosis of severe mental 
retardation. 
 
INTRODUCTION 
In 1978, Pitt and Hopkins described two unrelated patients with sporadic ‘‘mental retardation, 
wide mouth and intermittent overbreathing’’.227 After this initial report, only four other sporadic 
cases and one sibling pair with a similar phenotype of severe mental retardation, wide mouth 
and breathing anomalies were reported as possible cases of Pitt–Hopkins syndrome (PTHS, 
OMIM 610954).228-231 Recently in two patients, two deletions, one of 1.2 Mb and one of 1.8 
Mb, in 18q21.1, detected by molecular karyotyping using 100 K single nucleotide 
polymorphism (SNP) arrays and bacterial artificial chromosome arrays, respectively, led to 
the identification of haploinsufficiency of TCF4, encoding a basic helix–loop–helix (bHLH) 
transcription factor, as the underlying cause of PTHS.247,248 A recurrent de novo missense 
mutation in the bHLH domain region of the TCF4 gene in three patients and one other 
missense mutation at the same position,247,248 as well as one splice-site mutation and three 
stop mutations248 in further patients were later identified. In the meantime, two other patients 
with the PTHS or overlapping phenotype and a deletion of TCF4 were reported.249,250 
The TCF4 gene on chromosome 18 encodes a member of the bHLH transcription 
factor family (also called ‘‘E-proteins’’ as their basic domain binds to the Ephrussi-box (E-
box) consensus binding site ‘‘CANNTG’’).233 These transcription factors are able to bind DNA 
as homodimers or heterodimers with other classes of HLH proteins and play an important 
role in many developmental processes, including the differentiation of the vertebrate nervous 
system and the development of the cortex.251,252 TCF4 encodes at least two isoforms, 
differing in the presence of 4 amino acid residues (RSRS) 17 residues upstream of the HLH 
domain.242 
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Both null mutations and missense mutations located within the bHLH domain of TCF4 
impaired its interaction in vitro with ASCL1, a tissue-specific HLH protein from the PHOX-
RET pathway. As this pathway is involved in Hirschsprung disease (HSCR; OMIM 142623) 
and the Ondine hypoventilation syndrome (OMIM 209880) through its role in the 
development of noradrenergic derivatives, the finding of HSCR or severe constipation and 
breathing anomalies in patients with PTHS might be explained by impaired interaction with 
ASCL1.248 Investigations of tcf4 expression in Danio rerio embryos showed early expression 
in the pallium of the telencephalon, the diencephalon, the midbrain tegmentum, the hindbrain 
and the branchial arches, thus correlating with the phenotypical spectrum in humans with 
PTHS.250  
Because of its phenotypical overlap with Angelman and Rett syndromes, we 
speculated that PTHS might become an important differential diagnosis with these 
conditions. 
To further delineate the genotypic and phenotypic spectrum of PTHS and to establish 
its frequency in patients with severe mental retardation, we analyzed 117 patients with 
overlapping clinical features. 
 
METHODS 
Ethics approval for this study was obtained from the ethics committee of the Medical Faculty, 
University of Erlangen-Nuremberg, and informed consent was obtained from the parents or 
guardians to study the patients. 
 
Patients 
Our study population contained 117 patients including two sibling pairs, who were referred to 
us with severe mental retardation and variable additional features reminiscent of the PTHS 
spectrum, such as microcephaly, dysmorphic facial gestalt or breathing anomalies. At least 
70 of these patients had tested negative for Angelman and/or Rett syndrome. 
 
Molecular testing 
DNA samples derived from peripheral blood were screened for TCF4 mutations by 
bidirectional direct sequencing of the coding exons 2–19 and the non-coding exon 20 and 
intronic flanking regions (ABI BigDye Terminator Sequencing Kit V.2.1; Applied Biosystems, 
Foster City, California, USA) using an automated capillary sequencer (ABI 3730; Applied 
Biosystems). Primer pairs and PCR conditions are available on request.  
Paternity was verified in samples taken from patients 7 and 12 and their parents. 
Probes were verified by genotyping with 14 polymorphic microsatellite markers (PowerPlex 
16 System, Promega, Madison, Wisconsin, USA) to exclude any possibility of mistakes. 
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Reverse transcriptase (RT)-PCR was performed for patients 12 and 14, using primers 
located in exons 13 and 17 and exons 5 and 11, respectively, on cDNA obtained from mRNA 
(Superscript II Reverse Trancriptase; Invitrogen, Carlsbad, California, USA). For patient 12, 
mRNA was extracted from lymphoblastoid cell lines (RNeasy Mini Kit; Qiagen, Valencia, 
California, USA) and peripheral blood (PAXgene system; Preanalytix, Franklin Lakes, New 
Jersey, USA), using commercial kits in accordance with the manufacturers’ instructions. 
Aberrant transcripts were extracted from agarose gel (QiaQuick gel extraction kit; Qiagen) 
and sequenced after reamplification. 
 
Bioinformatic analyses 
Disordered protein segments and linear protein interactions motifs were identified using the 
software programs DisEMBL253 and ELM,254 respectively. The effect of the G358V mutation 
on the aggregation tendency of TCF4 was assessed using AGGRESCAN,255 a web-based 
software program for the prediction of aggregation-prone segments in protein sequences and 
the analysis of the effect of mutations on aggregation propensities of proteins. 
 
Functional testing 
Functional consequences of the G358V mutation were tested with a transcriptional reporter 
assay as described previously.248 Immunofluorescence was performed with a primary 
antibody against TCF4 (ab2233-100; Abcam, Cambridge, Massachusetts, USA) and a CY3-
labelled secondary anti-goat antibody (C2821-1ML; Sigma-Aldrich, St Louis, Missouri, USA) 
on JEG3 cells previously transfected with either wild-type TCF4 or mutant TCF4. 
 
RESULTS 
Clinical findings 
All 16 patients with proven TCF4 mutations in this study had severe mental retardation with 
very little speech (2 patients had < 5 words) or no speech (14 patients) and with limited 
walking abilities. They resembled each other with a specific facial phenotype characterized 
by deep-set eyes, broad and often beaked nasal bridge with down-turned, pointed nasal tip 
and flaring nostrils, wide mouth with widely spaced teeth, cupid’s bow upper lip, a protruding 
lower face, and mildly cup-shaped and fleshy ears (fig. 1). Microcephaly was observed in 
56% of the patients and breathing anomalies in 56%. Seizures occurred in 38% of the 
patients between the age of 0 and 5 years. MRI anomalies such as bulging of caudate nuclei, 
ventricular asymmetry, agenesis or hypoplasia of the corpus callosum and atrophy of the 
frontal and parietal cortex were observed in 44% of the patients. Hypotonia and constipation 
were common findings in 13 and 11 of the patients, respectively. Personality was described 
as happy in 15 of the patients. Single palmar creases were reported in 11 patients and 
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scoliosis in 4 patients. Other less common anomalies were myopia and fetal pads in four and 
six patients, respectively (table 1). 
 
Molecular testing 
Sequencing of TCF4 in 117 patients with severe mental retardation and clinical findings 
overlapping with PTHS revealed novel mutations in 16 patients. Large deletions of TCF4 
could be excluded by the identification of at least one heterozygous SNP in all but five of the 
remaining patients. Owing to their facial phenotype, there is a strong suspicion that two of the 
patients with normal TCF4 sequencing and exclusion of large deletions of the TCF4 gene do 
have PHTS. Single exon deletions or mutations in regulatory elements of TCF4 and locus 
heterogeneity may explain these patients and are also possibilities in the other, less 
characteristic patients. 
We identified 12 novel stop mutations, including two splice-site mutations, distributed 
over the gene, one novel frameshift mutation located towards the C-terminus and resulting in 
an elongation of the putative protein, two novel missense mutations in exon 18 coding for the 
HLH domain, and one novel missense mutation in exon 14 (table 2, fig. 2). De novo 
occurrence was proven in all but three stop mutations, for whom parental samples were not 
available. Assumed probe relationships were confirmed in the patients and both parents in 
the exceptional missense mutation in exon 14 and the unusual splice-site mutation 
IVS14+3ARG. The exceptional missense mutation in exon 14 was also excluded in 192 
healthy control chromosomes. RT-PCR performed on mRNA from a lymphoblastoid cell line 
of patient 12 with the IVS14+3ARG mutation revealed an aberrant transcript with skipping of 
exon 14, which leads to a frameshift that results in a premature stop after three amino acids 
(fig. 3B). RT-PCR in patient 14, who had the splice-site mutation IVS9+2insGT, also revealed 
an aberrant transcript, skipping exon 9, which leads to a frameshift resulting in a premature 
stop after 14 amino acids (fig. 3C). 
 
Bioinformatic analyses 
Computational analyses indicated that the N-terminal 550 amino acids of TCF4 are 
predominantly disordered and do not adopt a globular (domain-like) tertiary structure. There 
was also no evidence that position 358 is part of a specific linear protein interaction motif that 
might be destroyed by the mutation G358V (data not shown). 
An analysis of the TCF4 aggregation properties revealed that the G358V mutation 
leads to an increase in aggregation tendency as indicated by the larger hotspot area at the 
site of the mutation (fig. 3A). Compared with the size of adjacent hotspots, the hotspot 
emerging at the site of the G358V mutation is more than twice as large. 
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Functional testing 
Functional testing of the missense mutation G358V with a transcriptional reporter assay 
showed only inconsistently a mild reduction in transcriptional activity compared with the wild 
type (data not shown). Immunofluorescence with antibodies against TCF4 revealed no visible 
aggregates (data not shown). 
 
 
Figure 1  Clinical appearance of a selection of the patients.  
Note the characteristic facial phenotype with coarse face, high cheekbones, a beaked nasal tip, a 
protruding lower face, a wide mouth with cupid’s-bow shaped upper lip and wide-spaced teeth. A) 
Patient 3, aged 22 months; B) patient 12, aged 35 months; C) patient 15, aged 35 months; D) patient 
4, aged 3 years; E) patient 10, aged 10 years; F) patient 9, aged 14 years (right) and 16 years (left); 
G) patient 6, aged 17 years; H) patient 2, aged 17 years; I) patient 14, aged 18 years; J) patient 7, 
aged 20 years; K) patient 5, aged 20 years; L) MRI of patient 12 (note the bulging of the caudate 
nuclei); M) hand of patient 12. 
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DISCUSSION 
Clinical spectrum 
Including our 16 novel patients, 27 patients with molecularly confirmed PTHS are currently 
known.247,248,250 All of these patients are severely mentally retarded with no or only very 
limited speech and limited mobility. The earliest reported walking age was 2 years in patient 
8, whereas some of the older patients cannot walk without support (e.g. patient 2) or not at 
all (e.g. patient 1). Gait is often unstable and ataxic. Furthermore, muscular hypotonia seems 
to be a common feature particularly at younger ages. 
Breathing anomalies occurred in 18 of 27 (67%) patients, with age of onset varying 
from a few months to teenage years. These episodes were characterized by daytime periods 
of hyperventilation followed by apnoea. Milder anomalies may also occur such as ‘‘playing 
with breath’’ without apnoea in patient 9 or a singular occurrence of hyperventilation after 
narcosis in patient 16. The oldest patients without breathing anomalies were 18 years old. 
Microcephaly, both congenital and acquired, occurred in about 63% of all known patients. 
While birth weight was in the lower normal range in the patients in our first study,248 in this 
cohort birth weight was normal or high normal in all cases for whom this information was 
available. 
Further common symptoms were seizures with onset from birth up to 9 years of age 
(44%), constipation (67%) and minor anomalies such as single palmar creases and 
supernumerary phalangeal flexion creases (63%). Hirschsprung disease, which had occurred 
in one of the first patients,248 was not noticed in any of the present cohort. 
In 14 of 22 (64%) patients who had MRI studies performed, anomalies such as 
bulging of caudate nuclei, ventricular asymmetry, agenesis or hypoplasia of the corpus 
callosum, and atrophy of the frontal and parietal cortex or arachnoidal cysts were reported. 
Patients with early-onset seizures had mild broadening of the ventricular system (P4), mild 
atrophy of frontal and parietal cortex (P7) and a retrocerebellar arachnoidal cyst or mega 
cisterna magna (P16). Additional less common clinical findings were scoliosis (26%), myopia 
(19%), strabismus (30%), hypogenitalism (19%) and accessory nipples (19%). Hands and 
feet were often described as slender and small, with single palmar creases in many and fetal 
pads in some patients. The lack of gross malformations is in accordance with the embryonic 
tcf4 expression in D rerio, which is restricted to the brain and branchial arches.250 
Most of the patients showed a happy and placid personality; violent or autoaggressive 
behavior was only reported in three patients. Stereotypic movements were observed in 30% 
of patients and in patient 13, the loss of hand use was reported. These features, in addition 
to microcephaly, breathing anomalies, severe mental retardation and seizures, resemble the 
features seen in both Rett and Angelman syndromes. Accordingly, most of the patients 
referred to us with suspected PTHS had already been tested for these diseases previously. 
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As we found mutations in about 14% of the patients in this study, the important role of PTHS 
as a differential diagnosis of Rett and Angelman syndromes is further confirmed. The most 
consistent aspect distinguishing PTHS from the other two syndromes is the characteristic 
facial gestalt including a coarse face, high cheekbones, a beaked nasal tip, a protruding 
lower face, a wide mouth with cupid’s-bow shaped upper lip and wide-spaced teeth. 
However, the facial phenotype can be subtle as that seen in patient 5, who does not have the 
characteristic beaked nose and resembles the other patients mostly through the shape of her 
face, with high cheekbones. 
 
Mutational spectrum 
In this study, we could identify 16 novel mutations in TCF4, distributed over the gene. (table 
2, fig. 2); 13 of these are frameshift, nonsense or splice-site mutations, therefore further 
confirming TCF4 haploinsufficiency as the disease causing mechanism. One of these splice-
site mutations is an A>G exchange at position IVS14+3, where both A and G are possible.256 
Nevertheless, because this mutation occurred de novo, we assumed abnormal splicing. We 
found an aberrant transcript by RT-PCR using cDNA from the patient, even though this was 
weaker than the wild-type allele, and confirmed skipping of exon 14 by sequencing the 
aberrant transcript (fig. 3B). One proven de novo frameshift mutation is located in the C-
terminal exon 19 and results in an elongation of the putative protein by 37 amino acids. 
Owing to its location near to the C-terminus, nonsense-mediated mRNA decay, as assumed 
for stop mutations, might not occur, but impairment of protein function due to changes in 
protein structure is likely, particularly as the functional HLH domain is located in the C-
terminal part of the protein. 
 
 
Figure 2  Scheme of the TCF4 gene with localization of novel and previously published 
mutations.  
Exons 2–19 contain coding sequence (dark-grey boxes), exons 1 and 20 are non-coding (light-grey 
boxes) and exon 18 encodes the helix–loop–helix domain (HLH, black box). fs, frameshift mutation 
leading to an elongated protein; M, missense mutation; S, splice-site mutation; X, stop mutation 
(nonsense or frameshift). 
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Amiel et al247 had identified three missense mutations at the same amino acid position (576 
or 580, depending on the isoform) within the bHLH domain in four patients, thus indicating a 
mutational hot spot at this position. Surprisingly, in 22 patients with defects in TCF4 (7 and 
this study) we found this particular missense mutation only once (table 2). However, we 
found two further missense mutations in the bHLH domain located only two amino acid 
positions upstream of the reported recurrent mutation site, which lead to a change from 
arginine to proline or histidine at position 574 or 578, respectively. Both mutations at position  
576/580 and 574/578 affect evolutionarily highly conserved glutamic and arginine residues 
constituting the E-box recognition motif.247 We showed previously that such an impairment of 
the functional bHLH domain reduces interaction with ASCL1 in transactivating an E-box-
containing reporter construct, to a similar degree as haploinsufficient stop mutations.248 
 
 
Figure 3  A) Calculated aggregation tendency of wild-type (black) and G358V (red) TCF4. The 
‘‘hotspot area’’, which gives a measure of the aggregation tendency, was calculated using 
AGGRESCAN.255 Compared with the size of adjacent hotspots, the hotspot emerging at the site of the 
G358V mutation is more than twice as large, suggesting an important effect of this amino acid 
exchange, probably leading to an increased formation of aggregates and therefore impaired function 
of TCF4. B) RT-PCR of patient 12 with the splice-site mutation IVS14+3ARG, showing the aberrant 
transcript in comparison with two normal control persons (C1, C2) and sequence of the aberrant 
transcript. C) Reverse transcriptase PCR of patient 14 with splice-site mutation IVS9+2insGT, showing 
the aberrant transcript in comparison to two normal control persons (C1, C2) and sequence of the 
aberrant transcript. Neg, negative control. 
 
Interestingly, we also found the first missense mutation outside the bHLH domain. This 
G358V mutation in exon 14 affects an evolutionarily highly conserved position. The mutation 
was excluded in both parents and 192 healthy control chromosomes, and sampling errors 
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were excluded by short tandem repeat marker analysis. Nevertheless, as this mutation is not 
located within a known functional domain, the pathogenic mechanism remains unclear. 
Reporter-assay testing of interaction with ASCL1 showed a mild but not significant decrease 
in transcriptional activity (data not shown), which is not surprising as the mutation is not 
located within the DNA or protein-binding domain. Computational analyses indicated that the 
N-terminal 550 amino acids of TCF4 are predominantly disordered and do not adopt a 
globular (domain-like) tertiary structure. Such regions were reported previously to mediate  
 
Table 2  Overview of novel and published TCF4 defects 
 
Exon Genomic alteration Protein alteration Type Frequency Reference This 
study 
all Deletion 1.2Mb  de novo 1 Zweier248  
all Deletion 1.8Mb  de novo 1 Amiel247  
all Deletion 0.5Mb  de novo 1 Brocksch.250  
7 c.469C>T p.R157X de novo 1  P5 
IVS9 IVS9+2insGT splice de novo 1  P14 
IVS9 IVS9-1G>C splice not tested 1 Zweier248  
10 c.692-694insT p.G232fsX256 de novo 1 Zweier248  
11 c.791delG p.S264fsX306 not tested 1  P11 
11 c.908delC p.T303fsX306 de novo 1  P2 
12 c.937-940delG p.314QfsX390 not tested 1  P15 
12 c.949delA p.S317fsX390 de novo 1  P6 
12 c.965-969delATGCT p.D322fsX336 de novo 1 Zweier248  
14 c.1073G>T p.G358V de novo 1  P7 
IVS14 IVS14+3A>G splice de novo 1  P12 
15 c.1153C>T p.R385X not tested 1 Zweier248  
16 c.1413-1414delG p.V472fsX487 de novo 1  P4 
16 c.1468-1471delC p.Q491fsX534 de novo 1  P3 
17 c.1512insA p.S505fsX512 de novo 1  P10 
17 c.1518delC p.S507fsX534 de novo 1  P9 
18 c.1687/1699A>T  p.K563/567X not tested 1  P1 
18 c.1721/1733G>C p.R574/578P de novo 1  P13 
18 c.1721/1733G>A p.R574/578H ex. in moth 1  P16 
18 c.1726/1738C>T p.R576/580W de novo 3 Zweier,248 
Amiel247 
 
18 c.1727/1739 p.R576/580Q de novo 1 Amiel247  
19 c.1952-1957delCT p.S661fs de novo 1  P8 
 
either specific interactions via short linear sequence motifs254 or nonspecific interactions that 
might lead to aggregation.255 However, computerized investigation of whether position 358 is 
part of a specific linear protein interaction motif gave no evidence for such a role of this 
sequence region (data not shown). In contrast, an analysis of the TCF4 aggregation 
properties revealed that the G358V mutation leads to an increase of the aggregation 
tendency, thus offering an explanation for the slightly reduced transcriptional activity 
observed. The small overall effect, however, suggests that only small-sized or 
transient/reversible aggregates are formed. This is also consistent with the 
immunofluorescence data that did not reveal visible TCF4 aggregates in cells transfected 
with the mutant protein compared with the wild type. 
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In conclusion, we have further delineated the mutational and clinical spectrum of 
PTHS and confirmed its important role in the differential diagnosis of severe mental 
retardation. 
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Chapter 4 
 
CNTNAP2 and NRXN1 are mutated in 
autosomal-recessive Pitt-Hopkins-like mental 
retardation and determine the level of a 
common synaptic protein in Drosophila.  
 
Zweier C, de Jong EK, Zweier M, Orrico A, Ousager LB, Collins AL, Bijlsma EK, Oortveld 
MA, Ekici AB, Reis A, Schenck A, Rauch A. 
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Heterozygous copy-number variants and SNPs of CNTNAP2 and NRXN1, two distantly 
related members of the neurexin superfamily, have been repeatedly associated with a 
wide spectrum of neuropsychiatric disorders, such as developmental language 
disorders, autism spectrum disorders, epilepsy, and schizophrenia. We now identified 
homozygous and compound-heterozygous deletions and mutations via molecular 
karyotyping and mutational screening in CNTNAP2 and NRXN1 in four patients with 
severe mental retardation (MR) and variable features, such as autistic behavior, 
epilepsy, and breathing anomalies, phenotypically overlapping with Pitt-Hopkins 
syndrome. With a frequency of at least 1% in our cohort of 179 patients, recessive 
defects in CNTNAP2 appear to significantly contribute to severe MR. Whereas the 
established synaptic role of NRXN1 suggests that synaptic defects contribute to the 
associated neuropsychiatric disorders and to severe MR as reported here, evidence 
for a synaptic role of the CNTNAP2-encoded protein CASPR2 has so far been lacking. 
Using Drosophila as a model, we now show that, as known for fly Nrx-I, the CASPR2 
ortholog Nrx-IV might also localize to synapses. Overexpression of either protein can 
reorganize synaptic morphology and induce increased density of active zones, the 
synaptic domains of neurotransmitter release. Moreover, both Nrx-I and Nrx-IV 
determine the level of the presynaptic active-zone protein bruchpilot, indicating a 
possible common molecular mechanism in Nrx-I and Nrx-IV mutant conditions. We 
therefore propose that an analogous shared synaptic mechanism contributes to the 
similar clinical phenotypes resulting from defects in human NRXN1 and CNTNAP2. 
 
INTRODUCTION 
The etiology of severe mental retardation (MR) is heterogeneous, and, despite a significant 
number of identified disease genes,257 the majority of cases, especially non-syndromic 
cases, remain unsolved.14 Many of the currently known MR-related genes are involved in 
neurogenesis and neuronal migration, and awareness of the implication of synaptic 
organization and plasticity in MR has only recently begun to rise.4,258 In 2007, 
haploinsufficiency of the basic helix-loop-helix (bHLH) transcription factor 4 (TCF4) was 
identified as causative for Pitt-Hopkins syndrome (PTHS [MIM 610954]), a severe MR 
disorder with variable additional anomalies, such as breathing anomalies, epilepsy, and facial 
dysmorphism including a beaked nose and a wide mouth with a cupid’s-bow shaped upper 
lip.247,248 TCF4 belongs to the E-protein family of bHLH transcription factors, which bind as 
homo- and heterodimers to E-box consensus sequences in promoters of target genes.259 
Like other E-proteins, TCF4 shows a broad expression pattern and a high expression in the 
CNS.250,260 After the identification of the underlying gene in 2007, approximately 50 patients 
have been reported,247,248,250,260-262 demonstrating the importance of a diagnostic test for the 
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increased recognition and appreciation of a previously clinically underdiagnosed condition. 
Because of a similar severe degree of MR, commonly associated seizures, and 
microcephaly, PTHS has evolved as an important differential diagnosis to the two most 
common syndromic disorders in severe MR, Rett (MIM 312750) and Angelman (MIM 
105830) syndromes.262 Because only 12% of patients referred to us with suspected PTHS 
showed mutations in TCF4 (Zweier et al.262 and unpublished data), the clinically relatively 
homogenous group of 179 TCF4-mutation-negative patients, including two sibling pairs, 
represented a suitable study cohort for searching for additional candidate genes for 
overlapping disorders. 
Through molecular karyotyping and mutational analysis, we indeed identified 
recessive defects in two genes, CNTNAP2 and Neurexin I (NRXN1), in patients with a very 
similar severe MR disorder and variable additional symptoms, such as seizures and 
breathing anomalies, resembling Pitt-Hopkins syndrome. In light of the shared phenotype 
that characterizes our patients with recessive CNTNAP2 and NRXN1 defects, and on the 
basis of the theme of overlapping phenotypes being caused by genes that are linked with 
each other in molecular networks,178 we further aimed to address the hypothesis of a 
common molecular pathogenesis. We therefore utilized the fruit fly Drosophila melanogaster 
as a model and collected data that point to a common synaptic link between these two 
genes. 
 
SUBJECTS AND METHODS 
Patients 
Our study group consisted of 179 patients, including two sibling pairs, who were referred for 
TCF4 testing because of severe MR and variable additional features reminiscent of the 
PTHS spectrum, such as microcephaly, dysmorphic facial gestalt, or breathing anomalies. 
TCF4 mutational testing revealed normal results in all of these patients. Ethics approval for 
this study was obtained from the ethics committee of the Medical Faculty, University of 
Erlangen-Nuremberg, and informed consent was obtained from parents or guardians of the 
patients. 
 
Molecular Karyotyping 
Molecular karyotyping was performed in 48 patients with the Affymetrix 500 K SNPArray and 
in 12 patients with the Affymetrix 6.0 SNP Array, in accordance with the supplier’s 
instructions. In the index patient of family 1, hybridization was performed with an Affymetrix 
GeneChip Mapping 500K SNP array, and the second affected patient and both parents were 
analyzed with the Affymetrix GeneChip Mapping 250K Nsp SNP array. Copy-number data 
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were analyzed with the Nexus software (Biodiscovery) and the Affymetrix Genotyping 
Console 3.0.2 software. Molecular karyotyping in patients 2 and 3 was performed with the 
Affymetrix GeneChip Mapping 6.0 array platform, and copy-number data were analyzed with 
the Affymetrix software Genotyping Console 3.0.2. The identified copy-number variants 
(CNVs) were submitted to the Decipher database (patient 1a, 250902; patient 2, 250903; 
patient 3, 250904). 
 
Mutational screening 
DNA samples from 177 patients, derived from peripheral-blood or lymphoblastoid cell lines, 
were screened for CNTNAP2 (NM_014141) and NRXN1 (NM004801) mutations by 
unidirectional direct sequencing of the coding exons 1–24 of CNTNAP2 and the coding 
exons 2–22 of NRXN1, including intronic flanking regions (ABI BigDye Terminator 
Sequencing Kit v.3; Applied Biosystems), with the use of an automated capillary sequencer 
(ABI 3730; Applied Biosystems). Mutations were confirmed with an independent PCR and 
bidirectional sequencing. Primer pairs can be found in Table S1, available online. For splice-
site prediction, the online tools NNSPLICE 0.9 and HSF V2.3 were used. 
 
FISH and MLPA 
Fluorescence in situ hybridization (FISH) analysis was performed in family 1 with the directly 
Cy3-labeled bacterial artificial chromosome (BAC) clone RP4-558L10 on metaphase 
spreads, in accordance with standard protocols. 
Probes for all coding exons of CNTNAP2 were designed and MLPA reaction was 
performed in accordance with the guidelines of MRC-Holland. The deletion in patient 3 was 
confirmed with MLPA with the use of a probe within exon 2 and a control probe within exon 
12 of NRXN1. Probe sequences are listed in Table S2. 
 
Analysis of relationship 
The relationship of individuals within family 1 was analyzed, with a four-generation family 
with known relationships used as background, with the Graphical Representation of 
Relationships (GRR) software.263 For GRR, we selected, from Affymetrix 250K arrays, 
10,000 randomly distributed autosomal SNPs with a minimal minor allele frequency of 0.2 in 
Europeans. For each pair of individuals, GRR calculates over the 10,000 markers the 
identical by-state (IBS) mean and standard deviation. The graphical plot of IBS mean versus 
IBS standard deviation facilitates distinguishing between relationships such as parents and 
offspring, siblings, half siblings, and cousins, as well as identical or unrelated individuals. 
Additionally, SNP genotypes around CNTNAP2 were analyzed in the family members. 
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Drosophila genes and lines 
Drosophila orthologs of TCF4, NRXN1, and CASPR2 (daughterless [CG5102], Nrx-1 
[CG7050], and Nrx-IV [CG6827]) were identified by the ENSEMBLE genome browser or by 
the reciprocal BLAST best-hit approach. Two RNAi lines, to Nrx-IV and daughterless, 
respectively, were obtained from the Vienna Drosophila Research Center (VDRC) and gave 
consistent phenotypes. VDRC lines no. 9039 (Nrx-IV) and no. 51297 (daughterless) were 
utilized for further analysis. RNA interference was induced with the UASGal4 system. The 
w1118 line (VDRC no. 60000) was used as a control, representing the same genetic 
background as the RNAi lines. Flies were raised at 28°C for maximum efficiency of 
knockdown. The Nrx-I overexpression line pUAST-Nrx-I was obtained from Wei Xie from 
Nanjing, China. Gal4 driver lines and the inducible Nrx-IV overexpression line P(EP)Nrx-
IVEP604 were obtained from the Bloomington stock center. 
 
Quantitative Real-Time PCR 
RNA extraction from 333 L3 larvae of each genotype was performed with the RNeasy Lipid 
Tissue Kit (QIAGEN) in accordance with the supplier’s protocols. cDNA synthesis was 
performed with iScript (Biorad). Quantitative real-time PCR was performed with the Power 
SYBR Green PCR Master Mix on a 7500 Fast Real-Time PCR System (Applied Biosystems), 
and results were normalized to the endogenous control actin. Primer sequences can be 
found in Table S3. 
 
Immunostaining and data acquisition 
We harvested 10–18 hr embryos and fixed them with 3.7% PFA for 20–25 min. All primary 
antibodies—anti-elav (labels nuclei of all neurons), antibody 22c10 (sensory nervous 
system), antibody BP102 (axon tracts, central neuropile region), anti-fas II (motor and central 
pioneer axons), and antibody nc82 (anti-bruchpilot, synaptic active zones) (all from the 
Developmental Studies Hybridoma Bank [DHSB])—were used in a 1:100 dilution. Late stage 
(16/17), nc-82-labeled embryos were assigned to one of three phenotypic categories: strong 
peripheral staining, moderate staining, and weak or residual staining, respectively. We 
performed statistical analysis of 69 wild-type (WT) embryos (w1118) and 73 Nrx-IV 
knockdown embryos from three independent experiments with a chi-square test and a 
Fisher’s-exact test to obtain p values. The images for peripheral synaptic staining were 
obtained with a Zeiss Apotome. 
Brains were dissected from L3 larvae and fixed for 30 min in 3.7% PFA. Pictures of 
WT and mutant brains were acquired with the use of the same microscope settings. 
Intensities of nc82 immunostainings were measured with Image J within two fields at two 
standardized positions in each CNS, one in the upper third and one in the lower third of the 
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ventral nerve cord. The average of these two values was normalized to the average of 
controls for comparison of results from independent experiments. A total of 45 w1118 brains 
from six independent experiments, 11 elav-Gal4::Nrx-I brains from two independent 
experiments, 19 double elav-Gal4::Nrx-I brains from three independent experiments, 12 elav-
Gal4::Nrx-IV brains from two independent experiments, and 21 double-elav-Gal4::Nrx-IV 
brains from four independent experiments were measured. p values were obtained with a 
Wilcoxon test for two samples for comparison to the WT. 
Type 1b neuromuscular junctions (NMJs) of muscle 4 were analyzed after dissection 
of L3 larvae and fixation in 3.7% PFA for 30 min. Costaining was performed with nc82 and 
DLG (both from DHSB) or HRP (Jackson Immuno Research) antibodies in a dilution of 
1:500. NMJ pictures were stacked in ImageJ and processed in Adobe Photoshop. Numbers 
of active zones and branches were manually counted in an animated stack, and total 
synaptic area was determined by ImageJ. A total of 21 WT NMJs, 19 overexpression Nrx-I 
NMJs, and 20 overexpression Nrx-IV NMJs from at least two independent experiments were 
counted. For the evaluation of branches, 27 WT NMJs, 25 overexpression Nrx-I NMJs, and 
20 overexpression Nrx-IV NMJs from three experiments were counted. We performed 
statistical evaluation with the Wilcoxon test for two samples, comparing each of the 
genotypes to the WT. The antibody against NrxIV was obtained from Christian Klämbt, 
Münster, Germany.264 Secondary antibodies for all stainings were either Alexa 568- or Alexa 
488-labeled antibodies against mouse or rabbit (Molecular Probes). All data were acquired 
blind to the evaluated phenotype. 
 
RESULTS 
Identification of recessive deletions and mutations in CNTNAP2 and NRXN1 
Molecular karyotyping led to the identification of a homozygous deletion of exons 2–9 within 
the CNTNAP2 gene on chromosome 7q35-q36.1 in a sibling pair of European origin (P1a 
and P1b), formerly published as possible clinical cases of Pitt-Hopkins syndrome.228 This 
deletion was confirmed by FISH analysis (Figure S2) and MLPA (data not shown) and is 
predicted to be in frame but result in the loss of several functional domains (fig. 1A, fig. 2A, 
and fig. S1). Consanguinity of the parents had been denied,228 and no indication for 
consanguinity was found by analysis of relationship with the use of the information of 10.000 
SNPs. However, when the SNPs within and around CNTNAP2 were analyzed, they showed 
homozygosity in both children, indicating an allele of common ancestry. By subsequent 
mutational screening of CNTNAP2 in a larger cohort of 177 additional TCF4- mutation-
negative patients, we identified a third patient of European origin (P2) with compound 
heterozygosity for the splice mutation IVS10-1G>T and a partial in-frame deletion of exons  
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Figure 1  Pedigrees and results of molecular karyotyping. 
A) Pedigree of family 1, with two affected children and homozygous deletion of CNTNAP2 affecting 
exons 2–9. Both parents are heterozygous carriers of the deletion. Results are from molecular 
karyotyping with Affymetrix 250K SNP arrays and analysis with the Genotyping Console 3.0.2 
software (Affymetrix). The deletion-flanking SNPs in the 500K array of P1a are SNP_A-1991616 
(145,562,641 Mb; UCSC Human Genome Browser version 18 [hg18]) and SNP_A-1991672 
(146,730,410 Mb; hg18), with a maximal deletion size of 1,167,269 bp and a minimal size of 1,146,016 
bp (Nexus software). B) Pedigree of P2, with one affected child. The patient harbors an in-frame 180 
kb deletion affecting CNTNAP2 exons 5–8 and a splice-site mutation in the splice donor site of exon 
11. Results of molecular karyotyping data from the Affymetrix 6.0 SNP array were analyzed with the 
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Genotyping Console 3.0.2 software, showing a deletion from CN_1217185 (146,387,354 Mb; hg18) to 
SNP_A-4269862 (146,566,863 Mb; hg18). See Figure S1 for SNP copy-number profiles. 
 
5–8, identified by molecular karyotyping (fig. 1B and fig. 2A) and confirmed with MLPA. The 
splice-site mutation resulted in lack of recognition of the splice acceptor site by two splice-
site-prediction programs and is therefore predicted to result in loss of exon 10, leading to a 
frameshift, and the deletion is predicted to result in the loss of two laminin G domains. The 
splice-site mutation was not found in 384 control chromosomes, and no CNTNAP2 deletion 
was found in 667 molecularly karyotyped control individuals. In both families, the parents 
were heterozygous carriers of one of the respective defects. 
 
 
 
Figure 2  Structure of CNTNAP2 and NRXN1. 
A) Schematic drawing of the genomic structure of CNTNAP2 with color coding for domain-coding 
exons and localization of mutations and deletions. Black bars represent deletions. Abbreviations are 
as follows: SP, signal peptide; DISC, discoidin-like domain; LamG, laminin-G domain; EGF, epidermal 
growth factor-like domain; FIB, fibrinogen-like domain; TM, transmembrane region; PDZPB, 
PDZdomain-binding site ; F1, family 1; P2, patient 2; Amish, homozygous mutation in the Amish 
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population, published by Strauss et al.184 B) Schematic drawing of the genomic structure of a-NRXN1 
and b-NRXN1 with color coding for domain-coding exons and localization of the mutation and deletion 
in patient 3, the deletion being represented by a black bar. Abbreviations are as follows: SP, signal 
peptide; LamG, laminin-G domain; EGF, epidermal growth factor-like domain; TM, transmembrane 
region; PDZPB, PDZ-domain-binding site. C) Schematic drawing of the domain structure of neurexins, 
CASPR2, and CASPR in humans and Drosophila. In contrast to CASPR, CASPR2 contains a PDZ-
domain-binding site but lacks a PGY repeat region, rich in proline, glycine, and tyrosine residues. Both 
neurexin I and CASPR2/Nrx-IV contain PDZ-domain-binding sites at their intracellular C terminus but 
differ in the presence of discoidin-like and fibrinogen-like domains and in the order of laminin-G 
domains. 
 
In another European patient of our cohort who had a very similar phenotype (P3), we 
identified a heterozygous 180 kb deletion within the NRXN1 gene on chromosome 2p16.3, 
spanning exons 1–4, including the start codon. This deletion was inherited from the healthy 
mother, but no deletions affecting the coding region of NRXN1 were found in 667 molecularly 
karyotyped healthy controls. Subsequent sequencing of NRXN1 in this patient revealed a 
stop mutation in exon 15 on the second allele, which was inherited from the healthy father 
(fig. 1C and fig. 2B). Both mutations are predicted to result in loss of the so-called alpha-
isoform of NRXN1, one of two NRXN1 isoforms that are transcribed from alternative 
promoters. The presumably remaining shorter beta isoform (fig. 2B and 2C) appears not to 
be sufficient to ensure normal function, which is in accordance with findings in alpha-
neurexin knockout mice.265 Mutational screening of NRXN1 in our study cohort did not reveal 
any additional defects. 
 
Clinical characterization 
As far as data are available, birth measurements of all patients (P1a, P1b, P2, and P3) were 
normal. Further growth development was also normal, apart from short stature in the siblings 
from family 1 and additional microcephaly in one of them. All four patients with recessive 
defects in CNTNAP2 or NRXN1 showed severe MR with lack of speech or with speech 
limited to single words (P1b), whereas motor milestones were normal or only mildly delayed, 
with a walking age of 2 years in P3. Episodes of hyperbreathing occurred in all patients, and 
seizures with an age at onset between 4 months and 30 months were observed in P1a, P1b, 
and P2. Additional variable anomalies were cerebellar hypoplasia, autistic behavior, and 
stereotypic movements. Apart from a wide mouth with thick lips in P1a and P1b and a wide 
mouth in P3, no specific facial dysmorphism were noted (Figure 1D). Parents of all patients 
were healthy, and the deceased sister of the father of P3 was said to have had epilepsy and 
mild MR. P1a and P1b have been described in detail by Orrico et al.,228 and an overview of 
clinical details of all patients is shown in Table 1. Lack of NRXN1 and CNTNAP2 expression 
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in blood or fibroblasts (Bakkaloglu et al.266 and data not shown) precluded functional studies 
on human material. 
 
Table 1  Phenotype in patients with CNTNAP2 and NRXN1 mutations 
 
 Siblings    
Patients P1a P1b P2 Amish184 (N=9) P3 
Mutations CNTNAP2 
deletion exons 2-
9, homozygous 
CNTNAP2 
deletion exons 2-
9, homozygous 
CNTNAP2 
deletion exons 5-
8 + IVS10-1G>T 
CNTNAP2 
c.3709delG, 
homozygous 
NRXN1deletion 
exons 1-4 + 
p.S979X 
Age 20y 15y 11y 1-10y 18y 
Sex F M F not reported F 
Parents Healthy healthy healthy not reported healthy 
Birth weight 
Length 
OFC 
3700 g 
51 cm 
34,5 cm 
not known 3700 g 
at term 
not reported 3450 g 
normal 
normal 
Height <P3 <P3 normal P4-P57 P50-75 
Weight P10 P5-10 P50 not reported P50-75 
OFC <P3 P75 P75 P18-P99  P25 
MR Severe severe severe all severe 
Age of walking Normal normal not known 16-30m 2y 
Speech  None single words none yes, but 
regression 
none 
Seizures, age 
of onset 
22mo 25-30mo 4-8mo 14-20mo  none 
MRI cerebellar 
hypoplasia 
normal not known dysplasia in 43% normal 
Hyperbreathing Yes yes yes not reported yes 
Stereotypies None not noted tooth grind., rep. 
hand movements
 yes 
Autistic 
behaviour 
not noted not noted yes 67%  yes 
Developmental 
regression 
not noted  not noted considered 
normal until 8 
months 
yes, with onset of 
seizures 
 normal the first 
years 
Constipation not noted not noted No not reported yes 
Decreased 
deep tendon 
reflexes 
not known not known not known 89%  UE: decreased 
LE: normal  
Others broad mouth, 
thick lips 
broad mouth, 
thick lips 
dry skin  broad mouth, 
strabismus, 
protruding 
tongue,  
excessive 
drooling , 
abnormal sleep-
wake cycles, 
hypermotoric 
behavior 
Normal testinga FRAXA, UBE3A, 
MECP2, TCF4 
FRAXA, UBE3A, 
MECP2 
UBE3A, CDKL5, 
MECP2, TCF4 
 array CGHb, 
UBE3A, MECP2, 
ZEB2, TCF4 
Patients P1a and P1b are siblings from family 1, clinically described by Orrico et al.;228 f, female; m, male; mo, 
months; y, years; MR, mental retardation; OFC, occipito-frontal-circumference; rep. hand movements, repetitive 
hand movements; tooth grind., tooth grinding; UE, upper extremities; LE, lower extremities; a, Previous genetic 
testing with reported normal results; b, Array-based comparative-genome hybridization via an Agilent 244K 
oligonucleotide array (Agilent) 
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Analysis of CNTNAP2 and NRXN1 orthologs Nrx-IV and Nrx-I in Drosophila 
Although a synaptic role for NRXN1 is known, this has not yet been established for 
CNTNAP2. However, the high similarity of clinical phenotypes caused by defects in the two 
genes suggested a potential common molecular contribution. To address this, as well as a 
further possible connection with TCF4, we utilized Drosophila as a model organism. All three 
genes, TCF4, NRXN1, and CNTNAP2, are highly conserved in evolution and have orthologs 
in Drosophila. 
We initially hypothesized that the TCF4 ortholog daughterless might regulate Nrx-I 
and Nrx-IV as transcriptional targets. Knockdown of daughterless to 60% of WT levels by the 
use of two different ubiquitous driver lines (promoter-Gal4 lines that regulate inducible RNAi 
alleles; see Subjects and Methods) resulted in pupal lethality, confirming the importance of 
daughterless for fly development and viability.267 However, expression of Nrx-I and Nrx-IV in 
L3 larvae of these genotypes was not significantly changed (fig. S3). 
 
Drosophila Nrx-IV and Nrx-1 both determine the level of the synaptic protein 
bruchpilot 
Knockdown of Nrx-IV, either ubiquitously with the use of actin-Gal4 drivers or specifically in 
neurons with the use of an elav-Gal4 driver, resulted in late embryonic lethality, with animals 
completing embryogenesis but failing to hatch. Together with an only recently reported 
expression of Nrx-IV in neurons,264,268 this suggests a crucial role in this cell type. To 
evaluate the cause for lethality upon neuronal 
knockdown, we performed immunostainings on embryos with a series of neuronal 
markers, labeling all neuronal nuclei, the sensory nervous system, main central axon tracts, 
and motor- and central pioneer axons, respectively. None of these showed abnormal position 
or morphology (fig. S4 and data not shown). However, we noted an overall diminished 
staining intensity of the presynaptic protein bruchpilot (nc82) in Nrx-IV knockdown embryos 
(fig. 3A). Quantification revealed that the fraction of embryos with weak or residual staining 
on peripheral motor synapses was significantly increased to 33% in Nrx-IV knockdown 
embryos, compared to 9% in WT embryos, whereas the fraction of strongly stained embryos 
was decreased to 25% in Nrx-IV knockdown embryos, compared to 55% in the WT (fig. 3B). 
Interestingly, bruchpilot is known to colocalize with Nrx-I at presynaptic active zones, the 
domains of neurotransmitter release,269 and reduced levels of bruchpilot immunoreactivity 
have been reported in larval brains of Nrx-I mutants.270 We studied bruchpilot levels after 
neuronal overexpression of either Nrx-I or Nrx-IV and found a significant dosage-dependent 
increase of bruchpilot-staining intensity in larval brains. Upon overexpression with one copy 
of a panneuronal elav-Gal4 driver, bruchpilot intensity was increased 1.2- and 1.3-fold, and 
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introduction of a second copy (dbElav) resulted in a 1.6- and 1.8-fold increase (fig. 3C and 
3D). 
 
Figure 3  The presynaptic protein bruchpilot is misregulated in Nrx-IV knockdown embryos and 
larval brains with neuronal overexpression of Nrx-I and Nrx-IV. 
A and B) For quantitative evaluation, embryos have been assigned to one of three categories of 
bruchpilot (nc82) intensities: strong, moderate, and weak peripheral staining. A) Images of strong and 
moderate central (ventral nerve cord, left panel) and peripheral (middle panel) presynaptic bruchpilot 
staining, representing the major fraction in WT and Nrx-IV knockdown embryos, respectively (UAS-
Nrx-IVRNAi/þ; elav-Gal4/þ [Elav::RNAi Nrx-IV]). Note that peripheral and central synaptic staining of 
bruchpilot in the Nrx-IV knockdown embryos is diminished. Costaining with an anti-HRP marker, 
staining neuronal membranes, ensured the same focal plane in mutant and WT embryos. Arrowheads 
point to a specific identifiable synapse (the muscle 6/7 synapse). Bruchpilot staining of this synapse is 
depicted in insets in the middle panels. B) Quantitative analysis of nc82 (anti-bruchpilot, synaptic 
active zones) labeling. Diagram shows mean with standard deviation. C) Representative pictures of 
bruchpilot staining in brains with neuronal overexpression of Nrx-I or Nrx-IV as a result of the following 
genotypes: WT, UAS-Nrx-I/ elav-Gal4; elav-Gal4/þ (dbElav:: Nrx-I) and elav-Gal4/þ; UAS-Nrx-IV/ elav-
Gal4 (dbElav:: Nrx-IV). Bruchpilot immunoreactivity is increased in both mutant conditions. D) 
Quantitative assessment of bruchpilot immunoreactivity in brains of genotypes shown in C). The 
diagram shows the mean of normalized intensity with the standard error of the mean. p values in (B) 
and (D) are related to the WT, respectively. Single asterisk, p < 0.05; double asterisk, p < 0.01; triple 
asterisk, p < 0.0001. 
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Drosophila Nrx-IV is present at synapses and can, like Nrx-I, reorganize them 
For further analyses at the subsynaptic level, we utilized Drosophila larval NMJs, giant 
synapses that share a series of features with central excitatory synapses in the mammalian 
brain and represent an established model for the study of synaptic development and 
plasticity.271 Staining of these synapses with a recently characterized specific antibody264 for 
Nrx-IV detected the presence of Nrx-IV at synaptic terminals. Nrx-IV localizes in a pattern of 
subsynaptic foci that overlap active zones (fig. 4A), resembling the pattern previously 
reported for Nrx-I.20 
 
 
Figure 4 Nrx-IV localizes to synapses and its overexpression reorganizes synapse architecture. 
A) Presence of endogenous Nrx-IV at type 1b neuromuscular junctions (NMJs) of muscle 4, 
overlapping with active zones stained with nc82. White arrowheads point to Nrx-IV, labeling 
overlapping active zones. B) Synaptic terminal with increased bouton number and increased number 
of synaptic branches upon Nrx-I or Nrx-IV overexpression, stained with an anti-HRP marker and the 
nc82 antibody. The enlarged section depicts the increased density of active zones. C) Increased 
bouton number per mm2 NMJ area in UAS-Nrx-I/ elav-Gal4; elav-Gal4/þ (dbElav:: Nrx-I) and elav-
Gal4/þ; UAS-Nrx-IV/elav-Gal4 (dbElav:: Nrx-IV) versus control w1118 animals (contr1) and dbElav 
control animals (contr2). D) Quantitative analysis of increased active-zone density (number per mm2 
NMJ area) in neuronal Nrx-I and Nrx-IV overexpression. E) Increased number of synaptic branches in 
Nrx-I and Nrx-IV overexpression. Error bars indicate standard error of the mean. p values are related 
to the WT (contr1). Single asterisk, p < 0.008; double asterisk, p < 0.0003; triple asterisk, p < 0.0001. 
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Previous studies in Nrx-I null mutants revealed a decreased number of synaptic boutons in 
NMJs, whereas overexpression of Nrx-I resulted in an increased bouton number.26920 Our 
results, measuring total synaptic area in Nrx-I-overexpression animals, show that this goes 
along with a morphological reorganization into smaller boutons, as illustrated by an increased 
number of boutons per mm2 NMJ area (fig. 4B and 4C). Strikingly, overexpression of Nrx-IV 
is capable of inducing the same morphological changes (fig. 4B and 4C). Furthermore, 
overexpression of either Nrx-I or Nrx-IV resulted in a highly significant increase in density of 
active zones (fig. 4B and 4D) and in a significant increase in branching of synaptic terminals 
(fig. 4B and 4E). 
 
DISCUSSION  
Recessive defects in CNTNAP2 and NRXN1 cause severe MR 
We report here on homozygous and compound-heterozygous deletions and mutations in 
NRXN1 and CNTNAP2 that cause severe MR with additional features such as epilepsy, 
autistic behavior, and breathing anomalies. Heterozygous CNVs or SNPs in both genes have 
recently been extensively reported in association with autism-spectrum disorder (ASD) 
(AUTS15, [MIM 612100]), epilepsy, or schizophrenia.266,272-282 Additionally, for CNTNAP2, an 
association with Gilles de la Tourette syndrome and obsessive compulsive disorder2834 was 
reported to be due to a disruption of the gene but was not confirmed in another family.284 
Furthermore, a homozygous stop mutation in CNTNAP2 in Old Order Amish children was 
implicated in a distinct disorder, CDFE syndrome (MIM 610042), which is characterized by 
cortical dysplasia and early onset, intractable focal epilepsy leading to language regression, 
and behavioral and mental deterioration;184 as well as periventricular leukomalacia and 
hepatomegaly in an additional patient.285 Histological examination of temporal-lobe 
specimens of these patients showed evidence of abnormal neuronal migration and structure, 
as well as a possibly altered expression of Kv1.1 and Nav1.2 channels, therefore providing a 
possible explanation for the cortical dysplasia and epilepsy phenotypes.184 
Taken together, published data and the present study indicate that heterozygous 
defects or variants in both NRXN1 and CNTNAP2 can represent susceptibility factors for 
variable cognitive, neurological, and psychiatric disorders, whereas biallelic defects result in 
a fully penetrant, severe neurodevelopmental disease such as that observed in our patients, 
thus representing different ends of the clinical spectrum caused by either monoallelic or 
biallelic defects in these two genes. This is in accordance with a report by Zahir et al.,286 who 
described a patient with a heterozygous de novo NRXN1 deletion affecting the same exons 
as those in our patient 3 but without detectable mutation on the second allele. This 
heterozygous deletion was associated with vertebral anomalies, behavioral problems, and 
only mild cognitive abnormalities. Of note, in our families, none of the heterozygous parents 
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had a history of autism, epilepsy, or schizophrenia, and none of other family members are 
known to have these disorders. However, the deceased sister of the father of patient 3 was 
said to have had epilepsy and mild MR. Whether or not this relates to the mutation in the 
father’s family remains elusive. 
A common feature in the Amish patients with a homozygous stop mutation and in our 
patients with homozygous deletions or compound-heterozygous deletion and mutation in 
CNTNAP2 is the early onset of seizures. In contrast, none of our patients showed regression 
of speech development. Another difference is episodic hyperbreathing, present in our 
patients but not reported in the Amish patients. Cortical dysplasia, occurring in some of the 
Amish patients, was not observed in our patients; however, the number of patients examined 
with MRI is too low to allow any definite conclusions to be drawn. The phenotypic differences 
between our patients and the reported Amish patients may be explained by the loss of C-
terminal transmembrane and cytoplasmic domains in the Amish mutation184 and by the loss 
of N-terminal extracellular domains in our patients (fig. 2 and table 1). However, clinical bias 
cannot be excluded. 
Resemblance among the patients in this study who have recessive defects in 
CNTNAP2 or NRXN1 is high, with the exception of patient 3, who has NRXN1 defects but no 
seizures. It might even be speculated that the epilepsy, observed in patients with recessive 
CNTNAP2 defects but not in our patient with the compound-heterozygous NRXN1 defect, 
might be associated to the previously observed neuronal-migration anomalies,184 whereas 
the remaining common symptoms such as severe MR and autistic behavior might be caused 
by overlapping synaptic anomalies. All of the reported patients were originally referred for 
TCF4 analysis as a result of phenotypic resemblance to Pitt-Hopkins syndrome with regard 
to facial aspects, the severity of MR, and breathing anomalies. Nevertheless, phenotypical 
differences were noticeable. In contrast to patients with Pitt-Hopkins syndrome, who present 
an equally severe delay or lack of both motor and speech development, patients with 
CNTNAP2 or NRXN1 defects, also severely impaired in speech development, present with 
normal or only mildly to moderately delayed motor milestones. These findings are in line with 
the previously reported specific involvement of CNTNAP2 in language development.281 
Because of the similar phenotypes caused by defects in both NRXN1 and CNTNAP2 
and the resemblance to Pitt-Hopkins syndrome, caused by haploinsufficiency of TCF4, we 
investigated an as-yet-unappreciated common molecular basis contributing to these 
disorders, using the fruitfly Drosophila as a model. The Drosophila TCF4 ortholog 
daughterless belongs to the achaete-scute complex, which encodes members of the bHLH 
class of transcriptional factors with a well-established proneural function.267 Our initial 
hypothesis, that daughterless might regulate Nrx-I and Nrx-IV as transcriptional targets, 
could not be confirmed by our analysis of their expression levels in the daughterless 
Chapter 4  
80 
 
knockdown condition (fig. S3). However, given that the data were obtained from knockdown 
animals, not null animals, this excludes neither transcriptional regulation that is undetectable 
by our assay nor other nontranscriptional interactions. 
 
CNTNAP2 and NRXN1 Drosophila orthologs Nrx-IV and Nrx-I might be involved in a 
common synaptic mechanism 
Our identification of a fully penetrant and severe MR phenotype due to recessive defects in 
NRXN1 is in agreement with NRXN1’s important role in synaptic function, as previously 
suggested on the basis of its heterozygous alterations that are associated with 
neuropsychiatric disorders and work with animal models.287 NRXN1 belongs to the 
evolutionarily conserved family of neurexins, presynaptic transmembrane proteins. Each of 
the three vertebrate neurexins has two promoters, generating longer alpha-neurexins and 
shorter beta-neurexins. In addition, extensive alternative splicing occurs, generating a large 
number of variants, which may mediate target recognition and synaptic specificity.288 Alpha-
neurexins also play a role in neurotransmitter release by coupling Ca2þ channels to synaptic-
vesicle exocytosis.289 In contrast to the three neurexins in mammals, there is only one 
Drosophila neurexin, termed Nrx-I or DNRX.269,270 Previously, defects in several genes 
involved in synaptic pathways and complexes have been reported to be causative for or 
associated with MR or ASD, among them neurexin interactors. The extracellular region of 
neurexins binds to postsynaptic neuroligins, a family of proteins associated with autism and 
MR,290 which in turn interact with the postsynaptic protein SHANK3, also associated with 
ASD.291 The binding of neurexins to neuroligins connects pre- and postsynaptic neurons and 
mediates signaling across the synapse,287 and the NRXN-NLGN-SHANK pathway is 
supposed to be crucial during synaptogenesis, given that mutations within this pathway lead 
to abnormal synaptogenesis and excess of inhibitory currents.292 The intracellular domains of 
neurexins interact with the synaptic vesicle protein synaptotagmin and with PDZ-domain 
proteins such as CASK,288 in which X-linked recessive mutations were only recently identified 
to be causative for MR and brain malformations.133 
In contrast, a synaptic role of CNTNAP2 has not yet been established. CNTNAP2 
encodes CASPR2, a protein related to neurexins. However, on the basis of its additional 
motifs, different domain organization,288 and phylogenetic analyses, 269 only a distant 
relationship was assumed.293 Caspr2 regulates neuron-glia contact in vertebrates and has 
been shown to colocalize with Shaker-like K+ channels in the juxtaparanodal areas of 
Ranvier nodes in myelinated axons of both the central and peripheral nervous system.294,295 
Until recently, its fly ortholog Nrx-IV was reported to be almost exclusively expressed in glial 
cells296 and to regulate glia-glia contact in insects via septate junctions that are important for 
maintaining an intact blood-brain barrier.293 A detected decrease in evoked neurotransmitter 
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release and an occasional failure to form synapses in Nrx-IV null mutants was interpreted as 
a consequence secondary to glial dysfunction.296 However, recently, a neuronal Nrx-IV 
isoform was also identified.264,268 Despite the knowledge of neuronal expression of vertebrate 
Caspr2,297 so far only a report on detection of the protein in fractionated rat synaptic plasma 
membranes pointed to a possible synaptic presence.266 Our findings now support a synaptic 
localization of Nrx-IV (Figure 4). 
Previous studies at Drosophila neuromuscular junctions had reported a decreased 
number of synaptic boutons in Nrx-I null mutants and an increase upon overexpression of 
Nrx-I.269 Our observation that the latter goes in hand with an increased active-zone density 
and the finding that Nrx-IV overexpression is causing the very same phenotypes (Figure 4) 
suggest a crucial and possibly common role for both proteins in the morphological 
organization of synapses. Moreover, published data for Nrx-I mutants270 and our analysis of 
Nrx-IV knockdown and overexpression conditions of Nrx-I and Nrx-IV suggest an important 
role of both proteins in bidirectional regulation of bruchpilot levels. Bruchpilot is a presynaptic 
protein crucial for the structure of active zones, the subsynaptic domains of neurotransmitter 
release, and is present at most if not all synapses of Drosophila. It shows high sequence and 
functional homology to the vertebrate family of ELKS/CAST proteins,298 corresponding to 
ERC1 and ERC2 in humans with similar reported functions. The mechanism by which Nrx-I 
and Nrx-IV determine bruchpilot levels remains the subject of future study. Given that all 
three contain C-terminal PDZ-domain binding sites, which are necessary for the formation of 
large complexes with active-zone proteins,298 one reasonable hypothesis is that the three 
proteins might assemble into a synaptic complex or macromolecular network. 
In conclusion, we have identified here autosomal-recessive defects in CNTNAP2 and 
NRXN1 in patients with severe MR and variable additional features overlapping with Pitt-
Hopkins syndrome. With a frequency of at least 1% in this cohort, mutations in CNTNAP2 in 
particular appear to significantly contribute to severe MR. Using the fruitfly as a model 
organism, we observed that not only Nrx-I but also Nrx-IV, previously unrecognized as a 
synaptic protein in vertebrates and in Drosophila, is present at synapses and regulates levels 
of the active-zone protein bruchpilot. It is therefore tempting to hypothesize that 
misregulation of the human bruchpilot ortholog might underlie a common synaptic 
pathomechanism contributing to the similar phenotypes observed in patients with defects in 
CNTNAP2 and NRXN1. 
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SUPPLEMENTAL DATA 
 
Figure S1  SNP copy number profile in family 1 
SNP copy number profile (Log2 ratio) of the Affymetrix 250 K array, analyzed with the Genotyping 
Console 3.0.2 software (Affymetrix) in all members of family 1, showing a homozygous deletion within 
the CNTNAP2 gene in both affected children and a heterozygous deletion in both healthy parents. 
 
Figure S2  FISH analysis in family 1 
FISH analysis with the directly Cy3-labeled BAC clone RP4-558L10 on metaphase spreads. White 
arrowheads indicate chromosomes 7. In the patients (P1a, P1b) a homozygous deletion of the BAC 
clone can be seen, in both parents a heterozygous deletion each. 
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Figure S3. Expression of daughterless, Nrx-IV and Nrx-I in daughterless knockdown larvae  
A) Normalized expression of daughterless after a knockdown with two different ubiquitous drivers on 
the second (II, Actin-Gal4 17bFO1) and third (III, Actin-Gal4 25FO1) chromosome, respectively. In 
both cases the knockdown is down to 60% compared to the wt (w1118) B,C) Normalized expression 
of Nrx-IV and Nrx-I upon knockdown of daughterless, respectively. No significant changes were 
detected. 
 
 
Figure S4  Immunostaining of the embryonic nervous system 
Examples of immunofluorescence analysis of the nervous system in wild type and Nrx-IV panneuronal 
knockdown embryos. Anti-fas II stains motor- and central pioneer axons. Antibody BP102 stains axon 
tracts/the central neuropile region. No apparent morphological or structural alterations were observed 
in the Nrx-IV knockdown embryos compared to the wild type. 
 
Table S1  Primer sequences for amplification and sequencing of all coding exons of CNTNAP2 and 
NRXN1 
Exon primer sequence amplicon length (bp) 
CNTNAP2_e1F CCTCGCGTATTTGAGGACAG 345 
CNTNAP2_e1R AGTGGCTGCAAGTGTGTGAC  
CNTNAP2_e2F GAATTGCCTAAATTCCTTTGC 363 
CNTNAP2_e2R TGGTGTCTGCCAACATCTG  
CNTNAP2_e3F GCACTGCCAAGACCAATTAAG 427 
CNTNAP2_e3R TGATGAATAAATAGTTTCCCAATG  
CNTNAP2_e4F Catggatgaaaagacccaca 481 
CNTNAP2_e4R Aaggtagtttattgtcagagaaagca  
CNTNAP2_e5F Tctttgcagacacctgttgg 452 
CNTNAP2_e5R Tttttgaatgactaggtgtttcatt   
CNTNAP2_e6F Tcccaggttaactcgaatgg 477 
CNTNAP2_e6R Tgaaacgaattaatcaggttttt  
CNTNAP2_e7F GCCATAGATTTTGGAGGCAG 413 
CNTNAP2_e7R ACATCATTTTGCCCAAACAC  
CNTNAP2_e8F TCACTGAATCCATGCTCTGC 524 
CNTNAP2_e8R AAAACCTAATCCTGAGCGTGTAAC  
CNTNAP2_e9F Ttgtaagcagcactgtattttcc 497 
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CNTNAP2_e9R Ggccagaagaatatggtgaca  
CNTNAP2_e10F GAAACAGTAGTTGGATGTGATGG 408 
CNTNAP2_e10R GAATGGTAATTTCCACCTTACCTG  
CNTNAP2_e11F CCTTGGTAAGGCAACCTGG 365 
CNTNAP2_e11R GAAATGACAATTGGAATCTTGG  
CNTNAP2_e12F CTCTTTCCAGGAAGAACTACTCC 369 
CNTNAP2_e12R GCAATATGTTGCTGATTAGATGTTG  
CNTNAP2_e13F GCTCTCCTTAACACTGTTCTACACC 460 
CNTNAP2_e13R CTTATTTACAGCTTCCTTCCTACTG  
CNTNAP2_e14F Agagtattcctggggaagtgg 440 
CNTNAP2_e14R Ttgtcgcactgacctctttct  
CNTNAP2_e15F CCAAACGATTACTGAAATGTCATC 373 
CNTNAP2_e15R ATCTCTGCTTGGGTTGTGTG  
CNTNAP2_e16F Tgtgaggatttggtccaatg 469 
CNTNAP2_e16R Aggcttgtgtgtccacctct  
CNTNAP2_e17F TCGACCTTTGTAGGACGTGAC 479 
CNTNAP2_e17R GGCCAACACCTTTACTTTTGG  
CNTNAP2_e18F GCCTTATAGCCTGCAGGGAG 587 
CNTNAP2_e18R GATTAGGAAATGATTTTGGTTGG  
CNTNAP2_e19F TACTCAGATGCCCTTCCTGG 462 
CNTNAP2_e19R GCCTATGGGGAATAAATAACAAAC  
CNTNAP2_e20F Agcaggaattgaggggatgt 350 
CNTNAP2_e20R Ttatgcacttgtaggagaaagtgt  
CNTNAP2_e21F GAAAACCAGGGTTCAAAGAGTG 314 
CNTNAP2_e21R AAGATATTCGTGACTGGCCC  
CNTNAP2_e22F Gctttggacacaagcattca 462 
CNTNAP2_e22R Acgttcctttgccctttctt  
CNTNAP2_e23F Gttgtgattcttgtgggagaca 366 
CNTNAP2_e23R Cagcaaaatgaataatgtaaaaacc  
CNTNAP2_e24F GAGAGGGCTGTGTCTGACG 437 
CNTNAP2_e24R ATATTCCATTGCCTGCCTCC  
  
NRXN1_ex2aF CCCTTACCTTTCTGTCTCTCG 499 
NRXN1_ex2aR GTCGATGAAGAGCGTGGTGT  
NRXN1_ex2bF CGACTTCCTGGAGCTGATTC 696 
NRXN1_ex2bR Gagtcccccagaaacaaggt  
NRXN1_ex3F Tgattttgttttcccccttg 344 
NRXN1_ex3R Gatggcagggttgagaatgt  
NRXN1_ex4F Gtgcagcatatgccagtgtt 446 
NRXN1_ex4R Agccacaggaacaaaccaaa  
NRXN1_ex5F Aagccaggctgtctctgcta 386 
NRXN1_ex5R Tctggattggtctcgaggtt  
NRXN1_ex6F Ctgtttgactgagacagagttca 596 
NRXN1_ex6R Tggcaggaagattcatctcag  
NRXN1_ex7F Ctctgtgggaggcctacttg 418 
NRXN1_ex7R Cagatgaaaagaaggaggtcaaa  
NRXN1_ex8F Caggcatatcccaggattaca 341 
NRXN1_ex8R Gtgccgtttgactctggaac  
NRXN1_ex9F Tcgttgaaagttacatgagctg 595 
NRXN1_ex9R Tcacttttaggaatggcatgg  
NRXN1_ex10F Ttgtctgcctccaaggagtt 573 
NRXN1_ex10R Caatggtcagtgcaggtttg  
NRXN1_ex11F Tgaagaagatgaattgattttgtagt 493 
NRXN1_ex11R Cccccgaaaacctcaaatta  
NRXN1_ex12F Ttggccatttttaaaaccttc 432 
NRXN1_ex12R Gcagtgggaaagtcttcagc  
NRXN1_ex13F Ctctgtgaggttcatttgcttg 380 
NRXN1_ex13R Tgtcatttttgaggaaaaacacc  
NRXN1_ex14F Tgtgatattgttatgaaagcctaaa 599 
NRXN1_ex14R Tgccttcttatttgtcctcca  
NRXN1_ex15F Ggatggaaccacctgaaaaa 450 
NRXN1_ex15R Cagaggcttgtgtgttgtattg  
NRXN1_ex16F Tttagcactttggggaaaaca 433 
NRXN1_ex16R Ccaaattgggtatttgaccag  
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NRXN1_ex17F Cagcctctcagttcctaattca 429 
NRXN1_ex17R Cctttccgtagaaacaactgc  
NRXN1_ex18F Gccatagttttgtgtgtagagttga 416 
NRXN1_ex18R Tttcctataacaaagtactggtttctg  
NRXN1_ex19F Gaagtaaaattggaggaaagca 450 
NRXN1_ex19R Ggacagcattacattcacatgac  
NRXN1_ex20F Tgctctcattattcaccccata 541 
NRXN1_ex20R Ggaagctgtagtgcctaagatca  
NRXN1_ex21F Aaagggaaatagtgaatttggtttc 449 
NRXN1_ex21R Aagccctgtgtgctataccc  
NRXN1_ex22F Aggcaaagggatggctacat 550 
NRXN1_ex22R TGTGCTTCATAAAAAGGAAAGTAAA  
 
Table S2  Probe sequences for MLPA analysis of all coding exons of CNTNAP2 and exon 2 of NRXN1 
exon probe sequence probe 
length 
CNTNAP2_ex1_F 
GGGTTCCCTAAGGGTTGGATGCTGTGGATTGTCAGCAGCTGCCTC
T 96 
CNTNAP2_ex1_R 
GCAGAGCCTGGACGGCTCCCTCCACGTTCTAGATTGGATCTTGCT
GGCAC  
CNTNAP2_ex2_F 
GGGTTCCCTAAGGGTTGGAGTGATGAGCCACTTGTCTCTGGACTC
CCCCA 104 
CNTNAP2_ex2_R 
TGTGGCTTTCAGCAGCTCCTCCTCCATCTCTTCTAGATTGGATCTT
GCTGGCAC  
CNTNAP2_ex3_F 
GGGTTCCCTAAGGGTTGGAGTCTCCATCAGACAGCGACCATTATC
AATGGCT 
108 
CNTNAP2_ex3_R 
TCAGGTTGACTTTGGCAATCGGAAGCAGATCAGTCTAGATTGGATC
TTGCTGGCAC 
 
CNTNAP2_ex4_F 
GGGTTCCCTAAGGGTTGGAGAAACATTAACTCTGACGGTGTGGTC
CGGCACGAA 
112 
CNTNAP2_ex4_R 
TTACAGCATCCGATTATTGCCCGCTATGTGCGCATTCTAGATTGGA
TCTTGCTGGCAC 
 
CNTNAP2_ex5_F 
GGGTTCCCTAAGGGTTGGAGATGGCCATGTTGTATTACCATATAGA
TTCAGAAACAA 
116 
CNTNAP2_ex5_R 
GAAGATGAAAACACTGAAAGATGTCATTGCCTTGAATCTAGATTGG
ATCTTGCTGGCAC 
 
CNTNAP2_ex6_F 
GGGTTCCCTAAGGGTTGGAGCATTAACCTCACTCTGGACAGGAGC
ATGCAGCACTTCC 
120 
CNTNAP2_ex6_R 
GTACCAATGGAGAGTTTGACTACCTGGACTTGGACTATGTCTAGAT
TGGATCTTGCTGGCAC 
 
CNTNAP2_ex7_F 
GGGTTCCCTAAGGGTTGGAGAGGCATCCCTTTCTCTGGCAAGCCC
AGCTC 
104 
CNTNAP2_ex7_R 
CAGCAGTAGAAAGAATTTCAAAGGCTGCATGTCTAGATTGGATCTT
GCTGGCAC 
 
CNTNAP2_ex8_F 
GGGTTCCCTAAGGGTTGGAGGACGGCTTAACCAGGACCTGTTCTC
AGTCAGTTTCCAGTT 
124 
CNTNAP2_ex8_R 
TAGGACATGGAACCCCAATGGTCTCCTGGTCTTCAGTCACTTCTAG
ATTGGATCTTGCTGGCAC 
 
CNTNAP2_ex9_F 
GGGTTCCCTAAGGGTTGGAGAATGATGGACAGTGGCACGAGGTTC
GCTTCCT 
108 
CNTNAP2_ex9_R 
AGCCAAGGAAAATTTTGCTATTCTCACCATCGATCTAGATTGGATC
TTGCTGGCAC 
 
CNTNAP2_ex10_F 
GGGTTCCCTAAGGGTTGGACATTCCAAGGATGCATGCAGCTCATT
CAAGTGGA 
112 
CNTNAP2_ex10_R 
CGATCAACTTGTAAATTTATACGAAGTGGCACAAAGTCTAGATTGG
ATCTTGCTGGCAC 
 
CNTNAP2_ex11_F 
GGGTTCCCTAAGGGTTGGAGACAGCTTCAAATGCACTTGTGATGA
GAC 
100 
CNTNAP2_ex11_R 
AGGATACAGTGGGGCCACCTGCCACAACTTCTAGATTGGATCTTG
CTGGCAC 
 
CNTNAP2_ex12_F 
GGGTTCCCTAAGGGTTGGATATCTACGAGCCTTCCTGTGAAGCCT
ACAAA 
104 
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CNTNAP2_ex12_R 
CACCTAGGACAGACATCAAATTATTACTGGATCTAGATTGGATCTT
GCTGGCAC 
 
CNTNAP2_ex13_F 
GGGTTCCCTAAGGGTTGGAGCAGATGCAGACGCCTGTGGTCGGC
TACAACCCAGAA 
116 
CNTNAP2_ex13_R 
AAATACTCAGTGACACAGCTCGTTTACAGCGCCTCCATCTAGATTG
GATCTTGCTGGCAC 
 
CNTNAP2_ex14_F 
GGGTTCCCTAAGGGTTGGAGCCCTTACACTTGGTGGGTTGGCAAA
GCCAACG 
108 
CNTNAP2_ex14_R 
AGAAGCACTACTACTGGGGAGGCTCTGGGCCTGTCTAGATTGGAT
CTTGCTGGCAC 
 
CNTNAP2_ex15_F 
GGGTTCCCTAAGGGTTGGATTGGAGATACTGACCGTCAAGGCTCA
G 
96 
CNTNAP2_ex15_R 
AAGCCAAATTGAGCGTAGGTCCTCTGCTCTAGATTGGATCTTGCTG
GCAC 
 
CNTNAP2_ex16_F 
GGGTTCCCTAAGGGTTGGAGAAACTAGCGCTGACATTTCTTTCTAC
TTCAAAAC 
112 
CNTNAP2_ex16_R 
ATTAACCCCCTGGGGAGTGTTTCTTGAAAATATGGTCTAGATTGGA
TCTTGCTGGCAC 
 
CNTNAP2_ex17_F 
GGGTTCCCTAAGGGTTGGAGTGTCCTTTTCATTTGATGTGGGAAAT
GGGCCAGTAGAG 
120 
CNTNAP2_ex17_R 
ATTGTAGTGAGGTCACCAACCCCTCTCAACGATGACCAGTCTAGAT
TGGATCTTGCTGGCAC 
 
CNTNAP2_ex18_F 
GGGTTCCCTAAGGGTTGGACAAAGGTCACATCTGGGTTCATATCC
GGATGCTCGGGCCAT 
124 
CNTNAP2_ex18_R 
TGCACCAGCTATGGAACAAACTGTGAAAATGGAGGCAAATGTCTA
GATTGGATCTTGCTGGCAC 
 
CNTNAP2_ex19_F 
GGGTTCCCTAAGGGTTGGACCTGGCACAGGAGGAGATCCGCTTC
AGCTTCAGCACCACCA 
124 
CNTNAP2_ex19_R 
AGGCGCCCTGCATTCTCCTCTACATCAGCTCCTTCACCACATCTAG
ATTGGATCTTGCTGGCAC 
 
CNTNAP2_ex20_F 
GGGTTCCCTAAGGGTTGGATGGGTGGCACCCGAGAGCCATACAAT
ATT 
100 
CNTNAP2_ex20_R 
GACGTAGACCACAGGAACATGGCCAATGGTCTAGATTGGATCTTG
CTGGCAC 
 
CNTNAP2_ex21_F 
GGGTTCCCTAAGGGTTGGATCCTTCTGTGAGTTACCATCTGCCAA
GTT 
100 
CNTNAP2_ex21_R 
CATCCGACACCCTCTTCAATTCTCCCAAGTCTAGATTGGATCTTGC
TGGCAC 
 
CNTNAP2_ex22_F 
GGGTTCCCTAAGGGTTGGACAGGATTCACTGGTTGCCTCTCCAGA
GTCCAGTTCAACC 
120 
CNTNAP2_ex22_R 
AGATCGCCCCTCTCAAGGCCGCCTTGAGGCAGACAAACGTCTAGA
TTGGATCTTGCTGGCAC 
 
CNTNAP2_ex23_F 
GGGTTCCCTAAGGGTTGGAGACAAGGCCAAGCTATAAGAAATGGA
G 
96 
CNTNAP2_ex23_R 
TCAACAGAAACTCGGCTATCATTGGAGTCTAGATTGGATCTTGCTG
GCAC 
 
CNTNAP2_ex24_F 
GGGTTCCCTAAGGGTTGGACTGTGGTGATTTTCACCATCCTGTGC
ACCCTGGTCTT 
116 
CNTNAP2_ex24_R 
CCTGATCCGGTACATGTTCCGCCACAAGGGCACCTACTCTAGATT
GGATCTTGCTGGCAC 
 
   
NRXN1_ex2_F GGGTTCCCTAAGGGTTGGACGTGAGGGTCAACTCCTCGCAGG 88 
NRXN1_ex2_R 
TCCTGCCCGTGGACAGCGGCGAGTCTAGATTGGATCTTGCTGGCA
C 
 
 
Table S3  Primer sequences for quantitative real‐time PCR 
Gene primer sequence product length (bp) 
Daughterless_F CTCGCTGCAACAAAAGGAAT 120 
Daughterless_R AAGCAGTTCTGGAACACCTCA  
Neurexin-I_F AATCTGCGGCTGCAAGTC 105 
Neurexin-I_R GAAGAGACCACCCAGGTGAA  
Neurexin-IV_F TGCCATACATCAAACAATCCA 111 
Neurexin-IV_F AGGTTCTAGGGGACCACTGC  
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ABSTRACT 
Background 
Heterozygous copy-number and missense variants in CNTNAP2 and NRXN1 have 
repeatedly been associated with a wide spectrum of neuropsychiatric disorders such as 
developmental language and autism spectrum disorders, epilepsy and schizophrenia. 
Recently, homozygous or compound heterozygous defects in either gene were reported as 
causative for severe intellectual disability.  
Methods 
99 patients with severe intellectual disability and resemblance to Pitt-Hopkins syndrome 
and/or suspected recessive inheritance were screened for mutations in CNTNAP2 and 
NRXN1. Molecular karyotyping was performed in 45 patients. In 8 further patients with 
variable intellectual disability and heterozygous deletions in either CNTNAP2 or NRXN1, the 
remaining allele was sequenced. 
Results 
By molecular karyotyping and mutational screening of CNTNAP2 and NRXN1 in a group of 
severely intellectually disabled patients we identified a heterozygous deletion in NRXN1 in 
one patient and heterozygous splice-site, frameshift and stop mutations in CNTNAP2 in four 
patients, respectively. Neither in these patients nor in eight further patients with heterozygous 
deletions within NRXN1 or CNTNAP2 we could identify a defect on the second allele. One 
deletion in NRXN1 and one deletion in CNTNAP2 occurred de novo, in another family the 
deletion was also identified in the mother who had learning difficulties, and in all other tested 
families one parent was shown to be healthy carrier of the respective deletion or mutation. 
Conclusions 
We report on patients with heterozygous defects in CNTNAP2 or NRXN1 associated with 
severe intellectual disability, which has only been reported for recessive defects before. 
These results expand the spectrum of phenotypic severity in patients with heterozygous 
defects in either gene. The large variability between severely affected patients and mildly 
affected or asymptomatic carrier parents might suggest the presence of a second hit, not 
necessarily located in the same gene.  
 
BACKGROUND 
Recent data suggested that heterozygous variants or defects in NRXN1 (Neurexin 1) or 
CNTNAP2 (contactin associated protein 2), both genes encoding neuronal cell adhesion 
molecules, represent susceptibility factors for a broad spectrum of neuropsychiatric disorders 
such as epilepsy, schizophrenia or autism spectrum disorder (ASD) with reduced penetrance 
and no or rather mild intellectual impairment.266,272-283,286,299-307 In contrast, biallelic defects in 
either gene were reported to result in fully penetrant, severe neurodevelopmental disorders. 
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Strauss et al. reported on a homozygous stop mutation in CNTNAP2 in Old Order Amish 
children causing CDFE (Cortical Dysplasia – Focal Epilepsy) syndrome (MIM #610042), 
characterized by cortical dysplasia and early onset, intractable focal epilepsy leading to 
language regression, and behavioral and mental deterioration.184,285 In a former study we 
reported on homozygous or compound heterozygous defects in CNTNAP2 or NRXN1 in four 
patients with intellectual disability and epilepsy,308 resembling Pitt-Hopkins syndrome (PTHS, 
MIM #610954). A possible shared synaptic mechanism that was observed in Drosophila 
might contribute to the similar clinical phenotypes resulting from both heterozygous and 
recessive defects in human CNTNAP2 or NRXN1.308 
To further delineate the clinical phenotype associated with potentially recessive 
defects in any of the two genes, we screened a group of patients with either severe 
intellectual disability resembling Pitt-Hopkins syndrome or the phenotypes caused by 
recessive CNTNAP2 or NRXN1 defects. Additionally, we performed mutational testing in 
patients found to harbor heterozygous deletions in either gene. 
 
MATERIALS AND METHODS 
Patients 
Our total cohort of patients comprised four different subsets: 1. our new Pitt-Hopkins 
syndrome-like (PTHSL) screening group, 2. parts of our old PTHSL screening group308, 3. a 
group of patients with suspected recessive inheritance, and 4. patients with known 
heterozygous deletions in one of the two genes. 1. The new PTHSL screening group 
consisted of 90 patients who were initially referred with suspected Pitt-Hopkins syndrome for 
diagnostic testing of the underlying gene, TCF4, which encodes transcription factor 4. They 
all had severe intellectual disability and variable additional features reminiscent of the PTHS 
spectrum such as dysmorphic facial gestalt or breathing anomalies. Mutational testing of 
TCF4 revealed normal results. In all of these 90 patients mutational screening of NRXN1 and 
CNTNAP2 was performed in the current study. Molecular karyotyping was performed in 22 of 
them. This cohort does not overlap with the second subset, our old PTHSL screening group, 
which is a similar group of 179 patients, reported in a former study.308 No published 
information on mutational screening of that group was included in the current study, but 
previously unpublished information on molecular karyotyping of 23 patients.  3. Nine patients 
with severe intellectual disability were referred to us specifically for CNTNAP2/NRXN1 
testing because of suspected autosomal-recessive inheritance and/or phenotypic overlap 
with the previously published patients.308 4. In eight patients copy number changes in either 
NRXN1 or CNTNAP2 were identified in other genetic clinics. These were referred to us for 
mutational screening of the second allele. These patients had variable degrees of intellectual 
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disability and various other anomalies. An overview on tested patients is given in Table 1. 
This study was approved by the ethics committee of the Medical Faculty, University of 
Erlangen-Nuremberg, and written consent was obtained from parents or guardians of the 
patients. 
 
Table 1  Overview on screened patients 
 
Patient samples used in 
this 
Study 
 Sequencing of NRXN1 
number of patients 
Sequencing of CNTNAP2 
number of patients 
Molecular karyotyping 
number of patients  
1. new screening sample, 
n=90 90 90, including C1-C4 22, including N1 
2. old screening 
sample,308 n=179 
published308, results not 
used in this study 
published308, results not 
used in this study 23, not published before 
3. specific testing 
sample* 9 9  
4. NRXN1/CNTNAP2 
deletion group** 5, N2-N6 3, C5-C7 
8, (details on arrays see 
Table 3) 
*, Patients were referred to us specifically for NRXN1/CNTNAP2 testing due to suspected autosomal recessive 
inheritance and/or phenotypic overlap with the previously published cases. **, Patients were referred to us 
because of copy number changes in either NRXN1 or CNTNAP2 for screening of the respective second allele. 
 
Molecular karyotyping 
Molecular karyotyping was performed in 45 patients without TCF4 mutation with an 
Affymetrix 6.0 SNP Array (Affymetrix, Santa Clara, CA), in accordance with the supplier’s 
instructions. Copy-number data were analyzed with the Affymetrix Genotyping Console 3.0.2 
software. In patient C3 molecular karyotyping was performed with an Affymetrix 500K array 
and data analysis was performed using the Affymetrix Genotyping Console 3.0.2 software. 
The patients with heterozygous copy number variants (CNVs) referred for sequencing of the 
second allele, had been tested on different platforms. An overview on the array platforms, 
validation methods and segregation in the families is given in Tables 2 and 3.  
 
Mutational screening and MLPA  
DNA samples of 107 patients were derived from peripheral blood, and if sample material was 
limited, whole genome amplification was performed using the Illustra GenomiPhi V2 DNA 
Amplification Kit (GE Healthcare, Little Chalfont, Buckinghamshire, United Kingdom) 
according to the manufacturer’s instructions. All coding exons with exon-intron boundaries of 
CNTNAP2 (NM_014141) and of isoforms alpha1, alpha2 and beta of NRXN1 (NM_004801; 
NM_001135659; NM_138735) were screened for mutations by unidirectional direct 
sequencing (ABI BigDye Terminator Sequencing Kit v.3; AppliedBiosystems, Foster City, 
CA) with the use of an automated capillary sequencer (ABI 3730; Applied Biosystems). 
Mutations were confirmed with an independent PCR and bidirectional sequencing from 
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Table 3  Molecular findings in CNTNAP2 
 
 
CNTNAP2 Defect NRXN1/CNTNAP2 deletion Validation of Array 
data  
 
C1 CNTNAP2 
c.1175_1176dup; 
p.D393RfsX51 
Affymetrix 6.0 SNP Array, 
normal results for CNTNAP2 
and NRXN1 
  
C2 CNTNAP2 c.2153G>A, 
p.W718X 
Affymetrix 6.0 SNP Array, 
normal results for CNTNAP2 
and NRXN1 
  
C3 CNTNAP2 c.1083G>A, 
splice site (p.V361V) 
Affymetrix 500K SNP Array, 
normal results for CNTNAP2 
and NRXN1 
  
C4 CNTNAP2 c.1083G>A, 
splice site (p.V361V) 
 
Illumina 317 K SNP Array,  
normal results for CNTNAP2 
and NRXN1 
  
C5 CNTNAP2 deletion of exons 
2-3 
Affymetrix 6.0 SNP Array 
chr7:146.079.333-146.194.785 
115kb (69 array marker) 
Affymetrix 6.0 
SNP Array of the 
parents 
 
C6 CNTNAP2 deletion of exons 
3-4 
Illumina Human 660W-Quad 
chr7:146.144.267-146.374.539 
230kb (53 array marker) 
qPCR as reported 
previously 310 
 
C7 CNTNAP2 
deletion of exons 21-24 
 
Agilent 2X400K 
chr7:147.702.165-148.378.711  
677kb 
 
 
 
 
customized 
Oligonucleotide 
array 
 
published 
biallelic defects 
n=13184,285 
2x CNTNAP2 deletion of 
exons 2-9, homozygous,308 
1x CNTNAP2 deletion of 
exons 5-8 + IVS10-1G>T,308 
10x CNTNAP2 c.3709delG, 
homozygous184,285  
2x Affymetrix 500K / 250K Nsp 
SNP Array; 1x Affymetrix 6.0 
SNP Array,308 10x no 
  
published 
heterozygous defects 
n=12266,272,276,283,284,305 
 
2x translocation disrupting 
CNTNAP2,283,284 1x 
inversion disrupting 
CNTNAP2,266 5x CNTNAP2 
deletion,272,276,305 4x 
missense variant in 
CNTNAP2266 
3x BAC array,276 
1x NimbleGen custom array,305  
220kb-11Mb 
  
mat, maternal; pat, paternal; dup, duplication; del, deletion; ass., associated; qPCR, quantitative Real-Time-
PCR; non-polymorphic CNVs: CNVs that have not been reported in the Toronto Database of Genome Variants 
or have not been identified in one of our molecularly karyotyped healthy control indivuals 
 
 
original DNA. Primer pairs and conditions were used as previously described 308. For splice 
site prediction, eight different online tools were used as indicated in Table 4. Multiplex 
Ligation Dependent Probe Amplification (MLPA) for all coding exons of CNTNAP2 was 
performed for patients C1-C4 as described previously.308 
 
RESULTS 
Molecular Testing 
Mutational screening of NRXN1 in 90 TCF4 mutation negative patients and nine families with 
suspected recessive inheritance of severe intellectual disability did not reveal any point 
mutation, while in CNTNAP2 the heterozygous mutation c.1083G>A in the splice donor site 
of exon 7 was found in two patients (C3, C4). Eight prediction programs (table 4) showed  
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 Inheritance Carrier 
parent 
Other non-polymorphic CNVs NRXN1 
seq 
CNTNAP2 
seq 
 paternal healthy chr9:9.337.920-10.207.671 mat dup 
chr13:19.104.340-19.477.398 mat dup 
normal 
 
no 2nd 
mutation;  
MLPA normal 
 not known not known none normal 
 
no 2nd 
mutation;  
MLPA normal 
 paternal healthy none normal 
 
no 2nd 
mutation;  
MLPA normal 
 maternal 
 
healthy pathogenic frameshift mutation in 
MEF2C (P7)75 
normal 
 
no 2nd 
mutation;  
MLPA normal
 maternal healthy none normal, 
one silent 
variant 
no 2nd 
mutation 
 
 maternal healthy none normal 
 
no 2nd 
mutation 
 
 de novo 
 
healthy 
 
chr7:92.394.428-92.530.356 del 
chr7:93.464.449-94.430.690 del, both 
de novo, conventional karyotyping:  
46,XX,der(4)t(4;10)(q25;q24), 
der(7)t(4;7)(q25;q32),  
der(10)inv(10)(p13q24)(7;10)(q32;p13), 
de novo 
normal 
 
no 2nd 
mutation 
 
 parents 
heterozygous 
carriers 
 
 
 
    
 2x not reported 276, 
4x inherited 266, 2x 
paternal 272,305, 2x 
de novo 266,276 2x 
balanced in parent 
(translocation) 283,284 
 
    
 
 
 
diminished splice site recognition for this mutation, which is therefore predicted to result in an 
in-frame loss of exon 7. This possible splice site mutation was found in one of 384 control 
chromosomes. Furthermore, in patient C1 the heterozygous frameshift mutation 
p.D393RfsX51 in exon 8 and in patient C2 the heterozygous stop mutation p.W718X in exon 
14 were identified. Due to their nature and location both truncating mutations are predicted to 
result in mRNA decay and loss of the affected allele. For patient C2 parents were not 
available, but all other mutations were shown to be inherited from a healthy parent. No defect 
on the second allele was identified in any of these patients by sequencing and subsequent 
MLPA-analysis of all coding exons. In 942 controls sequenced by Bakkaloglu et al.,266 no 
truncating mutation in CNTNAP2 was found. No CNTNAP2 deletion was found in 667 control 
individuals molecularly karyotyped.308  
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Molecular karyotyping with an Affymetrix 6.0 SNP Array in 45 TCF4 mutation negative 
patients revealed a heterozygous deletion within the NRXN1 gene in one patient (N1). The 
father was shown to be healthy carrier, and no mutation on the second allele was found in 
this patient by sequencing of all coding exons.  
In three patients with CNTNAP2 deletions (C5-C7) and in five patients with NRXN1 
deletions (N2-N6) we could not identify any pathogenic mutation on the second allele by 
sequencing all coding exons. In patient N6 and in patient C7 the deletion within NRXN1 or 
CNTNAP2 was shown to be de novo. In all other families the deletion in CNTNAP2 or 
NRXN1 was also identified in one of the parents.  
In all patients with a heterozygous defect in CNTNAP2 we also screened NRXN1 and 
vice versa, without observing any anomalies. An overview of localization of novel and 
published mutations and deletions is shown in Figure 1 and 2. Mutation and array data of 
novel patients are shown in Tables 2 and 3. 
 
Table 4  Splice site prediction for splice donor variant c.1083G>A 
Program wild type score mutant score 
NNSplice 0.9311 0.99 0.6 
HSF V2.4312 91.56 80.98 
MaxEntScan313 
Maximum Entropy Model 
Maximum Dependence Decomposition Model 
First-order Markov Model 
Weight Matrix Model 
 
8.37 
11.88 
7.5 
8.9 
 
3.38 
9.78 
3.88 
5.73 
Splice Site Score Calculation275 8.1 5.2 
Splice Site Analyzer-Tool314 83.27  
∆G -7.1 
71.36 
∆G -4 
Splice Predictor315 0.967 splice site not recognized 
NetGene2316 0.95 0.55 
SplicePort276 1.06619 0.26169 
 
Clinical Findings 
Four of six patients with heterozygous CNVs in NRXN1 were severely intellectually disabled 
(N1-N4). Three had epilepsy and one episodic hyperbreathing. Patients N5 and N6 were only 
mildly intellectually disabled and N5 additionally had various malformations like choanal 
atresia, anal atresia, and skeletal anomalies. All patients had absent or impaired language 
abilities, while motor development was normal or only mildly delayed in four of them. The 
deletion in patient N6 was shown to be de novo, in all other families one parent was shown to 
be carrier of the deletion. The mother of N2 was reported to have had learning difficulties, all 
others were reported to be healthy and of normal intelligence. However, detailed 
neuropsychiatric testing was not performed. Summarized clinical details of the patients are 
shown in Table 5. 
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Figure 1  Schematic drawing of NRXN1 with localization of novel and published mutations and 
deletions.  
Schematic drawing of genomic structure of alpha 1 isoform of NRXN1 showing domain-coding exons 
and localization of mutations and deletions. Deletions found in our study are represented by black 
bars. Published biallelic aberrations are shown with black dotted lines, whereas heterozygous losses 
and gains are marked by grey solid and dashed lines, respectively. 
Abbreviations are as follows: SP, signal peptide; LamG, laminin-G domain; EGF, epidermal growth 
factor like domain; TM, transmembrane region; PDZBD, PDZ-domain binding site. 
  
All seven patients with heterozygous defects in CNTNAP2 in this study showed severe to 
profound intellectual disability. Speech was lacking in four patients (C1, C4-C6) and reported 
to be simple in C7. Patient C3 lost her speech ability at age 2.5 years. Motor impairment was 
also severe with no walking abilities in three patients (C4-C6), patient C7 started to walk at 
the age of 15 months, and patients C1 and C3 lost this function at age 2.5 – 3 years. Five 
patients had seizures. As far as data were available, epilepsy was of early onset and difficult 
to treat. At least in two of the patients episodes of hyperbreathing were reported. Congenital 
anomalies and malformations such as tetralogy of Fallot, pyloric stenosis, and variable other 
anomalies or septo-optical dysplasia were reported in patients C1 and C5, respectively. In 
the parents shown to be carriers, no neuropsychiatric anomalies were reported. However, 
NRXN1 (isoform alpha1)
1   2 3 4 6 7 8 9   10  12 16 17 18 19 20 21 22exons
LamGEGF LamG
LamG LamGEGF EGFLamG LamG
5 13 1415
TMSP PDZB
published heterozygous
Schizophrenia
Zahir et al. 2008 (Friedman et al. 2006)
Rujescu et al. 2009 Szatmari et al. 2007
Wisniowiecka-Kowalnik et al. 2010
Ching et al. 2010 
Kim et al. 2008 
(Insertion)
N1
N5
N4
N2
N3
N6
our study
c.2936C>G, p.S979X P3 Zweier et al. 2009
Kirov et al. 2008
Vrijenhoek et al. 2009
Rujescu et al. 2009
Walsh et al. 2008
Rujescu et al 2009. 
Awadalla et al. 2010: 
p.G1402DfsX29
Magri et al. 2010
published biallelic
ASD
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detailed neuropsychiatric testing was not performed. Summarized clinical details of the 
patients are shown in Table 6.  
 
Figure 2  Schematic drawing of CNTNAP2 with localization of novel and published mutations 
and deletions.  
Schematic drawing of genomic structure of CNTNAP2 showing domain-coding exons and localization 
of mutations and deletions. Mutations and deletions found in our study are represented by black 
arrows and bars. Published biallelic aberrations are shown with black dotted lines, whereas 
heterozygous defects are shown in grey. Abbreviations are as follows: SP, signal peptide; DISC, 
discoidin-like domain; LamG, laminin-G domain; EGF, epidermal growth factor like domain; FIB, 
fibrinogen-like domain; TM, transmembrane region; PDZBD, PDZ-domain binding site.  
 
DISCUSSION 
NRXN1. While the majority of the novel patients had severe intellectual disability, only two of 
the patients, N5 and N6, with heterozygous deletions in NRXN1 had mild intellectual 
disability as reported before for this kind of defects.278,280,286,299,300 Additionally, patient N5 had 
various congenital malformations and anomalies. Interestingly, one recently published patient 
with a NRXN1 defect and no significant intellectual impairment was reported with similar 
malformations resembling the VACTERL spectrum.299 Mild skeletal anomalies were also 
reported in the patient published by Zahir et al..286 A larger number of patients and therefore 
further delineation of the phenotype will probably clarify a possible relation of such 
malformations to NRXN1 defects.  
  
1 2 3 4 5 6 9 10 11 12 137 8 14 15 16     18    20
17      19   21
22 24
23 
CNTNAP2
exons
LamG LamG LamG LamGFIB EGFEGFDISC TMSP PDZB
C1: c.1175_1176dup; 
p.D393RfsX51
C2: c.2153G>A;
p.W718X
Strauss et al. 2006:
c.3709delG homozygous
C3 & C4: 
c.1083G>A; 
splice site
C5
C6 C7
our study
P2 IVS10-1G>T
Zweier et al. 2009
F1 homozygous
P2
Mefford et al. 2010 
Epilepsy
Belloso et al. 2007                
no Tourette (Translocation)
Friedman et al. 2008 
Schizophrenia and Epilepsy
Bakkaloglu et al. 2008 
ASD (Inversion)Alarcón et al. 2008 
ASD
Verkerk et al. 2003 
Tourette (Translocation)
Bakkaloglu et al. 2008: 
ASD, p.I869T
published biallelic
published heterozygous
                      Expanding the clinical spectrum associated with defects in CNTNAP2 and NRXN1  
99 
 
Ta
ble
 5 
 C
lin
ica
l fi
nd
ing
s a
ss
oc
iat
ed
 w
ith
 de
fec
ts 
in 
N
R
XN
1 
Ot
he
r fi
nd
ing
s 
hy
pe
rbr
ea
thi
ng
 
mu
sc
ula
r h
yp
oto
nia
, M
RI
: 
wid
e v
en
tric
les
 
no
ne
 
dro
oli
ng
, fr
ien
dly
 
pe
ctu
s e
xc
av
atu
m,
 si
ng
le 
tra
ns
ve
rse
 pa
lm
ar 
cre
as
e, 
ch
oa
na
l a
tre
sia
, a
na
l 
atr
es
ia,
 th
ick
 fin
ge
r jo
int
s, 
ure
ter
ste
no
sis
, d
ela
ye
d 
bo
ne
 ag
e, 
 sp
on
dy
lop
tos
is 
L5
/S1
mu
sc
ula
r h
yp
oto
nia
 
(im
pro
ve
d),
 sc
ap
ula
e a
lat
ae
, 
mi
ld 
lor
do
sis
, te
nd
en
cy
 to
 
dia
rrh
ea
 
ex
ce
ss
ive
 dr
oo
lin
g, 
de
ve
lop
me
nta
l re
gre
ss
ion
, 
ab
no
rm
al 
sle
ep
-w
ak
e-
cy
cle
s, 
de
cre
as
ed
 de
ep
-
ten
do
n r
efl
ex
es
 up
pe
r 
ex
tre
mi
tie
s
hy
pe
rbr
ea
thi
ng
1x
 VA
CT
ER
L a
ss
oc
iat
ion
,299
 
1x
 m
ild
 sk
ele
tal
 
an
om
ali
es
,286
 4x
 hy
po
ton
ia,
 
2x
 ve
ntr
icu
lar
 se
ptu
m 
de
fec
t,3
xh
em
an
gio
ma
29
9
TO
F, 
tet
ral
og
y o
f F
all
ot;
 f, 
fem
ale
; m
, m
ale
; y
, y
ea
r; m
o, 
mo
nth
s; 
AS
D,
 au
tis
m 
sp
ec
tru
m 
dis
ord
er;
 pu
bli
sh
ed
 re
po
rts
 on
 C
NT
NA
P2
 an
d N
RX
N1
: o
nly
 pa
pe
rs 
co
nta
ini
ng
 cl
ini
ca
l d
ata
 ar
e c
ite
d; 
as
s.,
 
as
so
cia
ted
; P
, c
en
tile
; le
arn
., l
ea
rni
ng
 pr
ob
lem
s. 
Fa
cia
l 
dy
sm
orp
his
m 
lar
ge
 m
ou
th,
 
wid
ely
 sp
ac
ed
 
tee
th,
 U
PF
, 
str
ab
ism
ma
cro
ce
ph
aly
 
(al
so
 m
ate
rna
l 
an
d p
ate
rna
l), 
lar
ge
 m
ou
th,
 
ret
rog
en
ia  
no
ne
 
bro
ad
 na
sa
l ti
p, 
po
int
ed
 ch
in  
mi
ld 
fac
ial
 
as
ym
me
try
, s
ma
ll 
ea
rs,
 br
oa
d n
os
e, 
bro
ad
 m
ou
th,
 
bu
sh
y e
ye
 br
ow
s, 
hig
h a
rch
ed
 
pa
lat
e
cle
ftl
ip
pro
tru
din
g e
ars
 
bro
ad
 m
ou
th,
 
str
ab
ism
, 
pro
tru
din
g t
on
gu
e  
11
x m
ild
 
dy
sm
orp
hic
 
fea
tur
es
28
6,2
99
,30
0  
Be
ha
vio
ral
 
an
om
ali
es
/ 
Ste
reo
typ
ies
 
ye
s, 
 
pu
ts 
ob
jec
ts 
in 
his
 
mo
uth
 
no
ne
 
ye
s 
ye
s, 
 ha
nd
 lic
kin
g 
no
ne
 
no
ne
 
ye
s, 
hy
pe
rm
oto
ric
 
be
ha
vio
r  
11
x A
SD
 or
 
As
pe
rge
r 
sy
nd
rom
e27
8,2
8
6,2
99
,30
0,3
06
 
We
igh
t 
He
igh
t 
OF
C 
P2
5-P
50
 
P2
5-P
50
 
P9
0 
No
rm
al 
<P
3 
>P
95
 
P5
0-P
75
 
P7
5-P
90
 
P5
0-P
75
 
P1
0-P
25
 
P2
5-P
50
 
<P
5
P3
-P
10
 
<P
3 
P5
0 
P1
0-P
25
 
P3
 
P1
0-P
25
 
P5
0-P
75
 
P5
0-P
75
 
P2
5 
no
t 
rep
ort
ed
 
bir
th 
We
igh
t, 
He
igt
h, 
OF
C
29
00
 g 
52
 cm
 
34
 cm
 
37
40
 g 
51
 cm
 
38
.5 
cm
 
33
50
 g 
52
 cm
 
35
 cm
 
35
30
 g 
51
 cm
 
33
cm
33
00
 g 
51
 cm
 
33
 cm
 
28
20
 g 
50
 cm
 
35
 cm
 
34
50
 g 
no
rm
al 
no
t 
rep
ort
ed
 
Se
izu
res
 
ag
e o
f 
on
se
t 
ye
s 
no
ne
 
no
ne
 
gra
nd
 m
al 
4y
 
gra
nd
 m
al,
 
6y
 (u
nti
l 
ag
e 1
1y
)  
no
ne
 
no
ne
 
1x
 ye
s29
9  
Ag
e o
f 
Wa
lkin g 14m
o 
16
mo
 
 
14
mo
 
No
 
no
t 
kn
ow
n  
21
mo
 
2y
 
5x
 
mo
tor
 
de
lay
28
6,
29
9  
Sp
ee
ch
 
3y
 m
ax
. 1
0 
wo
rds
, lo
st 
thi
s 
fun
cti
on
 
24
mo
 si
ng
le 
wo
rds
, tw
o w
ord
 
co
mb
. 
rec
ep
tiv
e >
 
ex
pre
ss
ive
 
no
 ac
tiv
e 
sp
ee
ch
 
No
ne
 
Im
pa
ire
d 
2 y
: fi
rst
 w
ord
s, 
ma
inl
y a
ctiv
e 
sp
ee
ch
 af
fec
ted
 
No
ne
 
14
x l
an
gu
ag
e 
de
lay
28
6,2
99
,30
0,3
06
 
ID 
Se
ve
re 
Se
ve
re 
Se
ve
re 
Se
ve
re 
Mi
ld 
Mi
ld 
Se
ve
re  
7x
 no
rm
al,
29
9  3
x l
ea
rn.
 
pro
ble
ms
,299
,30
0  2
x 
de
v. 
De
lay
,299
,30
6  3
x 
mi
ld 
ID
,278
,28
6,3
00
 2x
 
mo
de
rat
eI
D2
99
Se
x &
 
Ag
e 
m,
 14
y 
m,
 6y
 
m,
 3y
 
4m
o  
f, 1
6y
 
m,
 21
y 
f, 6
y 
3m
o  
f, 1
8y
 
 
NR
XN
1 
N1
 
N2
 
N3
 
N4
 
N5
 
N6
 
bia
lle
lic 
de
fec
t 
P3
, N
=1
30
8  
 pu
blis
he
d 
he
ter
oz
. 
de
fec
ts 
as
s. 
wit
h A
SD
 
N=
18
27
8,2
86
,29
9,3
00
,30
6
Chapter 5  
100 
 
Ta
ble
 6 
 C
lin
ica
l fi
nd
ing
s a
ss
oc
iat
ed
 w
ith
 de
fec
ts 
in 
C
N
TN
A
P2
 
Ot
he
r fi
nd
ing
s 
ha
pp
y, 
aff
ec
tio
na
te,
 
TO
F, 
py
lor
ic s
ten
os
is, 
ve
sic
ou
ret
eri
c r
efl
ux
, 
ag
en
es
is 
of 
lab
ia 
mi
no
ra,
 hi
rsu
tis
m,
 
tap
eri
ng
 fin
ge
rs 
hy
pe
rbr
ea
thi
ng
, a
pn
oe
 
ep
iso
de
s 
de
ve
lop
me
nta
l 
reg
res
sio
n f
rom
 15
mo
, 
sw
all
ow
ing
 pr
ob
lem
s, 
no
ctu
rna
l la
ug
hin
g, 
sco
lios
is, 
sp
as
tic
 
tet
rap
are
sis
, 
hy
pe
rre
fle
xia
, 
co
ns
tip
ati
on
, 
h
b
thi
ex
otr
op
ia,
 
he
ter
oc
hro
ma
sia
, h
igh
 
pa
in 
thr
es
ho
ld,
 co
ld 
fee
t, s
lee
pin
g 
pro
ble
ms
, jo
int
 
hy
pe
rla
xity
 
se
pto
-op
tica
l d
ysp
las
ia,
 
MR
I: a
ge
ne
sis
 of
 
se
ptu
m 
pe
lluc
idu
m 
Fa
cia
l 
dy
sm
orp
his
ms
 
syn
op
hry
s, 
lon
g 
ey
ela
sh
es
, 
pro
mi
ne
nt 
co
lum
ell
a, 
sh
ort
 ph
iltr
um
, 
arc
he
d p
ala
te,
 
wid
ely
 sp
ac
ed
 
tee
th,
 
pro
mi
ne
nt 
jaw
 
 
bro
ad
 m
ou
th,
 
pro
tru
din
g 
ton
gu
e 
bro
ad
 
for
eh
ea
d, 
pro
mi
ne
nt 
ea
r 
lob
es
, w
ide
ly 
sp
ac
ed
 te
eth
, 
ten
ted
 up
pe
r 
li p
 
hig
h a
rch
ed
 
pa
lat
e, 
up
sla
nti
ng
 
pa
lpe
bra
l 
fiss
ure
s, 
sm
all 
tee
th,
 pr
om
ine
nt 
for
eh
ea
d
Be
ha
vio
ral
 
an
om
ali
es
/ 
Ste
reo
typ
ies
 
ha
nd
 
mo
ve
me
nts
 
? ye
s 
ye
s  
We
igh
t 
He
igh
t 
OF
C 
<P
3 
<P
3 
<P
3 ? P1
0 
<P
3 
P1
0 P5
 
<P
2 
P5
0 
P7
5 
P2
5-5
0 
 
bir
th 
We
igh
t
He
igt
 
OF
C 
24
30
 g 
45
 cm
 
no
t 
rep
ort
ed
 
? 
35
10
 g 
34
00
 g 
40
30
 g 
53
 cm
 
38
 cm
 
Se
izu
res
 
ag
e o
f 
on
se
t 
ye
s, 
res
ist
. 
to 
tre
atm
en
t 
co
mp
lex
, 
ea
rly
 
on
se
t 
3y
 
3-6
mo
 
no
ne
 
Ag
e o
f 
Wa
lkin
g 
2y
 wi
th 
aid
, 
los
t th
is 
fun
ctio
n  
(3y
) ? 
2,5
y, 
los
t 
thi
s f
un
ctio
n 
no
ne
 
no
ne
 
Sp
ee
ch
 
no
ne
 
? 
few
 wo
rds
, 
los
t th
is 
fun
ctio
n 
no
ne
 
no
ne
 
ID Se
ve
re 
Se
ve
re 
Se
ve
re 
Pro
fou
nd
 
Pro
fou
nd
 
Se
x &
 
Ag
e 
f, 8
y 
m,
 18
y 
f, 1
1y
 
f, 7
y 
f, 2
y 
8m
o 
CN
TN
AP
2 
C1
 
C2
 
C3
 
C4
75
 
C5
 
 
                      Expanding the clinical spectrum associated with defects in CNTNAP2 and NRXN1  
101 
 
bir
th 
at 
29
th  w
ee
k o
f 
ge
sta
tio
n, 
blin
dn
es
s, 
hy
dro
ce
ph
alu
s, 
du
ctu
s 
art
eri
os
us
, s
yn
da
cty
ly 
toe
s 2
-3,
 hy
po
ton
ia,
 
sp
as
tici
ty 
of 
leg
s, 
ob
stip
ati
on
, liq
uid
 
up
tak
e b
y P
EG
 tu
be
 
ov
erf
rie
nd
lin
es
s, 
pu
be
rta
s p
rae
co
x, 
de
lay
ed
 bo
ne
 ag
e, 
ret
en
tive
 m
em
ory
, 
ex
ce
ssi
ve
 em
pa
thy
, 
au
toa
gre
ssi
ve
 
be
ha
vio
r, f
lat
 fe
et 
1x
 dr
y s
kin
, 1
x r
eg
res
sio
n, 
1x
 ce
reb
ell
ar 
hy
po
pla
sia
, 
3x
 hy
pe
rbr
ea
thi
ng
,30
8  
10
x d
ev
elo
pm
en
tal
 
reg
res
sio
n w
ith
 on
se
t 
of 
se
izu
res
, 9
x 
de
cre
as
ed
 de
ep
 te
nd
on
 
ref
lex
es
,18
4,2
85
 4x
 M
RI
: 
co
rtic
al 
dy
sp
las
ia,
18
4  1
x 
MR
I: l
eu
ko
ma
lac
ia,
 1x
 
he
pa
tos
ple
no
me
ga
ly2
85
 
1x
 m
ult
ipl
e c
on
ge
nit
al 
ma
lfo
rm
ati
on
s,2
84
 1x
 
Gil
les
 de
 la
 To
ure
tte
 
syn
dro
me
,28
3  3
x 
Sc
hiz
op
hre
nia
27
6  
TO
F, 
tet
ral
og
y o
f fa
llo
t; f
, fe
ma
le;
 m
, m
ale
; y
, y
ea
r; m
o, 
mo
nth
; A
SD
, a
uti
sm
 sp
ec
tru
m 
dis
ord
er;
 pu
blis
he
d r
ep
ort
s o
n C
NT
NA
P2
 an
d N
RX
N1
: o
nly
 pa
pe
rs 
co
nta
ini
ng
 
clin
ica
l d
ata
 ar
e c
ite
d; 
as
s.,
 as
so
cia
ted
; P
, c
en
tile
 
mi
ld 
syn
op
hry
s, 
low
 se
t, l
arg
e 
ea
rs,
 fle
sh
y 
ea
r lo
be
s, 
thi
n 
up
pe
r li
p, 
low
 
fro
nta
l h
air
lin
e 
ep
ica
nth
al 
fol
ds
, te
nte
d 
up
pe
r li
p, 
sh
ort
 
co
lum
ell
a, 
bu
lbo
us
 no
se
 
2x
 wi
de
 m
ou
th 
an
d t
hic
k 
lips
30
8  
no
t re
po
rte
d 
 
su
sp
ec
ted
 
in 
inf
an
cy
 
8x
 
ye
s,1
84
,30
8  
1x
 to
oth
 
gri
nd
ing
 an
d 
rep
eti
tiv
e 
ha
nd
 
mo
ve
me
nts
3
08
 8x
 
ye
s26
6,2
72
,27
6  
<P
3 
<P
3 
<P
5 
P2
5-P
50
 
P5
0 
<P
5 
<P
3-n
orm
al 
no
t re
po
rte
d 
<P
3-P
99
 
no
t 
rep
ort
ed
 
11
60
 g 
35
 cm
 
28
 cm
 
38
60
 g 
54
 cm
 
34
 cm
 
no
t 
rep
ort
ed
 
no
t 
rep
ort
ed
 
ye
s, 
res
ist
. 
to 
tre
atm
en
t 
no
ne
 
13
x y
es
, 
4m
o-3
0m
o 
5x
 no
t 
rep
ort
ed
,26
6,2
7
2  2
x n
o,2
83
,28
4  
5x
 
ye
s,2
66
,27
6,3
05
 
0y
-34
y 
no
 
15
mo
 
2x
 no
rm
al,
 
1x
 no
t 
kn
ow
n,3
08
 
10
x  
16
mo
-
30
mo
18
4,2
85
 
11
x n
ot 
rep
ort
ed
,26
6,2
72
,27
6,2
83
,30
5  
1x
 no
28
4  
no
ne
 
sim
ple
 
2x
 no
, 1
x 
sin
gle
 
wo
rds
,30
8  
10
x y
es
, 
bu
t 
reg
res
sio
n
18
4,2
85
 
6x
 no
t 
rep
ort
ed
,26
6,2
72
,30
5  1
x 
no
rm
al,
27
6  
3x
 sp
ee
ch
 
im
pa
irm
en
t
,27
6,2
83
 2x
 
no
27
6,2
84
 
Pro
fou
nd
 
mo
de
rat
e 
to 
se
ve
re 
Se
ve
re 
6x
 no
t 
rep
ort
ed
,26
6,2
72
,30
5  1
x 
no
rm
al,
27
6  
2x
 m
ild-
mo
de
rat
e,2
66
,27
6  3
x 
se
ve
re2
76
,2
83
,28
4  
8y
 
f, 8
y 
2x
 f, 
1x
 
m,
 10
x 
no
t 
rep
ort
e
d,1
-20
y 
 
C6
 
C7
 
pu
blis
he
d 
bia
lle
lic 
de
fec
ts 
N=
13
18
4,2
85
 
 pu
blis
he
d 
he
ter
oz
yg
ou
s 
de
fec
ts 
N=
12
26
6,2
72
,27
6,2
83
,28
4,3
05
 
 
Chapter 5  
102 
 
All other four patients with heterozygous NRXN1 deletions were severely intellectually 
disabled without specific further anomalies. Their phenotype resembled the patient reported 
with a compound heterozygous defect in this gene.308 Except for patient N4, speech 
impairment was severe compared to a rather mild motor delay. Because of the severe 
phenotype in the patients in contrast to the normal or only mildly impaired intellectual function 
in the respective carrier parent, a defect of the second allele was suspected in the patients, 
but not found. 
CNTNAP2. Most of the clinical aspects and the severity of intellectual disability in the 
herewith reported patients with heterozygous CNTNAP2 defects resembled those observed 
in patients with biallelic defects in CNTNAP2 reported before (Table 6). Two of the patients 
(C1, C3) showed language and motor regression correlating with onset of epilepsy. All others 
showed lacking or severely impaired speech development. However, in contrast to the 
published patients with recessive defects and normal or only mildly delayed motor 
development,184,308 all but one patients in this study also showed severe motor retardation. 
We could not identify a defect on the second allele in any of the novel patients.  In most of 
the families the defect was inherited from a healthy parent. Despite a significantly higher 
frequency (p<0.01, Fisher’s exact test) of two truncating mutations in our cohort of 99 
severely to profoundly intellectually disabled patients compared to no truncating mutation in 
942 normal controls266 definite proof that the respective mutation is fully responsible for the 
phenotype is so far lacking. This also applies to the other identified defects in CNTNAP2 or 
NRXN1.  
Congenital malformations as described in patients C1 or C5 (Table 6) have not yet 
been reported in any other patient with a CNTNAP2 defect. Furthermore, the fact that the 
expression of the gene is restricted to the nervous system297 does not explain these 
anomalies. Therefore, another genetic cause for these malformations might exist. Thus it is 
difficult to define if the intellectual disability is associated with the CNTNAP2 mutation at all in 
these patients. Other factors like premature complicated birth in patient C6 might contribute 
to impaired intellectual function. C3 and C4 carried the same splice site mutation and both 
showed a similar phenotype with severe intellectual disability and seizures, C3 also with 
breathing anomalies. In a parallel research project, a mutation in the MEF2C gene was 
identified in patient C4 and shown to be capable of causing all of her symptoms.75 Therefore, 
it remains unclear if this splice mutation has a pathogenic effect at all, or only a mild effect 
that is masked by the severe consequences of the MEF2C mutation. The fact that this 
variant is supposed to lead to an in-frame loss of a single exon with a possibly milder effect 
than more deleterious defects supports the idea of no or only minor relevance of this splice 
mutation. Regarding the relatively high frequency of the splice site mutation in two families 
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and one control, a founder effect might be considered, however, common regional 
background in these persons is not obvious. 
Expanding the observations from previous studies we now found that heterozygous defects 
in CNTNAP2 or NRXN1 can also be seen in association with severe intellectual disability. 
Possible explanations might be: 1. No pathogenic relevance of the identified defect. This 
might indeed be the case for those patients with a “mild mutation” such as the splice-site 
mutation in CNTNAP2, or for patients with an atypical phenotype or congenital 
malformations. In those, the true causative defect might not be detected yet. However, 
published data and our data together still support a pathogenic role for both genes in 
neurodevelopmental disorders. 2. Inability to identify a defect on the second allele in spite of 
extensive screening for mutations and/or deletions. However, mutations in regulatory 
elements or in additional alternative isoforms cannot be excluded in any case. 3. A larger 
phenotypic variability associated with heterozygous defects in each gene. The finding of 
homozygous or compound heterozygous defects in previous patients with severe 
phenotypes184,285,308 indicates the existence of second hits or additional major contributors. 
These might not necessarily be affecting the same gene. Only recently, a two-hit model for 
severe developmental delay in patients with a recurrent 16p12.1 microdeletion was 
postulated.45 This might also be the case for microdeletions or even point mutations within a 
single gene as already reported for digenic inheritance in specific ciliopathies like Bardet-
Biedl syndrome.48 In four of our patients additional de novo or parentally inherited CNVs were 
identified (see Tables 2 and 3), however, the significance of these CNVs is unclear. The 
possible functional synaptic link between CNTNAP2 and NRXN1184,285,308 prompted us to 
screen CNTNAP2 in patients with NRXN1 defects and vice versa, however, without any 
mutation detected. 
 
CONCLUSION 
We found heterozygous defects in CNTNAP2 and NRXN1 in patients with severe intellectual 
disability, therefore expanding the clinical spectrum associated with monoallelic defects in 
either gene. This large variability implicates difficulties for genetic counseling in such families. 
To explain the larger phenotypic variability and severity in some patients we suggest a 
contribution of major additional genetic factors. To identify these possible contributors and 
modifiers will be a great challenge for the near future.  
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SUMMARY 
Intellectual disability (ID) is clinically and genetically highly heterogeneous, and the 
underlying genes are only incompletely identified so far. Understanding individual ID gene 
function and connecting genes and proteins in common functional networks and complexes 
will be a prerequisite to better understand the mechanisms of cognitive function and 
dysfunction and to possibly develop future therapeutic interventions. 
To facilitate both disease gene prediction as well as functional prediction, we now 
established a curated list of all known, highly reliable ID genes and introduced them into a 
database that is supplemented with many other datasets. We furthermore established a 
classification of ID genes based on the clinical manifestation of the associated disorders and 
analyzed whether and how the genes in the ID classes related to clinical and biologic 
features such as inheritance, expression, synaptic localization or haploinsufficiency.  
 
INTRODUCTION 
Intellectual disability (ID) affects 2%-3% of the population in western countries and is 
characterized by significant limitations in both intellectual functioning and adaptive behavior 
that begins before the age of 18 years and is reflected in an IQ below 70.1,2 ID is clinically 
and genetically extremely heterogeneous. It can occur isolated in non-syndromic ID or in the 
context of syndromes with additional specific features such as malformations or other 
anomalies, specific biochemical findings, or a distinct facial phenotype. Though an increasing 
number of underlying genetic alterations for ID has been identified, the etiology still remains 
unsolved in many patients.4,14 
Next to chromosomal aberrations and to some complex causes, that are yet poorly 
understood, a large fraction of ID disorders is supposed to be based on monogenic 
defects.317 These are assumed to be highly heterogeneous. In contrast to chromosomal 
aberrations, that can now reliably be detected with molecular karyotyping,10,15,70 the 
systematic and large-scale detection and identification of disease associated genes and of 
point mutations remains still challenging and probably contributes to the still high proportion 
of patients with unclear cause of ID. Due to the advances in disease gene identification over 
the past decade, more than 400 genes involved in ID have been identified.3 Estimations, 
based on the number of known X-chromosomal ID genes, assume a total of 1500 to 2000 ID-
genes.2,3 
Since recently, next-generation-sequencing (NGS) technologies provide for the first 
time a possibility to systematically screen for the underlying mutations, both in X-linked 
recessive (Kalscheuer et al., Next-generation sequencing in 248 families with X-linked 
intellectual disability; Abstract #84, Presented at the 12th International Congress of Human 
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Genetics/61st Annual Meeting of The American Society of Human Genetics, October 13th, 
2011, Montreal, Canada) and autosomal recessive ID63 as well as in sporadic ID by 
identifying de novo mutations.34,35,42 NGS can be utilized for the diagnostic detection of 
mutations in known ID genes as well as for the identification of novel ID genes. 
However, the technical advance is accompanied by several challenges. Mutations in 
novel candidate genes have to be confirmed, either by finding more patients, or by proving a 
pathogenic relevance of the mutation or the candidate gene functionally. In order to be able 
to predict ID genes, we first have to understand the specifics of an ID gene. This we can best 
deduce from the features of the currently known ID genes. Furthermore, molecular networks 
have to be established to provide the basis for the long-term creation of therapeutic 
intervention which will rather target central points in pathways than single genes.  
Linking ID genes in common molecular or functional pathways indicates a general 
regulatory role of these networks in cognitive function and dysfunction2,318‐321 and supports the 
idea that similar phenotypes are caused be defects in functionally related genes.178 
Examples for such networks are “rasopathies”,179 “ciliopathies”, “cohesinopathies” or 
“channelopathies”180, all comprising a group of identical or overlapping clinical phenotypes 
caused by defects in genes belonging to the same pathway or biological process.  
To cope with the arising challenges and to further identify and delineate the complex 
networks of cognitive function and dysfunction, a systematic, large-scale and collaborative 
interdisciplinary approach is required. 
Here we present a comprehensive inventory of all known ID associated genes 
compiled into a database together with available datasets on functional, molecular and 
clinical properties. These highly reliable disease genes are classified according to their 
phenotypic outcome when mutated. By investigating correlations among molecular, 
functional, and clinical datasets, patterns for future disease gene prediction and delineation 
of networks and pathways are established. 
 
METHODS 
Gene list 
A list of genes in which mutations are sufficient to cause ID (ID genes) was compiled from 
primary and secondary257 literature and public databases like OMIM 
(http://www.ncbi.nlm.nih.gov/omim/), using text-mining and search terms such as “mental 
retardation”, “intellectual disability”, “cognitive disability”, or “developmental delay”. 
This list has been subsequently manually curated in order to comprise only genes 
with reliable association to ID. Reasons to exclude genes were: 1. Low evidence, indicated 
by only a single patient with a mutation in a particular gene, by gene-disrupting translocations 
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or deletions but no mutational confirmation of the candidate gene in other patients, or by 
clinical description of the disorder without genetic testing or confirmation. 2. Pure 
neurodegenerative manifestation, indicated by secondary onset of intellectual disability with 
regression of initial normal abilities, or by a progressive disease course with deterioration of 
cognitive abilities. 3. Very early lethality, thus precluding proper assessment of psychomotor 
development. 4. Treatability, indicated by avoidance of decline in cognitive ability by 
substitution of certain factors, e.g. consequences of hypothyroidism which can be avoided by 
thyroid hormone substitution. 5. Neurologic phenotype without clear indication of cognitive 
impairment. 
 
Phenotypic Classification  
All high confident ID genes and their ID associated disease phenotypes were classified into 
nine main classes, according to the occurrence of non-syndromic or syndromic ID with or 
without congenital malformations (syndromic and non-syndromic groups, x-axis) and 
according to character, severity, and penetrance of ID (classic severe, mild, and non-classic 
groups, y-axis) (figure 1). 
For the phenotypic classification clinical information from the respective entries in 
Gene reviews (http://www.ncbi.nlm.nih.gov/sites/GeneTests/review?db=GeneTests) and/or 
OMIM (http://www.ncbi.nlm.nih.gov/omim) were used. Where necessary, information from 
primary literature was consulted. In case of genetically heterogeneous disorders only gene-
specific clinical information was used for the respective phenotype classification.  
The group of “classic” ID (classes 1-6) comprises ID disorders characterized by 
primary ID that is stable and without obvious signs of regression or degeneration. They are 
further distinguished into the classic severe group (CS) (classes 1-3), characterized by 
moderate to profound ID with full penetrance and in the classic-mild-to-moderate-group (CM) 
(classes 4-6) with either very variable ID or ID in the mild/borderline range. The “non-classic” 
ID  group (NC) (classes 7-9) comprises ID disorders which are predominantly characterized 
by non-ID clinical features and in which ID occurs only in a low frequency or disorders in 
which ID is atypical in its manifestation, for example progressive. Regarding class 8 this 
resulted in a splitting into 8a for rare ID and 8b for atypical course of ID. 
The syndromic classes (1, 2, 4, 5, 7, 8) contain disorders that show recognizable or 
specific phenotypes such as malformations, facial dysmorphism or specific 
biochemical/metabolic anomalies. In syndromic classes 1, 4, and 7, structural anomalies of 
limbs, brain or other organs are reported (SWSM, syndromic with structural malformations), 
in syndromic classes 2, 5, and 8 ID is accompanied by a specific syndromic feature but not 
by structural malformations (SWOSM, syndromic without structural malformation). The non-
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syndromic group (NS) comprises classes 3, 6, and 9 and includes ID disorders without any 
additional recognizable phenotype.  
The phenotypic classification was done by the same clinical expert and the main 
classes were revised independently by a second clinician. Discrepancies were discussed 
and jointly agreed on. 
 
 
                                      SWSM                                          SWOSM                                              NS 
 
 
CS 
 
 
 
 
 
CM 
 
 
 
 
 
 
 
NC 
1 
classic ID, moderate to 
severe, fully penetrant 
 
 syndromic with 
organic/brain/limb 
anomalies or 
malformations 
2
classic ID, moderate to 
severe, fully penetrant 
 
 syndromic without 
structural malformations 
3 
classic ID, moderate to 
severe, fully penetrant 
 
 non-syndromic 
 
 
4 
classic ID, either 
mild/borderline to moderate 
or very variable 
 
 syndromic with 
organic/brain/limb 
anomalies or 
malformations 
5
classic ID, either 
mild/borderline to moderate 
or very variable 
 
 syndromic without 
structural malformations 
 
 
6 
classic ID, either 
mild/borderline to moderate 
or very variable 
 
 non-syndromic 
7 
non-classic ID, (either 
atypical or) only rare or 
minor aspect 
 
 syndromic with 
organic/brain/limb 
anomalies or 
malformations 
 
 
8a
non-classic ID, only rare or 
minor aspect  
 syndromic without 
structural malformations 
 
9 
non-classic ID, (either 
atypical or) only rare or 
minor aspect 
 
 non-syndromic 
 
 
 
8b
non-classic ID, atypical 
manifestation 
(degenerative/progressive) 
 syndromic without 
structural malformations 
 
 
Figure 1  Definition of a novel ID classification scheme: Nine individual clinical classes 
organized in six groups.  
The SWSM group contains disorders that are syndromic with structural malformations and comprises 
classes 1, 4, and 7; the SWOSM group contains disorders that are syndromic without structural 
malformations and are included in classes 2, 5, and 8; the NS group contains non-syndromic 
disorders, that are included in classes 3, 6, and 9. The CS group contains disorders with classic 
severe manifestation of ID and comprises classes 1, 2, and 3; the CM group includes disorders with 
classic mild to moderate or variable manifestation of ID and comprises classes 4, 5, and 6; the NC 
group contains disorders with a rare or atypical manifestation of ID and includes classes 7, 8, and 9.  
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In addition to the classification system with nine main classes we established an additional 
classification system for ID-accompanying phenotypes. These comprise 25 additional 
features describing further symptoms and anomalies of various organ systems (table 1). 
Letters A-X indicate the presence of specific clinical features and were added when the 
(estimated) reported frequency of the respective symptom was around 20 to 30%. Letter Z 
indicates limited clinical data, usually due to a small number of affected patients.  
 
Table 1  Summary of additional phenotypic information 
Letter feature(s) or organ systems 
A short stature/growth failure; AA, short stature syndrome, Aa (acquired), Ac (congenital) 
B Microcephaly; BB, microcephaly syndrome; Ba (acquired), Bc (congenital) 
C early lethality or shortened life span 
E epilepsy/seizures 
F overgrowth/tall stature and/or macrocephaly 
G developmental regression and/or disease progression 
H neurological symptoms, e.g. spasticity, ataxia, severe hypotonia, etc. 
I cancer, tumors 
J immunological anomalies (for example susceptibility to infections) 
K endocrine anomalies 
L 
brain malformations or (specific) brain anomalies; structural malformations (in groups 
1,4,7) as well as non-structural MRI anomalies (e.g. white matter anomalies, 
myelination anomalies in groups 2,5,8) 
M metabolic, mitochondrial 
N obesity 
O vegetative symptoms (breathing anomalies, obstipation, sweating, sleeping, etc.) 
P behavioral anomalies, autism, autistic behavior, stereotypies, aggression 
Q muscular anomalies, including cardiomyopathies 
R blood anomalies, e.g. anemia or coagulation defects 
S skin, hair, nails 
T eye anomalies (structural malformations, but also minor anomalies like myopia) 
U 
bone/skeletal anomalies; Ua: limb malformations/anomalies (syndactyly, polydactyly, 
split hand/foot, etc.); Ub: skeletal/skull malformation/anomalies (fused vertebras, 
craniosynostosis, etc.); Uc: cleft palate, midline clefts 
V congenital heart defects, cardiac malformations 
W urogenital anomalies and/or renal malformations/disease 
X other malformations 
Z only few single patients (<5) or only 1 family, limited clinical data 
 
SysID database 
All manually curated ID genes and their classification were implemented into a MYSQL 
database and supplemented with a variety of additional information and details on different 
levels. Gene related details include a short gene description, the official gene number, 
synonyms, and chromosomal location. Gene related disease information is given by the 
associated diseases, both ID- and non-ID-related ones, if applicable, by MIM numbers of 
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those (http://www.ncbi.nlm.nih.gov/omim/), and by mode of inheritance. Further clinical 
information is provided either by a non-standardized summary of characteristic symptoms or 
by referring to PMIDs from GeneTest review entries 
(http://www.ncbi.nlm.nih.gov/sites/GeneTests/review?db=GeneTests) or to a reference from 
primary literature. 
 
Datasets for enrichment analyses 
Datasets used for enrichment analyses were: 1) A dataset of 1458 human postsynaptic 
density (hPSD) proteins that were identified from human neocortex by mass spectrometry322 
and that constitute 7% of the human genome. 2) A dataset of 299 haploinsufficiency genes 
(HI) that were identified by text-searching and database-mining strategies323 and which 
constitute 1,5% of the human genome. 3) A microarray dataset of human gene expression 
data (GNF atlas) containing expression profiles from 84 different human tissues and cell 
types.324 The significance of the gene expression was statistically tested using a Wilcoxon 
two sample test (p-value >0.05).  
 
Enrichment analyses 
All analyses were done on an initial set of 388 ID genes that were reported and classified in 
2010. Enrichment analyses were performed for the above mentioned hPSD and HI datasets 
as well as for inheritance patterns. Two different backgrounds were used: 1) The human 
genome, containing ~20500 genes, and 2) the background of all 388 listed ID genes. The 
human genome background was used to determine the characteristic features of ID genes in 
general. The 388 ID gene background was used to determine features of specific ID gene 
classes among all ID genes. To determine enrichment of inheritance patterns, only the 388 
gene background was used. 
The genes from each of the six groups (CS, CM, NC, SWSM, SWOSM, NS) or each 
of the nine individual classes (class 1-9) were mapped to the respective dataset, and the 
mapping frequency was determined (number of mapped genes/number of genes in group or 
class). After establishing the frequency of genes from the respective dataset to the 
background data (either: all genes from the dataset/human genome background of ~20500 
genes, or: mapped genes from the dataset/background of 388 genes from the list), the fold 
enrichment was calculated (frequency of mapped genes in groups or classes/frequency of 
mapped genes in the background). Uncorrected P-values were determined with a chi-square 
test. 
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Expression analyses 
Expression levels for various tissues from the GNF atlas324 (Genomics Institute of the 
Novartis Research Foundation) were mapped to the genes from the gene list. Subsequently, 
the average expression level for each tissue was determined for each of the six groups and 
the nine individual classes and compared to the mean expression level of either the human 
genome background or the background of the 388 gene list. The significance of gene 
expression was statistically tested using the Wilcoxon two sample test (p-value < 0.05). 
 
RESULTS 
Classes 
In May 2013 the list contained 518 genes (data not shown) that were distributed over nine 
main classes according to their phenotypes (table 2). Table 3 shows the distribution for the 
earlier 388 gene set (supplement) that was used for the enrichment analyses.  
 
Table 2  current set of 518 genes 
 SWSM - 150 - 28% SWOSM - 333 - 62% NS - 56 - 10% 
CS - 150 - 27% class 1 - 55 - 10% class 2 - 89 - 15% class 3 - 10 - 2% 
CM - 266 - 46% class 4 - 80 - 14%  class 5 - 147 - 25% class 6 - 46 - 8% 
NC - 150 - 27% class 7 - 26 - 5% class 8 - 123 - 21% 
subclass 8a - 50 
subclass 8b - 79 
class 9 - 1 - 0.2% 
 
Of the 518 genes from current gene list, 459 belonged to only one clinical ID class, while 55 
genes belonged to two different classes, and two genes to three or four classes, respectively. 
Additional to the classified ID phenotype, mutations in 93 of the 518 genes (18%) also cause 
non-ID disorders with a different OMIM disease number, e.g. a muscular or skeletal disorder 
without ID. 
 
Table 3  earlier set of 388 genes  
 SWSM - 106 - 26% SWOSM - 256 - 63% NS - 45 - 11% 
CS - 102 - 24% class 1 - 36 - 8% class 2 - 60 - 14% class 3 - 10 - 2% 
CM - 200 - 47% class 4 - 59 - 13% class 5 - 112 - 26% class 6 - 35 - 8% 
NC - 126 - 29% class 7 - 21 - 5% class 8 - 104 - 24% 
class 8a - 46 
class 8b - 64 
class 9 - 1 - 0.2% 
 
Inheritance 
The 388 ID gene set (2010) comprises 227 genes (59%) with autosomal recessive 
mutations, 89 X-linked genes (23%), 80 genes with autosomal dominant mutations (21%), 
and nine mitochondrially encoded ID genes (2.3%).  
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The 518 ID gene set from 2013 included 306 genes (59%) with autosomal recessive 
mutations, 102 X-linked genes (20%), 125 genes with autosomal dominant mutations (24%), 
and nine mitochondrially encoded ID genes (1.7%). 
 
Enrichment analyses 
Enrichment and distribution of post-synaptic density localization within ID genes 
ID gene enrichment analysis for a set of 1458 post-synaptic density genes322 was performed 
against the background of the human genome, containing ~20500 genes. When comparing 
the CS, CM, and NC groups, they were significantly, but similarly enriched for hPSD genes. 
Differential enrichment was found among the syndromic versus non-syndromic groups. Non-
syndromic (NS) genes showed 4.1 fold enrichment compared to only 2.4 fold enrichment of 
the syndromic genes. Interestingly, among the syndromic genes, the SWSM genes did not 
show enrichment for hPSD genes at all. Accordingly, among the individual classes, class 3 
and class 6 showed highest enrichment, 5.6 fold and 3.6 fold, respectively. Classes 1, 2, 5, 
and 8 were lower, but still significantly enriched for hPSD genes, too (table 4). 
Performing the enrichment analysis against the background of 388 ID genes did, due 
to less statistic power, not result in significant differences of hPSD enrichments between 
groups or classes of ID genes (data not shown). 
 
Enrichment and distribution of haploinsufficiency within ID genes 
ID gene enrichment analysis for a set of 299 haploinsufficiency genes323 was performed 
against the background of the human genome, containing ~20500 genes. Both classic (CS, 
CM) and non-classic (NC) groups showed significant enrichment for HI genes. Regarding 
syndromic (SWSM, SWOSM) and non-syndromic groups (NS), significant enrichment was 
found among all groups, too. However, with a very high 12.3 fold enrichment for HI genes in 
the SWSM group, and a 7.6 fold enrichment among syndromic groups as a whole, 
haploinsufficiency is less enriched among non-syndromic groups (4.6 fold). Accordingly, 
class 1 (11.4 fold), class 4 (11.6 fold), and class 7 (13.1 fold) showed highest enrichment for 
HI ID genes. Also class 5 (8 fold) and class 8a (11.9 fold) showed significant enrichment 
(table 4). 
Performing the enrichment analyses against the background of all ID genes did not 
result in significant enrichment for HI genes in any of the groups or classes.  
 
Enrichment for inheritance patterns within ID genes 
ID gene enrichment analysis was performed with three major inheritances modes (autosomal 
recessive, autosomal dominant, X-linked (excluding X-linked dominant)) against the 
background of the 388 ID gene set.  
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Table 4  Enrichment analyses for hPSD, HI, and inheritance 
 classic and non-classic groups 
 
hPSD 
HI 
aut dom 
aut rec 
x-linked 
CS – 102
21, 2.9 fold, p = 4.04e-07 
7, 4.7 fold, p = 4.30e-05 
21, 1 fold, p = 1 
60, 1 fold, p = 1 
25, 1.2 fold, p = 0.4 
 
hPSD 
HI 
aut dom 
aut rec 
x-linked 
CM – 200
37, 2.6 fold, p = 1.412e-09 
25, 8.6 fold, p = 2.08e-34 
42, 1 fold, p = 1 
114, 1 fold, p = 0.8 
50, 1.2 fold, p = 0.2 
 
hPSD 
HI 
aut dom 
aut rec 
x-linked 
NC – 126
20, 2.23 fold, p = 0.0003 
14, 7.6 fold, p = 2.44e-17 
25, 1 fold, p = 1 
75, 1 fold, p = 0.9 
16, 0.6 fold, p = 0.7 
 syndromic and non-syndromic groups 
 
hPSD 
HI 
aut dom 
aut rec 
x-linked 
SWSM – 106 
12, 1.6 fold, p = 0.14 
19, 12.3 fold, p = 1.7e-40 
41, 1.9 fold, p = 0.0002 
46, 0.7 fold, p = 0.008 
17, 0.8fold, p = 0.4 
SWOSM – 256
50, 2.8 fold, p = 7.06e-14 
21, 5.6 fold, p = 2.93e-17 
36, 0.7 fold, p = 0.044 
177, 1.2 fold, p = 0.008 
43, 0.8 fold, p = 0.3 
NS – 45 
13, 4.1 fold, p = 7.9e-08 
3, 4.6 fold, p = 0.023 
8, 0.9 fold, p = 0.8 
9, 0.3 fold, p = 2e-06 
30, 3.3 fold, p = 4.3e-11 
 individual classes 
 
hPSD 
HI 
aut dom 
aut rec 
x-linked 
C1 – 36 
8, 3.1 fold, p = 0.001 
6, 11.4 fold, p = 7.5e-12 
11, 1.5 fold, p = 0.23 
16, 0.8 fold, p = 0.15 
9, 1.2 fold, p = 0.66 
C2 – 60
10, 2.3 fold, p = 0.009 
1, 1.1 fold, p = 1 
9, 0.7 fold, p = 0.4 
42, 1.2 fold, p = 0.12 
13, 1.1 fold, p = 0.95 
C3 – 10 
4, 5.6 fold, p = 0.0006 
0, 0 fold, p = 1 
1, 0.5 fold, p = 0.67 
2, 0.3 fold, p = 0.035 
7, 3.4 fold, p = 0.0007 
 
hPSD 
HI 
aut dom 
aut rec 
x-linked 
C4 - 59 
6, 1.4 fold, p = 0.51 
10, 11.6 fold, p = 2.7e-20 
19, 1.6 fold, p = 0.07 
30, 0.9 fold, p = 0.33 
10, 0.8 fold, p = 0.66 
C5 - 112
23, 2.9 fold, p = 1.14e-07 
13, 8 fold, p = 5.1e-17 
18, 0.8 fold, p = 0.4 
77, 1.2 fold, p = 0.06 
21, 0.9 fold, p = 0.81 
C6 - 35 
9, 3.6 fold, p = 8.12e-05 
3, 5.9 fold, p = 0.0052 
7, 1 fold, p = 1 
7, 0.3 fold, p = 2.5e-05 
23, 3.2 fold, p = 6.6e-09 
 
hPSD 
HI 
aut dom 
aut rec 
x-linked 
C7 - 21 
1, 0.7fold, p = 1 
4, 13.1fold, p = 7.7e-09 
21, 3.2fold, p = 3.9e-06 
4, 0.3fold, p = 0.0009 
1, 0.2fold, p = 0.14 
C8 - 104
19, 2.6fold, p = 2.57e-05 
9, 5.9fold, p = 1.8e-08 
11, 0.5fold, p = 0.03 
71, 1.2fold, p = 0.09 
14, 0.7fold, p = 0.15 
C9 - 1 
0, 0fold, p = 1 
1, 68.5fold, p = 5.3e-05 
0, 0fold, p = 1 
0, 0fold, p = 0. 9 
1, 4.9fold, p = 0.5 
Result of enrichment analyses for the six major groups and the nine individual classes of ID genes 
against the human genome (~20500 genes). Additional to inheritance modes from the ID catalogue 
database (in green), a dataset of 1458 hPSD genes322 (in blue), and a dataset of 299 HI genes323 (in 
red) were used; behind the group or class the number of ID genes within the group or class in given; 
order of results: number of mapped genes, fold enrichment, uncorrected p-value with chi-square test; 
bold letters indicate results with significant p-values. 
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No significant enrichment of inheritance patterns was found in the CS, CM, and NC groups. 
The SWSM group showed significant enrichment for autosomal dominant inheritance 
(1.9 fold), while it was depleted for autosomal recessive inheritance (0.7 fold). The SWOSM 
group was significantly enriched for autosomal recessive inheritance (1.2 fold), while it was 
significantly depleted for autosomal dominant inheritance (0.7 fold). The non-syndromic 
group was highly enriched for X-linked inheritance (3.3 fold), while it was significantly 
depleted for autosomal recessive inheritance (0.3 fold) (table 4). 
Regarding individual classes, classes 3 and 6 were significantly enriched for X-linked 
inheritance (3.5 fold and 3.2 fold respectively), and class 7 was significantly enriched for 
autosomal dominant inheritance (3.2 fold). Classes 3, 6, and 7 were significantly depleted for 
autosomal recessive inheritance, and class 8, in particular its subclass 8b, was significantly 
depleted for autosomal dominant inheritance (table 4). 
 
Expression patterns 
When analyzing expression levels of ID genes against the whole genome background, the 
classic severe group showed significantly enriched expression patterns for different brain 
regions. The genes from the classic mild to moderate group did not show significantly 
enriched expression levels, and the non-classic group showed significantly increased 
expression in several abdominal organs as well as in various blood and immune cells (table 
5).   
While the SWSM group did not show significantly increased expression levels, genes 
from the SWOSM group were significantly enriched in blood and immune cells, abdominal 
organs, and brain regions. The NS group showed significantly increased expression 
exclusively in several brain regions. 
Regarding individual classes, class 2 and class 6 showed significantly enriched 
expression in various brain regions, while class 1 showed a wide and heterogeneous 
expression pattern in brain and organs and class 8b in brain regions, organs and blood and 
immune cells. Class 5 showed significantly increased expression in liver and CD34+ cells. 
When comparing the classes against the background of all 388 ID genes, the CS 
group showed significantly increased expression in fetal brain, whereas CM and NC groups 
showed no significant expression enrichment. SWSM, SWOSM, and NS groups showed no 
significant expression pattern, either.  
Regarding individual classes, class 1 genes showed significantly higher expression in 
various brain regions and tissues (fetal brain, dorsal root ganglion, trigeminal ganglion, 
prefrontal cortex, ciliary ganglion, globus pallidus, skin, cerebellum, atrio ventricular node, 
cerebellum peduncles, retina, adrenal cortex, superior cervical ganglion, medulla oblongata, 
colorectal carcinoma, subthalamic nucleus, occipital lobe, cingulate cortex, temporal lobe, 
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ovary, spinal cord, caudate nucleus, appendix, and olfactory bulb). Class 4 genes showed 
significantly lower expression in several blood cell lines (BDCA4+ dendritic cells, CD105+ 
endothelial, X721_B lymphoblasts, CD34+, CD56+ NK cells, CD33+ myeloid, and CD14+ 
monocytes). Class 8b genes showed significant increased expression in X721_B 
lymphoblasts, CD33+ myeloid, BDCA4+ dendritic cells, CD14+ monocytes, CD56+ NK cells, 
CD34+, CD105+ endothelial, CD8+ T-cells, CD4+ T-cells, Cd19+ B-cells (neg. sel.), 
leukemia promyelocytic HL-60, colon, small intestine, thyroid, lymph node, adrenal gland, 
heart, lymphoma burkitts (Daudi), and thymus). 
 
Table 5  Significant enrichment of expression in 84 different human tissues and cell 
types against the background of the human genome (13100 genes) 
classic and non-classic groups 
CS – 102 (92)
fetal brain, amygdala, whole brain, prefrontal cortex, occipital lobe, globus pallidus, medulla oblongata, parietal 
lobe, temporal lobe, cingulate cortex, subthalamic nucleus, pineal gland (night), cerebellum, caudate nucleus, 
pineal gland (day), cerebellum peduncles, hypothalamus, thalamus, pons, retina 
CM – 200 (175)
no significant enrichment of expression in specific tissues 
NC – 126 (111)
liver, CD33+ myeloid, X721_B lymphoblasts, colon, CD105+ endothelial, CD34+, thyroid, CD14+ monocytes, 
kidney, pineal gland (night), BDCA4+ dendritic cells, small intestine, CD56+ NK cells, bronchial epithelial cells, 
pineal gland (day), fetal liver, CD8+ T cells and leukemia promyelocytic-HL-60 
syndromic and non-syndromic groups
SWSM – 106 (92) 
no significant expression 
SWOSM – 256 (225)
liver, CD34+, X721_B lymphoblasts, pineal gland 
(night), leukemia promyelocytic-HL-60, CD105+ 
endothelial, leukemia chronic myelogenous K-562, 
kidney, pineal gland (day), BDCA4+ dendritic cells, 
whole brain, thyroid, lymphoma burkitts (Daudi), 
amygdala, fetal liver, leukemia, lymphoblastic 
(MOLT-4), CD56+ NK cells, hypothalamus, CD33+ 
myeloid, adipocyte, prefrontal cortex, occipital 
lobe, bronchial epithelial cells, CD19+ B cells (neg. 
sel.), caudate nucleus, small intestine, thalamus, 
CD14+ monocytes, colon, spinal cord 
NS – 45 (38)
fetal brain, prefrontal 
cortex, amygdala, 
occipital lobe, 
cingulate cortex 
individual classes 
C1 – 36 (35)
fetal brain, prefrontal cortex, cerebellum, 
occipital lobe, globus pallidus, amygdala, 
cerebellum peduncles, dorsal root 
ganglion, medulla oblongata, whole brain, 
subthalamic nucleus, retina, caudate 
nucleus, temporal lobe, trigeminal 
ganglion, spinal cord, cingulate cortex, 
olfactory bulb, hypothalamus, colorectal 
adenocarcinoma, ciliary ganglion, parietal 
lobe, colon, pineal gland (night), pineal 
gland (day), thalamus, atrio-ventricular 
node, pons, skin, ovary, adrenal cortex, 
superior cervical ganglion, uterus, adrenal 
gland, skeletal muscle, adipocyte, uterus 
corpus, prostate, trachea, appendix, 
C2 – 60 (51)
amygdala, whole brain, occipital lobe 
C3 – 10 (8)
no significant 
expression 
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kidney, small intestine, testis leydig cell, 
pituary  
C4 – 59 (47)
no significant expression 
C5 – 112 (103)
liver, CD34+ 
C6 – 35 (30)
prefrontal cortex, fetal 
brain, cingulate 
cortex, amygdala, 
occipital lobe, 
subthalamic nucleus, 
medulla oblongata,  
temporal lobe 
 
C7 – 21 (20)
no significant expression 
 
C8 - 104
8a (42): no significant expression 
8b (53): X721_B-lymphoblasts, CD34+, CD33+ 
myeloid, BDCA4+ dendritic cells, CD105+ 
endothelial, leukemia promyelocytic-HL-60, CD56+ 
K cells, CD14+ monocytes, thyroid, colon, kidney, 
CD8+ T-cells, liver, lymphoma burkitts (Daudi), 
adrenal gland, small intestine, CD4+ T-cells, 
CD19+ B-cells (neg. sel.), fetal liver, pancreatic 
islet, pineal gland (night), leukemia lymphoblastic 
(MOLT-4), bronchial epithelial cells, lymphoma 
burkitts (Raji), heart, adipocyte, pineal gland (day), 
fetal thyroid, lymph node, leukemia-chronic 
myelogenous K-562, thymus, whole blood, tongue, 
prostate, CD71+ early erythroid, hypothalamus, 
salivary gland, colorectal adenocarcinoma, whole 
brain, adrenal cortex 
C9 – 1 (0)
 
numbers in brackets show number of genes with available expression data; tissues are given in the 
order of increasing p-values (all given with a p-value <0.05) 
 
DISCUSSION 
The need for an ID gene catalogue and a database 
To cope with the arising challenges resulting from NGS technologies and to identify and 
characterize the complex networks of cognitive function and dysfunction, a systematic, large-
scale and collaborative interdisciplinary approach is required. 
In the past, several attempts have been undertaken to create comprehensive lists of 
ID genes. In 2003, Inlow and Restifo257 collected 282 ID associated genes from the OMIM 
database and through literature search. They also developed a biological functions 
classification scheme including information on metabolic pathways, signaling pathways, 
transcription and other aspects of neuronal and glial function. Furthermore, they investigated 
the conservation of human ID genes in Drosophila melanogaster.257 Betancur325 and Kou et 
al.96 developed curated lists of 114 genes for autism spectrum disorders (ASD) and 223 ID 
genes, respectively. The ASD gene list is reported to be exhaustive, the overlapping ID gene 
list to be diverse but not exhaustive. These lists were used to prioritize genes and pathways 
for ASD and ID.96  
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All of these lists do either contain an incomplete inventory of ID genes or did not fulfill 
our requirements for reliability of data e.g. via independent evidence. We therefore aimed at 
an own, systematic catalog containing all genes reliably underlying ID, thus not including 
genes and disorders with clinically or genetically low evidence, treatable metabolic 
conditions, clearly neurodegenerative disorders or disorders with early lethality.   
This list is integrated into a database, supplemented with various information on 
associated disorders and inheritance patterns, and connected to various datasets from both 
human and animal models. After publication the database will be public. 
The list and the database are supposed to meet different aims: 1) To provide a 
repository of genes, mutations in which are sufficient to cause ID. The catalog is supposed to 
be regularly updated, manually curated, and accessible to others. 2) This gene catalog 
provides the basis for large-scale functional screens of ID genes in Drosophila melanogaster 
in order to gain more insight into neuronal function and dysfunction. A first approach has 
examined visual behavior, photoreceptor physiology and multiparametric morphological 
characteristics, resulting in a high number of novel eye phenotypes and the identification of 
highly connected functional modules.326 3) Data from these screens is supposed to allow 
mapping of novel functional networks. This might be contributing to recognition of common 
themes underlying ID and to the prediction of disease genes in short-term, and to the 
establishment of therapeutic interventions in long-term. 4) The list can be used for 
diagnostics. Whole exome sequencing usually results in a large number of potential variants. 
These can be compared to the ID gene catalog in order to facilitate interpretation of results. 
As the main list does only contain highly reliable ID genes fulfilling certain criteria, for this 
purpose the secondary list with a larger number of less reliable, but potential ID genes, can 
be used additionally. 
The periodically updated catalog might also be a nice tool to reflect the changes in ID 
genetics. So far, the majority of ID genes follow an autosomal-recessive inheritance pattern, 
and also the proportion of X-linked genes is quite high. This is probably due to the fact that 
gene identification for autosomal-recessive and X-linked ID genes was facilitated by many 
recessive genes being involved in recognizable metabolic disorders and that familial ID 
allowed the usage of linkage analyses for quite some time. Autosomal-dominant genes are 
underrepresented as sporadic ID is usually caused by de novo mutations. These could not 
be systematically searched for until recently. With NGS technologies large-scale screens for 
de novo mutations have now become possible.34,35,42 It will be interesting to see if these 
advancing changes in technologies will be reflected in the proportion of inheritance modes of 
ID genes over time. When comparing the set of 388 ID genes from 2010 with the set of 518 
ID genes from May 2013, only mild changes can be seen. The fraction of autosomal 
recessive genes is unaltered (59%), probably due to the successful combination of linkage 
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analysis or homozygosity mapping with NGS technologies in consanguineous ID families. 
The number of mitochondrial genes is unaltered, and the fraction of X-linked genes slightly 
decreased from 23% to 20%. Related to their small genomic proportion there are probably 
only few X-linked and mitochondrially encoded genes remaining to be still identified. The 
impact of NGS on increasing identification of genes with de novo mutations in relation to 
other inheritance modes is not yet very obvious but potentially reflected in a mild increase 
from 21% to 24% autosomal dominant ID genes. In this regard a continuously increasing 
proportion is to be expected for the future. 
 
The rationale for a classification 
Though a definition of ID exists, there is no clear definition of what constitutes an ID disorder. 
ID disorders are not only genetically but also clinically extremely heterogeneous. During the 
last years many examples were found to support the idea of similar phenotypes being 
caused by defects in functionally related genes.178-180 We therefore aimed at a phenotypic 
classification of ID disorders using a manageable and comprehensive amount of phenotype 
classes based on clinical manifestation and severity. The idea was that these groups, 
classified according to specific phenotypic features, might mirror disruptions of certain 
molecular functions or processes.  
So far, similar attempts are limited to a description of frequency and nature of 
symptoms in ID disorders. An example is the Human Phenotype Ontology (HPO)327,328 which 
aims to establish a standardized, controlled vocabulary for phenotypic information in order to 
exploit semantic similarities for database searches for clinical diagnostics or for large-scale 
computational analysis of gene expression patterns.327 HPO uses clinical information from 
OMIM and considers frequencies but is not manually curated. Also OMIM provides an 
overview of clinical symptoms via the “clinical synopsis” function, but no data on frequencies 
is available there.   
 Our approach is the first to use manually curated data and a newly introduced 
classification system comprising nine individual classes and six higher-order overlapping 
groups according to severity and nature of ID on one hand and according to syndromic or 
non-syndromic occurrence on the other hand (figure 1). From this sorting we expect more 
reliable computational analyses compared to using a large amount of more detailed, but not 
manually curated, error-prone data.  
Of course, the classification is highly subjective and depending on the respective 
clinician. To minimize this “human” effect and to provide consistency, all genes were 
classified by the same clinician, the author of this thesis, and all entries were revised by a 
second, independent clinician. In addition, we also used information on symptoms with 
frequencies being taken into account (table 1). Also here, highly reliable, manually curated 
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data is used. Another possible objection, which however would apply to all kind of such 
classifications, is the availability and detailedness of the data underlying the classification. 
Depending on the background of the authors and the aim of the respective reports in 
literature and databases, biases might exist, and clinical information can extremely vary in 
amount and quality. To take into account limitations in clinical data for later enrichment 
analyses, we marked those entries accordingly (letter Z in additional phenotype information 
(table 1)). 
 
First enrichment patterns 
Regarding the first analyzed datasets, several patterns could already be deduced.  
In general, ID genes are enriched for hPSD genes and HI genes when compared to 
the whole genome background. Both observations were to be expected as it has been shown 
previously that a high number of brain diseases involves hPSD genes322 and as many of the 
phenotypes associated with haploinsufficiency include ID and developmental disorders.323 
Of note, patterns for haploinsufficiency, localization in the postsynaptic density, and 
inheritance could rather be found for the syndromic versus non-syndromic ID groups than for 
the the classic versus non-classic groups. Interesting patterns regarding expression data 
could be found for both classic/non-classic groups as well as for syndromic/non-syndromic 
groups. These first observations of patterns between the six higher- order groups confirm the 
rationale for the classification.  
Some major patterns were identified in the current dataset: 
1) hPSD genes are highly significantly enriched in the non-syndromic group (NS), 
while they are not enriched in the SWSM group. This is in accordance with 
significantly increased expression levels for NS genes in fetal brain and several brain 
regions. The brain specific localization and function of NS genes goes in hand with rather 
brain specific, non-syndromic manifestation of ID. In contrast, SWSM genes did not show 
significantly enriched expression patterns, and the SWOSM genes rather show a 
heterogeneous expression pattern. 
Of note, X-linked inheritance is enriched in the NS group, whereas autosomal 
recessive inheritance is significantly depleted. This might indicate a high proportion of 
synaptic genes on the X-chromosome. This was indeed discussed in a previous study 
that found 28% of X-linked ID genes to encode postsynaptic genes and 49% of X-
chromosomal PSD genes to be involved in human psychiatric disorders.329 Our data with 
20% of X-linked genes in the NS group being hPSD genes and with 46% of hPSD genes 
in the NS group being X-linked genes, confirms this observation and additionally points to 
non-syndromic ID as the associated clinical manifestation. 
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Whereas also numerous other reports noted an increasing role of genes with synaptic 
function in ID,3,4,49,77,78,317 the significance of this observation has remained 
controversial.63 Here we show that the frequency of synaptic genes amongst ID genes 
might correlate with the associated clinical phenotype and/or the inheritance mode. 
Diversity of clinical phenotypes and inheritance modes between different studies due to 
specific selection criteria for the patient cohorts might therefore explain discrepancies in 
their observations and further confirms the value of our classification system. 
2) The highest enrichment of HI genes is found in the SWSM group. This is in 
accordance with the significant enrichment of autosomal dominant inheritance (in terms 
of de novo mutations) in the SWSM group, while it is underrepresented or not enriched in 
the SWOSM and NS groups. This observation emphasizes the role of HI genes in 
disorders that affect brain and organ development.  
Of note, the SWSM group does not show any significant expression pattern, though 
specific organ or other tissue expression might have been expected due to the broad 
syndromic phenotypic spectrum. However, when looking at the individual classes, class 1 
(SWSM) indeed shows significantly high expression for a large number of brain and other 
tissues, while class 2 (SWOSM) and class 6 (NS), that are not associated with structural 
malformations, rather show brain specific expression.  
3) Autosomal-recessive inheritance is significantly enriched in the SWOSM group 
while it is significantly depleted in the SWSM and the NS groups. This indicates that 
mutations in autosomal recessive genes predominantly cause syndromic ID but without 
structural malformations. This is true for most metabolic disorders, which are indeed 
predominantly in the SWOSM group (data not shown). The expression pattern of 
SWOSM genes is very heterogeneous. Significant expression of genes in class 8b which 
contains many mitochondrial disorders (data not shown) includes several blood or tumor 
cells as well as organs that are typically affected in mitochondrial disorders: liver, heart, 
and brain.  
4) Expression in brain correlates with severity of ID. CS genes show increased 
expression in various brain regions, while CM genes show no significant expression 
pattern, and NC genes are heterogeneously expressed in organs, brain tissues, and 
blood or immune cells. Thus, the high and specific expression of CS genes in brain is 
correlating with the severity of ID.  
 
Conclusion and outlook 
The above described analyses and observations are only one part and the first step to 
predict disease genes and molecular networks in a systems biology-like approach. While it is 
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not the first attempt to systematically pool and use data on ID genes, it is the first approach 
using highly reliable, manually curated data, a novel clinical classification system and 
merging it with both publically available datasets and with systematic functional data from 
model organism screens (e.g. Oortveld et al.,326). 
First enrichment analyses in this study already show patterns that might be of help to achieve 
these goals in the near future. 
                                                                                                        Genetics of ID- an inventory  
125 
 
Supplementary table 
gene inheritance inheritance 
main 
class 
additional 
phenotypes disorder 
ABCD1 Mendelian X-linked not sure 8a, 8b L, G, K, H, M, P ADRENOLEUKODYSTROPHY 
ABHD5 Mendelian autosomal recessive 8a M, Q, S CHANARIN-DORFMAN SYNDROME 
ACOX1 Mendelian autosomal recessive 8b M, H, E, G, C, L Peroxisomal acyl-CoA oxidase deficiency 
ACSL4 Mendelian X-linked recessive 6 MENTAL RETARDATION, X-LINKED  
ACVR1 Mendelian autosomal dominant 7 A, Ub 
FIBRODYSPLASIA OSSIFICANS 
PROGRESSIVA 
ADCK3 Mendelian autosomal recessive 8b 
M, L, E, H, G, C, 
Q Primary coenzyme Q10 deficiency 
ADSL Mendelian autosomal recessive 5 M, P, E Adenylosuccinase deficiency 
AFF2 Mendelian X-linked not sure 6 P MENTAL RETARDATION, X-LINKED 
AGA Mendelian autosomal recessive 8b M, G, H, (S), (C) ASPARTYLGLUCOSAMINURIA 
AGPAT2 Mendelian autosomal recessive 8a M, Q, K 
LIPODYSTROPHY, CONGENITAL 
GENERALIZED 
AGTR2 Mendelian X-linked recessive 3 E, (P) Mental retardation, X-linked 
AHCY Mendelian autosomal recessive 5 M, H, (Q), (L) 
HYPERMETHIONINEMIA WITH S-
ADENOSYLHOMOCYSTEINE 
HYDROLASE DEFICIENCY 
AHI1 Mendelian autosomal recessive 4 H, L, O, T, W Joubert syndrome 
AK1 Mendelian autosomal recessive 8a M, R 
Hemolytic anemia due to adenylate 
kinase deficiency 
ALDH18A1 Mendelian autosomal recessive 5 A, H, S, T, (M) CUTIS LAXA 
ALDH3A2 Mendelian autosomal recessive 2 H, S, T, M, A, E SJOGREN-LARSSON SYNDROME 
ALDH5A1 Mendelian autosomal recessive 5 M, E, H, L, P 
SUCCINIC SEMIALDEHYDE 
DEHYDROGENASE DEFICIENCY 
ALG1 Mendelian autosomal recessive 2 
M, E, B, R, L, J, 
C, W, (Q) Congenital disorder of glycosylation 
ALG12 Mendelian autosomal recessive 2 
M, H, B, R, J, E, 
V Congenital disorder of glycosylation 
ALG2 Mendelian autosomal recessive 2 M, E, T Congenital disorder of glycosylation 
ALG3 Mendelian autosomal recessive 2 M, E, B, T, L Congenital disorder of glycosylation 
ALG6 Mendelian autosomal recessive 5 M, E, H, T, K Congenital disorder of glycosylation 
ALG9 Mendelian autosomal recessive 5 M, H, E, B Congenital disorder of glycosylation 
AMT Mendelian autosomal recessive 8b M, H, E, C, (G) GLYCINE ENCEPHALOPATHY 
ANO10 Mendelian autosomal recessive 8a G, L, N, Q 
SPINOCEREBELLAR ATAXIA, 
AUTOSOMAL RECESSIVE 
AP1S1 Mendelian autosomal recessive 2 (M), H, C, S, O 
MENTAL RETARDATION, 
ENTEROPATHY, DEAFNESS, 
PERIPHERAL NEUROPATHY, 
ICHTHYOSIS, AND KERATODERMA 
AP1S2 Mendelian X-linked recessive 6 P, (L) 
MENTAL RETARDATION, X-LINKED, 
SYNDROMIC 
AP3B1 Mendelian autosomal recessive 8a T, R, J Hermansky-Pudlak syndrome 
APTX Mendelian autosomal recessive 5 H, G, L 
ATAXIA, EARLY-ONSET, WITH 
OCULOMOTOR APRAXIA AND 
HYPOALBUMINEMIA 
ARFGEF2 Mendelian autosomal recessive 2 B, L, (H), (E), (J) Periventricular heterotopia  
ARHGEF6 Mendelian X-linked recessive 6 MENTAL RETARDATION, X-LINKED  
ARL13B Mendelian autosomal recessive 4 L, (T), (O) JOUBERT SYNDROME  
ARL6 Mendelian autosomal recessive 4 N, T, Ua, W, K, P Bardet-Biedl syndrome 
ARX Mendelian X-linked recessive 
1, 2, 3, 
5 E, H, L MENTAL RETARDATION, X-LINKED 
ARX Mendelian X-linked recessive 
1, 2, 3, 
5 E, H, L 
EPILEPTIC ENCEPHALOPATHY, 
EARLY INFANTILE 
ARX Mendelian X-linked recessive 
1, 2, 3, 
5 E, H, L 
PARTINGTON X-LINKED MENTAL 
RETARDATION SYNDROME 
ARX Mendelian X-linked recessive 
1, 2, 3, 
5 E, H, L 
CORPUS CALLOSUM, AGENESIS OF, 
WITH ABNORMAL GENITALIA 
ARX Mendelian X-linked recessive 
1, 2, 3, 
5 E, H, L, C Lissencephaly 
ASL Mendelian autosomal recessive 8a M, H, P, E, S 
Urea Cycle Disorders, 
ARGININOSUCCINIC ACIDURIA 
ASPA Mendelian autosomal recessive 2, 5 M, F, H, G, C, L CANAVAN DISEASE 
ASPM Mendelian autosomal recessive 5 BBc, (L) 
MICROCEPHALY, PRIMARY, 
AUTOSMAL RECESSIVE 
ATP1A2 Mendelian autosomal dominant 5 H, E, G 
ALTERNATING HEMIPLEGIA OF 
CHILDHOOD  
ATP2A2 Mendelian autosomal dominant 8a S DARIER-WHITE DISEASE 
ATP6AP2 Mendelian X-linked recessive 6 E, (H) 
MENTAL RETARDATION, X-LINKED, 
SYNDROMIC 
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ATP6V0A2 Mendelian autosomal recessive 1 E, G, H, L, S, T 
CUTIS LAXA, AUTOSOMAL 
RECESSIVE 
ATP6V0A2 Mendelian autosomal recessive 5 E, G, H, L, S, T WRINKLY SKIN SYNDROME 
ATP7A Mendelian X-linked recessive 8b M, E, H, G, C, S Menkes disease 
ATP7A Mendelian X-linked recessive 5 S OCCIPITAL HORN SYNDROME 
ATR Mendelian autosomal recessive 5 AA, BB Seckel syndrome 
ATRX Mendelian X-linked recessive 2 H, U, W, K 
MENTAL RETARDATION-HYPOTONIC 
FACIES SYNDROME, X-LINKED 
ATRX Mendelian X-linked recessive 2 A, B, W, R, (E) 
ALPHA-THALASSEMIA/MENTAL 
RETARDATION SYNDROME, X-LINKED 
AUH Mendelian autosomal recessive 5 M, H, G 3-METHYLGLUTACONIC ACIDURIA 
B3GALTL Mendelian autosomal recessive 4 A, T, Uc, V PETERS-PLUS SYNDROME 
B4GALT1 Mendelian autosomal recessive 4 M, L, R Congenital disorder of glycosylation 
B4GALT7 Mendelian autosomal recessive 5 A, S 
EHLERS-DANLOS SYNDROME, 
PROGEROID FORM 
BBS1 Mendelian autosomal recessive 4 N, T, Ua, W, K, P Bardet-Biedl syndrome 
BBS10 Mendelian autosomal recessive 4 N, T, Ua, W, K, P Bardet-Biedl syndrome 
BBS12 Mendelian autosomal recessive 4 N, T, Ua, W, K, P Bardet-Biedl syndrome 
BBS2 Mendelian autosomal recessive 4 N, T, Ua, W, K, P Bardet-Biedl syndrome 
BBS4 Mendelian autosomal recessive 4 N, T, Ua, W, K, P Bardet-Biedl syndrome 
BBS5 Mendelian autosomal recessive 4 N, T, Ua, W, K, P Bardet-Biedl syndrome 
BBS7 Mendelian autosomal recessive 4 N, T, Ua, W, K, P Bardet-Biedl syndrome 
BBS9 Mendelian autosomal recessive 4 N, T, Ua, W, K, P Bardet-Biedl syndrome 
BCKDHA Mendelian autosomal recessive 8a 
M, (H) 
(untreated), (C) 
(untreated) MAPLE SYRUP URINE DISEASE 
BCKDHB Mendelian autosomal recessive 8a 
M, (H) 
(untreated), (C) 
(untreated) MAPLE SYRUP URINE DISEASE 
BCOR Mendelian X-linked recessive 4 T, Uab, W, B MICROPHTHALMIA, SYNDROMIC  
BCS1L Mendelian autosomal recessive 8b 
M, L, E, H, G, C, 
Q mitochondrial complex III deficiency 
BCS1L Mendelian autosomal recessive 8b 
M, L, E, H, G, C, 
Q LEIGH SYNDROME 
BLM Mendelian autosomal recessive 5 A, S, I, J, K, C BLOOM SYNDROME 
BRAF Mendelian autosomal dominant 4 A, S, V, E, Q, (I) 
CARDIOFACIOCUTANEOUS 
SYNDROME 
BRAF Mendelian autosomal dominant 4 A, S, V, E, Q, (I) Leopard syndrome 
BRAF Mendelian autosomal dominant 4 A, S, V, E, Q, (I) Noonan syndrome  
BRWD3 Mendelian X-linked recessive 5 F head MENTAL RETARDATION, X-LINKED 
BSCL2 Mendelian autosomal recessive 5 M, K, Q 
LIPODYSTROPHY, CONGENITAL 
GENERALIZED  
BUB1B Mendelian autosomal recessive 4 A, B, I, U, V, W, X
MOSAIC VARIEGATED ANEUPLOIDY 
SYNDROME  
CA2 Mendelian autosomal recessive 5 M, A, W, U 
OSTEOPETROSIS, AUTOSOMAL 
RECESSIVE 
CACNA1C Mendelian autosomal dominant 4 H, C, V, Ua, J, P TIMOTHY SYNDROME 
CASK Mendelian X-linked not sure 1 B, L, H, (A) 
MENTAL RETARDATION AND 
MICROCEPHALY WITH PONTINE AND 
CEREBELLAR HYPOPLASIA 
CASK Mendelian X-linked recessive 2 P FG syndrome 
CBS Mendelian autosomal recessive 5 M, T, R, F, Ub, E 
HOMOCYSTINURIA DUE TO 
CYSTATHIONINE BETA-SYNTHASE 
DEFICIENCY 
CC2D1A Mendelian autosomal recessive 3 
MENTAL RETARDATION, AUTOSOMAL 
RECESSIVE  
CC2D2A Mendelian autosomal recessive 4 T, L, O Joubert syndrome 
CC2D2A Mendelian autosomal recessive 4 T, L, O COACH SYNDROME 
CDK5RAP2 Mendelian autosomal recessive 5 BBc 
MICROCEPHALY, PRIMARY, 
AUTOSOMAL RECESSIVE 
CDKL5 Mendelian X-linked not sure 2 E, B, H ANGELMAN SYNDROME 
CDKL5 Mendelian X-linked not sure 2 E, H, Ba, O, P 
EPILEPTIC ENCEPHALOPATHY, 
EARLY INFANTILE 
CENPJ Mendelian autosomal recessive 8a AAc, BBc, Z  Seckel syndrome 
CENPJ Mendelian autosomal recessive 2 BBc, (E ) 
MICROCEPHALY, PRIMARY, 
AUTOSOMAL RECESSIVE 
CEP290 Mendelian autosomal recessive 4 
L, H, O, T, W, 
(H), (Ua) Joubert syndrome 
CEP290 Mendelian autosomal recessive 4 
L, H, O, T, W, 
(H), (Ua) Bardet-Biedl syndrome 
CHD7 Mendelian autosomal dominant 4 A, V, T, W, X, Uc CHARGE SYNDROME 
CNTNAP2 Mendelian autosomal recessive 2 E, O, G, P 
CORTICAL DYSPLASIA-FOCAL 
EPILEPSY SYNDROME 
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CNTNAP2 Mendelian autosomal dominant 6 AUTISM, SUSCEPTIBILITY TO  
COG1 Mendelian autosomal recessive 5 M, A, B, L, V Congenital disorder of glycosylation 
COG7 Mendelian autosomal recessive 8b M, H, C, E, S, U Congenital disorder of glycosylation 
COG8 Mendelian autosomal recessive 2 B, E, H, M Congenital disorder of glycosylation 
COL4A1 Mendelian autosomal dominant 7 H, E, L, T PORENCEPHALY 
COQ2 Mendelian autosomal recessive 8b 
M, L, E, H, G, C, 
Q 
COENZYME Q10 DEFICIENCY, 
PRIMARY 
COX10 Mendelian autosomal recessive 8b 
M, L, E, H, G, C, 
Q 
Encephalopathy, progressive 
mitochondrial, with proximal renal 
tubulopathy due to cytochrome c oxidase 
deficiency 
COX15 Mendelian autosomal recessive 8b M, L, H, G, Q LEIGH SYNDROME 
COX15 Mendelian autosomal recessive 8b 
M, L, E, H, G, C, 
Q 
CARDIOENCEPHALOMYOPATHY, 
FATAL INFANTILE, DUE TO 
CYTOCHROME c OXIDASE 
DEFICIENCY 
CRBN Mendelian autosomal recessive 6 
MENTAL RETARDATION, AUTOSOMAL 
RECESSIVE 
CREBBP Mendelian autosomal dominant 1 A, T, V, W, Ua RUBINSTEIN-TAYBI SYNDROME 
CTDP1 Mendelian autosomal recessive 5 
A, H, T, K, Q, L, 
U, G 
CONGENITAL CATARACTS, FACIAL 
DYSMORPHISM, AND NEUROPATHY 
CUL4B Mendelian X-linked recessive 5 A, H, K, N, P 
MENTAL RETARDATION, X-LINKED, 
WITH SHORT STATURE, 
HYPOGONADISM, AND ABNORMAL 
GAIT 
CYB5R3 Mendelian autosomal recessive 2 
M, A, B, G, H, C, 
E 
METHEMOGLOBINEMIA DUE TO 
DEFICIENCY OF METHEMOGLOBIN 
REDUCTASE 
D2HGDH Mendelian autosomal recessive 5 M, E, H, (L), (Q) D-2-HYDROXYGLUTARIC ACIDURIA  
DARS2 Mendelian autosomal recessive 8a L, M, H, G 
LEUKOENCEPHALOPATHY WITH 
BRAINSTEM AND SPINAL CORD 
INVOLVEMENT AND LACTATE 
ELEVATION 
DBT Mendelian autosomal recessive 8a 
M, H, (C) (if 
untreated) MAPLE SYRUP URINE DISEASE 
DCX Mendelian X-linked not sure 1, 4 B, E, L, P, C LISSENCEPHALY 
DHCR24 Mendelian autosomal recessive 1 M, V, Uc, A DESMOSTEROLOSIS 
DHCR7 Mendelian autosomal recessive 1 
M, A, B, Ua, Uc, 
V, W, P SMITH-LEMLI-OPITZ SYNDROME 
DIP2B Mendelian autosomal dominant 5, 6 MENTAL RETARDATION 
DKC1 Mendelian X-linked recessive 4 
A, B, I, J, R, H, L, 
S 
HOYERAAL-HREIDARSSON 
SYNDROME 
DKC1 Mendelian X-linked recessive 8a  I, J, R, H, S DYSKERATOSIS CONGENITA  
DLD Mendelian autosomal recessive 5 
M, H, (C) (if 
untreated) 
DIHYDROLIPOAMIDE 
DEHYDROGENASE DEFICIENCY 
DLG3 Mendelian X-linked recessive 3 MENTAL RETARDATION, X-LINKED  
DMD Mendelian X-linked recessive 8a C, Q MUSCULAR DYSTROPHY  
DMPK Mendelian autosomal dominant 8a Q, T, (C) MYOTONIC DYSTROPHY  
DNAJC19 Mendelian autosomal recessive 5 A, M, H, Q, W, R 3-METHYLGLUTACONIC ACIDURIA 
DNMT3B Mendelian autosomal recessive 5 J 
IMMUNODEFICIENCY-CENTROMERIC 
INSTABILITY-FACIAL ANOMALIES 
SYNDROME 
DPAGT1 Mendelian autosomal recessive 5 M, H, E, B Congenital disorder of glycosylation 
DPM1 Mendelian autosomal recessive 5 M, B, E, H Congenital disorder of glycosylation 
DPYD Mendelian autosomal recessive 5 M, E, H 
DIHYDROPYRIMIDINE 
DEHYDROGENASE DEFICIENCY 
DYM Mendelian autosomal recessive 5 AA, B, U 
DYGGVE-MELCHIOR-CLAUSEN 
DISEASE 
EHMT1 Mendelian autosomal dominant 1 
H, V, W, J, E, P, 
N, B KLEEFSTRA SYNDROME 
EIF2AK3 Mendelian autosomal recessive 8a AA, C, K, U 
EPIPHYSEAL DYSPLASIA, MULTIPLE, 
WITH EARLY-ONSET DIABETES 
MELLITUS 
EMX2 Mendelian autosomal dominant 4 L, H, E SCHIZENCEPHALY 
EP300 Mendelian autosomal dominant 1 
A, (N), (Ua), (T), 
(V), (W) RUBINSTEIN-TAYBI SYNDROME  
ERCC2 Mendelian autosomal recessive 8b B, H, G, S, T, I XERODERMA PIGMENTOSUM  
ERCC2 Mendelian autosomal recessive 2 
A, B, T, W, U, S, 
C 
CEREBROOCULOFACIOSKELETAL 
SYNDROME  
ERCC2 Mendelian autosomal recessive 5 B, H, G, S, T, I TRICHOTHIODYSTROPHY 
ERCC3 Mendelian autosomal recessive 8a B, H, G, S, T, I XERODERMA PIGMENTOSUM 
ERCC3 Mendelian autosomal recessive 5 B, H, G, S, T, I TRICHOTHIODYSTROPHY 
ERCC5 Mendelian autosomal recessive 8b B, H, G, S, T, I XERODERMA PIGMENTOSUM 
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ERCC6 Mendelian autosomal recessive 5 
Aa, L, H, G, S, T, 
C COCKAYNE SYNDROME 
ERCC6 Mendelian autosomal recessive 5 
Aa, L, H, G, S, T, 
C DE SANCTIS-CACCHIONE SYNDROME 
ERCC6 Mendelian autosomal recessive 8b 
Aa, L, H, G, S, T, 
C 
CEREBROOCULOFACIOSKELETAL 
SYNDROME 
ERCC8 Mendelian autosomal recessive 5 
Aa, L, H, G, S, T, 
C COCKAYNE SYNDROME 
ESCO2 Mendelian autosomal recessive 4 Ac, C, Ua, Uc ROBERTS SYNDROME 
ESCO2 Mendelian autosomal recessive 4 Ac, C, Ua, Uc SC PHOCOMELIA SYNDROME 
ETHE1 Mendelian autosomal recessive 2, 8b 
M, C, G, H, (S), 
(O) ENCEPHALOPATHY, ETHYLMALONIC 
FANCD2 Mendelian autosomal recessive 8a R, A, Ua, I, C, P FANCONI ANEMIA 
FGD1 Mendelian X-linked not sure 4 A, W, P AARSKOG-SCOTT SYNDROME 
FGFR2 Mendelian autosomal dominant 4 Ua, Ub APERT SYNDROME 
FGFR2 Mendelian autosomal dominant 4 Ua, Ub, S, W 
BEARE-STEVENSON CUTIS GYRATA 
SYNDROME 
FGFR2 Mendelian autosomal dominant 7 Ua, Ub, X, (E, C) PFEIFFER SYNDROME 
FGFR2 Mendelian autosomal dominant 7 Ua, Ub, T SAETHRE-CHOTZEN SYNDROME 
FGFR2 Mendelian autosomal dominant 4 Ua 
SCAPHOCEPHALY, MAXILLARY 
RETRUSION, AND MENTAL 
RETARDATION 
FGFR3 Mendelian autosomal dominant 7 Ua, Ub MUENKE SYNDROME 
FH Mendelian autosomal recessive 2 
M, H, G, C, L, P, 
E, B FUMARASE DEFICIENCY 
FKRP Mendelian autosomal recessive 1 Q, L, T, (C) 
MUSCULAR DYSTROPHY-
DYSTROGLYCANOPATHY 
(CONGENITAL WITH OR WITHOUT 
MENTAL RETARDATION) 
FKRP Mendelian autosomal recessive 1 Q, L, T, (C) 
MUSCULAR DYSTROPHY-
DYSTROGLYCANOPATHY 
(CONGENITAL WITH BRAIN AND EYE 
ANOMALIES) 
FKTN Mendelian autosomal recessive 4 Q, L, H, C, T 
MUSCULAR DYSTROPHY-
DYSTROGLYCANOPATHY 
(CONGENITAL WITH BRAIN AND EYE 
ANOMALIES) 
FLNA Mendelian X-linked dominant 5 L, E HETEROTOPIA, PERIVENTRICULAR 
FLNA Mendelian X-linked recessive 5 L, E FG SYNDROME 
FLNA Mendelian X-linked not sure 1 
Ua, Ub, X, W, V, 
C, (L) OTOPALATODIGITAL SYNDROME 
FMR1 Mendelian X-linked not sure 2, 3 P 
FRAGILE X MENTAL RETARDATION 
SYNDROME 
FOXG1 Mendelian autosomal dominant 2 Ba, E, P, L 
RETT SYNDROME, CONGENITAL 
VARIANT 
FOXP1 Mendelian autosomal dominant 6 P 
MENTAL RETARDATION WITH 
LANGUAGE IMPAIRMENT AND 
AUTISTIC FEATURES 
FRAS1 Mendelian autosomal recessive 7 T, Ua, W, X FRASER SYNDROME 
FTO Mendelian autosomal recessive 1 
AAc, B, C, L, E, 
V, W 
GROWTH RETARDATION, 
DEVELOPMENTAL DELAY, COARSE 
FACIES, AND EARLY DEATH 
FTSJ1 Mendelian X-linked recessive 3 P MENTAL RETARDATION, X-LINKED 
FUCA1 Mendelian autosomal recessive 8b 
M, A, J, H, U, S, 
E, G, (C) FUCOSIDOSIS 
GAD1 Mendelian autosomal recessive 2 H 
CEREBRAL PALSY, SPASTIC 
QUADRIPLEGIC 
GALE Mendelian autosomal recessive 8a M GALACTOSE EPIMERASE DEFICIENCY
GALT Mendelian autosomal recessive 8b 
M, H, (G) without 
treatment GALACTOSEMIA 
GAMT Mendelian autosomal recessive 5 M, E, P, H 
GUANIDINOACETATE 
METHYLTRANSFERASE DEFICIENCY 
GATM Mendelian autosomal recessive 5 M, P, (E) 
ARGININE:GLYCINE 
AMIDINOTRANSFERASE DEFICIENCY 
GCH1 Mendelian autosomal recessive 8b M, E, H, G HYPERPHENYLALANINEMIA  
GCSH Mendelian autosomal recessive 2 M, H, E, C, (G) GLYCINE ENCEPHALOPATHY 
GDI1 Mendelian X-linked recessive 6 MENTAL RETARDATION, X-LINKED  
GFAP Mendelian autosomal dominant 5 L, C, H, E, G, F ALEXANDER DISEASE 
GJC2 Mendelian autosomal recessive 5 H, L, G LEUKODYSTROPHY 
GJC2 Mendelian autosomal recessive 5 H, L, G 
SPASTIC PARAPLEGIA, AUTOSOMAL 
RECESSIVE 
GK Mendelian X-linked recessive 5 M HYPERGLYCEROLEMIA 
GLDC Mendelian autosomal recessive 2 M, H, E, C, (G) GLYCINE ENCEPHALOPATHY 
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GLI2 Mendelian autosomal dominant 7 L, Ua, Uc, K, (C) HOLOPROSENCEPHALY 
GLI3 Mendelian autosomal dominant 7 F, Ua 
GREIG CEPHALOPOLYSYNDACTYLY 
SYNDROME 
GLI3 Mendelian autosomal dominant 7 C, K, Ua, L PALLISTER-HALL SYNDROME 
GNAS Mendelian autosomal dominant 5 A, K PSEUDOHYPOPARATHYROIDISM 
GNAS Mendelian autosomal dominant 8a A, K PSEUDOHYPOPARATHYROIDISM 
GNAS Mendelian autosomal dominant 8a A, K, N 
PSEUDOPSEUDOHYPOPARATHYROID
ISM 
GNPAT Mendelian autosomal recessive 5 A, M, U, (T) 
RHIZOMELIC CHONDRODYSPLASIA 
PUNCTATA 
GNS Mendelian autosomal recessive 5, 8b M, G, P, H MUCOPOLYSACCHARIDOSIS  
GPC3 Mendelian X-linked not sure 4 
F, I, Uabc, V, W, 
X 
SIMPSON-GOLABI-BEHMEL 
SYNDROME 
GPHN Mendelian autosomal recessive 8b E, G, C 
MOLYBDENUM COFACTOR 
DEFICIENCY 
GPR56 Mendelian autosomal recessive 2 E, H, L POLYMICROGYRIA 
GRIA3 Mendelian X-linked recessive 6 H MENTAL RETARDATION, X-LINKED 
GRIK2 Mendelian autosomal recessive 6 
MENTAL RETARDATION, AUTOSOMAL 
RECESSIVE  
GSS Mendelian autosomal recessive 5 M, R, H 
GLUTATHIONE SYNTHETASE 
DEFICIENCY 
GTF2H5 Mendelian autosomal recessive 5 A, S, (H) TRICHOTHIODYSTROPHY 
GUSB Mendelian autosomal recessive 5 M, A, U MUCOPOLYSACCHARIDOSIS  
HCCS Mendelian X-linked dominant 7 S, T MICROPHTHALMIA, SYNDROMIC 
HESX1 Mendelian autosomal recessive 7 K, L SEPTOOPTIC DYSPLASIA 
HLCS Mendelian autosomal recessive 8b M, C 
HOLOCARBOXYLASE SYNTHETASE 
DEFICIENCY 
HOXA1 Mendelian autosomal recessive 5 H, O, V 
ATHABASKAN BRAINSTEM 
DYSGENESIS SYNDROME 
HPD Mendelian autosomal recessive 5 M, H TYROSINEMIA 
HPRT1 Mendelian X-linked recessive 2 M, H, P LESCH-NYHAN SYNDROME 
HRAS Mendelian autosomal dominant 1 A, I, S, V COSTELLO SYNDROME 
HRAS somatic N/A 7 T, L, U, S 
SCHIMMELPENNING-FEUERSTEIN-
MIMS SYNDROME 
HSD17B10 Mendelian X-linked recessive 5 H, P, M MENTAL RETARDATION, X-LINKED 
HSD17B10 Mendelian X-linked not sure 8b M, G, H, C 
17-BETA-HYDROXYSTEROID 
DEHYDROGENASE X DEFICIENCY 
HSD17B10 Mendelian X-linked not sure MENTAL RETARDATION, X-LINKED  
IDS Mendelian X-linked recessive 8b 
M, A, G, C, Ub, F, 
V, P MUCOPOLYSACCHARIDOSIS  
IDUA Mendelian autosomal recessive 5, 8b 
M, A, G, C, Ub, T, 
V MUCOPOLYSACCHARIDOSIS  
IDUA Mendelian autosomal recessive 5, 8b 
M, A, G, C, Ub, T, 
V MUCOPOLYSACCHARIDOSIS  
IDUA Mendelian autosomal recessive 
5, 8a, 
8b 
M, A, G, C, Ub, T, 
V MUCOPOLYSACCHARIDOSIS  
IGF1 Mendelian autosomal recessive 5 AA, K 
INSULIN-LIKE GROWTH FACTOR I 
DEFICIENCY 
IKBKG Mendelian X-linked dominant 8a S, T INCONTINENTIA PIGMENTI 
IL1RAPL1 Mendelian X-linked not sure 6 (P) MENTAL RETARDATION, X-LINKED  
INPP5E Mendelian autosomal recessive 5 N, T, W 
MORM, MENTAL RETARDATION, 
TRUNCAL OBESITY, RETINAL 
DYSTROPHY, AND MICROPENIS 
INPP5E Mendelian autosomal recessive 5 T, H, L, (W) JOUBERT SYNDROME 
IQSEQ2 Mendelian X-linked not sure 3 (P), (E ) MENTAL RETARDATION, X-LINKED 
KCNJ11 Mendelian autosomal dominant 5 M, H, E 
DIABETES MELLITUS, PERMANENT 
NEONATAL 
KCNK9 Mendelian autosomal dominant 2 P, H, Q 
BIRK-BAREL MENTAL RETARDATION 
DYSMORPHISM SYNDROME 
KDM5C Mendelian X-linked recessive 5, 6 A, H, E, P, (B) MENTAL RETARDATION, X-LINKED 
KIAA1279 Mendelian autosomal recessive 1 B, X, L 
GOLDBERG-SHPRINTZEN 
MEGACOLON SYNDROME 
KRAS Mendelian autosomal dominant 4 A, V, R, T, S, Q NOONAN SYNDROME 
KRAS Mendelian autosomal dominant 4 A, V, R, T, S, Q 
CARDIOFACIOCUTANEOUS 
SYNDROME 
KRBOX4 Mendelian X-linked recessive 6 
CHROMOSOME Xp11.3 DELETION 
SYNDROME 
L1CAM Mendelian X-linked recessive 1 L, H 
HYDROCEPHALUS DUE TO 
CONGENITAL STENOSIS OF 
AQUEDUCT OF SYLVIUS 
L1CAM Mendelian X-linked recessive 4 L, H MASA SYNDROME 
L1CAM Mendelian X-linked recessive 4 L, H 
CORPUS CALLOSUM, PARTIAL 
AGENESIS OF, X-LINKED 
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L2HGDH Mendelian autosomal recessive 8b M, H, P, E, L, F L-2-HYDROXYGLUTARIC ACIDURIA 
LAMA2 Mendelian autosomal recessive 8a Q, (E, L) 
MUSCULAR DYSTROPHY, 
CONGENITAL 
LAMP2 Mendelian X-linked not sure 5 M, Q, G, C DANON DISEASE 
LARGE Mendelian autosomal recessive 1 Q, L, M, T, C 
MUSCULAR DYSTROPHY-
DYSTROGLYCANOPATHY 
(CONGENITAL WITH MENTAL 
RETARDATION) 
LARGE Mendelian autosomal recessive 1 Q, L, M, T, C 
MUSCULAR DYSTROPHY-
DYSTROGLYCANOPATHY 
(CONGENITAL WITH BRAIN AND EYE 
ANOMALIES) 
LIG4 Mendelian autosomal recessive 5 A, B, J, I, S LIG4 SYNDROME 
LRPPRC Mendelian autosomal recessive 8b 
M, L, E, H, G, C, 
Q LEIGH SYNDROME 
MAGT1 Mendelian X-linked not sure 6 MENTAL RETARDATION, X-LINKED 
MAGT1 Mendelian X-linked not sure 5 M Congenital Disorders of Glycosylation 
MAN2B1 Mendelian autosomal recessive 5 
M, G, Q, H, J, L, 
Ub, C MANNOSIDOSIS, ALPHA  
MANBA Mendelian autosomal recessive 5 M MANNOSIDASE, BETA  
MAOA Mendelian X-linked recessive 5 P, M BRUNNER SYNDROME 
MAP2K1 Mendelian autosomal dominant 4 A, S, V 
CARDIOFACIOCUTANEOUS 
SYNDROME 
MAP2K2 Mendelian autosomal dominant 4 A, S, V 
CARDIOFACIOCUTANEOUS 
SYNDROME 
MAT1A Mendelian autosomal recessive 8a M 
METHIONINE 
ADENOSYLTRANSFERASE 
DEFICIENCY 
MBD5 Mendelian autosomal dominant 6 P, (E) 
MENTAL RETARDATION, AUTOSOMAL 
DOMINANT 
MCCC1 Mendelian autosomal recessive 5 M, H, G, E 
3-METHYLCROTONYL-CoA 
CARBOXYLASE DEFICIENCY 
MCCC2 Mendelian autosomal recessive 5, 8b M, (G) 
3-METHYLCROTONYL-CoA 
CARBOXYLASE DEFICIENCY 
MCOLN1 Mendelian autosomal recessive 2 M, H, T, L, (G) MUCOLIPIDOSIS 
MCPH1 Mendelian autosomal recessive 5 B, A 
MICROCEPHALY, PRIMARY, 
AUTOSOMAL RECESSIVE 
MECP2 Mendelian X-linked dominant 2, 8b 
B, E, G, P, H, A, 
O, U RETT SYNDROME 
MECP2 Mendelian X-linked not sure 2, 8b 
B, E, G, P, H, A, 
O, U 
ENCEPHALOPATHY, NEONATAL 
SEVERE 
MECP2 Mendelian X-linked recessive 2, 8b 
B, E, G, P, H, A, 
O, U 
LUBS X-LINKED MENTAL 
RETARDATION SYNDROME 
MECP2 Mendelian X-linked recessive 5, 6 H, P MENTAL RETARDATION, X-LINKED 
MECP2 Mendelian X-linked recessive 2 B, E, H ANGELMAN SYNDROME 
MED12 Mendelian X-linked recessive 4 H, L, E, P, V OPITZ-KAVEGGIA SYNDROME 
MED12 Mendelian X-linked recessive 5 H, P LUJAN-FRYNS SYNDROME 
MEF2C Mendelian autosomal dominant 2 E 
MENTAL RETARDATION, AUTOSOMAL 
DOMINANT 
MGAT2 Mendelian autosomal recessive 5 M, E, R, P 
CONGENITAL DISORDER OF 
GLYCOSYLATION 
MID1 Mendelian X-linked recessive 4 L, W, Uc, V, X OPITZ GBBB SYNDROME 
MKKS Mendelian autosomal recessive 4 N, T, Ua, W, K, P Bardet-Biedl syndrome 
MKKS Mendelian autosomal recessive 7 Ua, W, X, C MCKUSICK-KAUFMAN SYNDROME 
MLL2 Mendelian autosomal dominant 4 
A, H, Uc, V, W, J, 
(E), (K) KABUKI SYNDROME  
MLYCD Mendelian autosomal recessive 5 M, E, H 
MALONYL-CoA DECARBOXYLASE 
DEFICIENCY 
MMAA Mendelian autosomal recessive 8a, 8b M, H, W, A METHYLMALONIC ACIDURIA  
MMACHC Mendelian autosomal recessive 8a, 8b M, H, R, (C) 
METHYLMALONIC ACIDURIA AND 
HOMOCYSTINURIA 
MMADHC Mendelian autosomal recessive 5 M, H, R, E 
METHYLMALONIC ACIDURIA AND 
HOMOCYSTINURIA 
MOCS1 Mendelian autosomal recessive 2 M, H, G, C, E 
MOLYBDENUM COFACTOR 
DEFICIENCY 
MOCS2 Mendelian autosomal recessive 2 M, H, G, C, E 
MOLYBDENUM COFACTOR 
DEFICIENCY 
MPDU1 Mendelian autosomal recessive 2 M, O, S 
CONGENITAL DISORDER OF 
GLYCOSYLATION 
MPLKIP Mendelian autosomal recessive 5 A, S, H, K TRICHOTHIODYSTROPHY 
MT-ATP6 Mitochondrial N/A 8b M, H, T, Q, G 
NEUROPATHY, ATAXIA, AND 
RETINITIS PIGMENTOSA 
MT-CO2 Mitochondrial N/A 8b M, H, G, C, Q CYTOCHROME c OXIDASE 
                                                                                                        Genetics of ID- an inventory  
131 
 
DEFICIENCY 
MT-CO3 Mitochondrial N/A 8b M, H, G,Q 
MITOCHONDRIAL COMPLEX IV 
DEFICIENCY 
MT-COI Mitochondrial N/A 8b M, H, E 
CYTOCHROME c OXIDASE I 
DEFICIENCY 
MT-ND5 Mitochondrial N/A 8b 
M, L, E, H, G, C, 
Q Leigh syndrome 
MT-ND5 Mitochondrial N/A 8b M, L, E, H, G, Q MELAS 
MTR Mendelian autosomal N/A 8b M, H METHYLCOBALAMIN DEFICIENCY 
MTRR Mendelian autosomal recessive 8b M, H 
HOMOCYSTINURIA-MEGALOBLASTIC 
ANEMIA DUE TO DEFECT IN 
COBALAMIN METABOLISM 
MT-TK Mitochondrial N/A 8b 
M, L, E, H, G, C, 
Q Leigh syndrome 
MT-TK Mitochondrial N/A 8b 
M, L, E, H, G, C, 
Q MELAS syndrome 
MT-TK Mitochondrial N/A 8b 
M, L, E, H, G, C, 
Q MERFF syndrome 
MT-TL1 Mitochondrial N/A 8b 
M, L, E, H, G, C, 
Q, A MELAS syndrome 
MT-TL1 Mitochondrial N/A 8b 
M, L, E, H, G, C, 
Q, A Leigh syndrome 
MT-TS1 Mitochondrial N/A 8b 
M, L, E, H, G, C, 
Q mitochondrial complex IV deficiency 
MT-TV Mitochondrial N/A 8b 
M, L, E, H, G, C, 
Q Leigh syndrome 
MUT Mendelian autosomal recessive 8a, 8b M, H, W, A METHYLMALONIC ACIDURIA  
MVK Mendelian autosomal recessive 5 M, R, H, J, E, (C) MEVALONIC ACIDURIA 
MYCN Mendelian autosomal dominant 4 B, X, Ua, V FEINGOLD SYNDROME 
MYO5A Mendelian autosomal recessive 5 H, S GRISCELLI SYNDROME 
NAGA Mendelian autosomal recessive 5 M, H, G, S SCHINDLER DISEASE 
NAGA Mendelian autosomal recessive 5 M, H, G, S KANZAKI DISEASE 
NAGLU Mendelian autosomal recessive 8b M, G, P, C MUCOPOLYSACCHARIDOSIS  
NBN Mendelian autosomal recessive 5 A, B, I, J, K NIJMEGEN BREAKAGE SYNDROME 
NDP Mendelian X-linked recessive 8a T, P NORRIE DISEASE 
NDUFA1 Mendelian X-linked not sure 8b 
M, L, E, H, G, C, 
Q 
MITOCHONDRIAL COMPLEX I 
DEFICIENCY 
NDUFA11 Mendelian autosomal recessive 8b 
M, L, E, H, G, C, 
Q 
MITOCHONDRIAL COMPLEX I 
DEFICIENCY 
NDUFS1 Mendelian autosomal recessive 8b 
M, L, E, H, G, C, 
Q 
MITOCHONDRIAL COMPLEX I 
DEFICIENCY 
NDUFS2 Mendelian autosomal recessive 8b 
M, L, E, H, G, C, 
Q 
MITOCHONDRIAL COMPLEX I 
DEFICIENCY 
NDUFS3 Mendelian autosomal recessive 8b 
M, L, E, H, G, C, 
Q 
MITOCHONDRIAL COMPLEX I 
DEFICIENCY 
NDUFS3 Mendelian autosomal recessive 8b 
M, L, E, H, G, C, 
Q LEIGH SYNDROME 
NDUFS4 Mendelian autosomal recessive 8b 
M, L, E, H, G, C, 
Q LEIGH SYNDROME 
NDUFS4 Mendelian autosomal recessive 8b 
M, L, E, H, G, C, 
Q 
MITOCHONDRIAL COMPLEX I 
DEFICIENCY 
NDUFS7 Mendelian autosomal recessive 8b 
M, L, E, H, G, C, 
Q LEIGH SYNDROME 
NDUFS8 Mendelian autosomal recessive 8b 
M, L, E, H, G, C, 
Q LEIGH SYNDROME 
NDUFV1 Mendelian autosomal recessive 8b 
M, L, E, H, G, C, 
Q 
MITOCHONDRIAL COMPLEX I 
DEFICIENCY 
NEU1 Mendelian autosomal recessive 5 M, H, G, U NEURAMINIDASE DEFICIENCY 
NF1 Mendelian autosomal dominant 8a I, S, T NEUROFIBROMATOSIS 
NF1 Mendelian autosomal dominant 8a I, S, T 
NEUROFIBROMATOSIS-NOONAN 
SYNDROME 
NF1 Mendelian autosomal dominant 5 I, S, T WATSON SYNDROME 
NHS Mendelian X-linked not sure 7 T, X NANCE-HORAN SYNDROME 
NIPBL Mendelian autosomal dominant 1 A, B, Ua, V, P, W CORNELIA DE LANGE SYNDROME 
NKX2-1 Mendelian autosomal dominant 8a K, H 
CHOREOATHETOSIS, 
HYPOTHYROIDISM, AND NEONATAL 
RESPIRATORY DISTRESS 
NLGN3 Mendelian X-linked not sure 6 P, (E) 
ASPERGER SYNDROME, X-LINKED, 
SUSCEPTIBILITY TO 
NLGN3 Mendelian X-linked not sure 6 P AUTISM, SUSCEPTIBILITY TO  
NLGN4X Mendelian X-linked not sure 6 P AUTISM, SUSCEPTIBILITY TO 
NLRP3 Mendelian autosomal dominant 8a J, H, S, G, (A) CINCA SYNDROME 
NPHP1 Mendelian autosomal recessive 4 H, L, O, W JOUBERT SYNDROME 
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NRXN1 Mendelian autosomal recessive 2 O, E, P PITT-HOPKINS-LIKE SYNDROME  
NRXN1 Mendelian autosomal dominant 6 P ASD/autism 
NSD1 Mendelian autosomal dominant 4, 5 
F, P, V, W, E, L, 
Ub SOTOS SYNDROME 
NSD1 Mendelian autosomal dominant 4, 5 
F, P, V, W, E, L, 
Ub WEAVER SYNDROME  
NTRK1 Mendelian autosomal recessive 5 H, O, S, P 
INSENSITIVITY TO PAIN, 
CONGENITAL, WITH ANHIDROSIS 
OCRL Mendelian X-linked not sure 5 
M, H, E, A, T, W, 
P 
LOWE OCULOCEREBRORENAL 
SYNDROME 
OCRL Mendelian X-linked not sure 5 M, A, W DENT DISEASE  
OFD1 Mendelian X-linked dominant 4 L, Ua, Uc, W OROFACIODIGITAL SYNDROME  
OFD1 Mendelian X-linked recessive 4 
L, Ua, T, W, (H, 
O) JOUBERT SYNDROME  
OFD1 Mendelian X-linked recessive 1 
W, F, Ua, Uc, S, 
V, X, H 
SIMPSON-GOLABI-BEHMEL 
SYNDROME 
OPHN1 Mendelian X-linked recessive 1 L, H, E MENTAL RETARDATION, X-LINKED 
PAFAH1B1 Mendelian autosomal dominant 1 Ba, E, L, C, H LISSENCEPHALY 
PAK3 Mendelian X-linked recessive 6 (B), P MENTAL RETARDATION, X-LINKED  
PANK2 Mendelian autosomal recessive 8b H, G, L, T, C, P 
NEURODEGENERATION WITH BRAIN 
IRON ACCUMULATION  
PANK2 Mendelian autosomal recessive 8b H, G, L, T, M 
HYPOPREBETALIPOPROTEINEMIA, 
ACANTHOCYTOSIS, RETINITIS 
PIGMENTOSA, AND PALLIDAL 
DEGENERATION 
PAX6 Mendelian autosomal dominant 4 T, H, (L) 
ANIRIDIA, CEREBELLAR ATAXIA, AND 
MENTAL RETARDATION 
PAX6 Mendelian autosomal dominant 7 T, (A) COLOBOMA OF OPTIC NERVE 
PAX6 Mendelian autosomal dominant 7 T, (L) ANIRIDIA 
PC Mendelian autosomal recessive 5 M, C, E, H, G, L 
PYRUVATE CARBOXYLASE 
DEFICIENCY 
PCNT Mendelian autosomal recessive 8a AA, B, U 
MICROCEPHALIC OSTEODYSPLASTIC 
PRIMORDIAL DWARFISM 
PDHA1 Mendelian X-linked not sure 8b M, H, G, E, C, L 
PYRUVATE DEHYDROGENASE E1-
ALPHA DEFICIENCY 
PDHA1 Mendelian X-linked not sure 8b M, H, G, E, C, L LEIGH SYNDROME 
PDSS1 Mendelian autosomal recessive 8b M, H, T, O, V 
COENZYME Q10 DEFICIENCY, 
PRIMARY 
PDSS2 Mendelian autosomal recessive 8b 
M, L, E, H, G, C, 
W 
COENZYME Q10 DEFICIENCY, 
PRIMARY 
PEPD Mendelian autosomal recessive 5 M, J, S PROLIDASE DEFICIENCY 
PEX1 Mendelian autosomal recessive 2 M, E, H, T, C, L 
PEROXISOME BIOGENESIS 
DISORDER (ZELLWEGER) 
PEX1 Mendelian autosomal recessive 5 M, H, T, G 
PEROXISOME BIOGENESIS 
DISORDER  
PEX10 Mendelian autosomal recessive 2 
M, E, H, T, G, C, 
L 
PEROXISOME BIOGENESIS 
DISORDER (ZELLWEGER) 
PEX10 Mendelian autosomal recessive 5 M, E, H, T, G, C 
PEROXISOME BIOGENESIS 
DISORDER  
PEX12 Mendelian autosomal recessive 2 
M, E, H, T, G, C, 
L 
PEROXISOME BIOGENESIS 
DISORDER (ZELLWEGER) 
PEX12 Mendelian autosomal recessive 2 
M, E, H, T, G, C, 
L 
PEROXISOME BIOGENESIS 
DISORDER  
PEX13 Mendelian autosomal recessive 2 
M, E, H, T, G, C, 
L 
PEROXISOME BIOGENESIS 
DISORDER (ZELLWEGER) 
PEX13 Mendelian autosomal recessive 2 M, E, H, T, G, C 
PEROXISOME BIOGENESIS 
DISORDER  
PEX26 Mendelian autosomal recessive 8b M, E, H, L, C, (G) 
PEROXISOME BIOGENESIS 
DISORDER (ZELLWEGER) 
PEX26 Mendelian autosomal recessive 8b M, E, H, L, C, (G) 
PEROXISOME BIOGENESIS 
DISORDER  
PEX5 Mendelian autosomal recessive 2 
M, E, H, T, G, C, 
L 
PEROXISOME BIOGENESIS 
DISORDER (ZELLWEGER) 
PEX5 Mendelian autosomal recessive 2 M, E, H, T, G, C 
PEROXISOME BIOGENESIS 
DISORDER 
PEX6 Mendelian autosomal recessive 2 M, E, H, T, G, C 
PEROXISOME BIOGENESIS 
DISORDER (ZELLWEGER) 
PEX6 Mendelian autosomal recessive 2 M, T, H, C, G 
PEROXISOME BIOGENESIS 
DISORDER 
PEX7 Mendelian autosomal recessive 1 
AAa, M, E, T, C, 
Ub 
RHIZOMELIC CHONDRODYSPLASIA 
PUNCTATA 
PEX7 Mendelian autosomal recessive 5 M, H, T, G 
PEROXISOME BIOGENESIS 
DISORDER  
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PGK1 Mendelian X-linked recessive 8a H, Q, R, M 
PHOSPHOGLYCERATE KINASE 1 
DEFICIENCY 
PHF6 Mendelian X-linked recessive 5 O, A, K 
BORJESON-FORSSMAN-LEHMANN 
SYNDROME 
PHF8 Mendelian X-linked recessive 4 Uc 
SIDERIUS X-LINKED MENTAL 
RETARDATION SYNDROME 
PHGDH Mendelian autosomal recessive 5 M, Bc, E 
PHOSPHOGLYCERATE 
DEHYDROGENASE DEFICIENCY 
PLP1 Mendelian X-linked recessive 2 H, L, E, (C) PELIZAEUS-MERZBACHER DISEASE 
PMM2 Mendelian autosomal recessive 5 
M, H, L, T, A, C, 
R 
CONGENITAL DISORDER OF 
GLYCOSYLATION 
PNP Mendelian autosomal recessive 8a M, J, H 
PURINE NUCLEOSIDE 
PHOSPHORYLASE DEFICIENCY 
POMGNT1 Mendelian autosomal recessive 1 
Q, L, T, C, E, P, 
G 
MUSCULAR DYSTROPHY-
DYSTROGLYCANOPATHY 
(CONGENITAL WITH BRAIN AND EYE 
ANOMALIES) 
POMGNT1 Mendelian autosomal recessive 4 Q, L, T 
MUSCULAR DYSTROPHY-
DYSTROGLYCANOPATHY 
(CONGENITAL WITH MENTAL 
RETARDATION) 
POMT1 Mendelian autosomal recessive 1 Q, L, T, B, C 
MUSCULAR DYSTROPHY-
DYSTROGLYCANOPATHY 
(CONGENITAL WITH BRAIN AND EYE 
ANOMALIES) 
POMT1 Mendelian autosomal recessive 4 Q, L, T, C 
MUSCULAR DYSTROPHY-
DYSTROGLYCANOPATHY 
(CONGENITAL WITH MENTAL 
RETARDATION) 
POMT2 Mendelian autosomal recessive 1 Q, L, C, T, B 
MUSCULAR DYSTROPHY-
DYSTROGLYCANOPATHY 
(CONGENITAL WITH BRAIN AND EYE 
ANOMALIES) 
POMT2 Mendelian autosomal recessive 1 Q, L, C, B, T 
MUSCULAR DYSTROPHY-
DYSTROGLYCANOPATHY 
(CONGENITAL WITH MENTAL 
RETARDATION) 
PORCN Mendelian X-linked dominant 7 S, T, Ua, Uc, X FOCAL DERMAL HYPOPLASIA 
PPOX Mendelian autosomal not sure 8a M, H, S, E PORPHYRIA VARIEGATA 
PQBP1 Mendelian X-linked recessive 1 A, B, W, X RENPENNING SYNDROME 
PRPS1 Mendelian X-linked recessive 5 H, J, C, M ARTS SYNDROME 
PRSS12 Mendelian autosomal recessive 6 
MENTAL RETARDATION, AUTOSOMAL 
RECESSIVE  
PTCH1 Mendelian autosomal dominant 4 L, Uc HOLOPROSENCEPHALY  
PTEN Mendelian autosomal dominant 8a F, P, (I) MACROCEPHALY/AUTISM SYNDROME
PTPN11 Mendelian autosomal dominant 7 A, V, R, T, S, Q NOONAN SYNDROME  
PTPN11 Mendelian autosomal dominant 7 A, V, R, T, S, Q LEOPARD SYNDROME 
PUS1 Mendelian autosomal recessive 8a M, Q, R 
MYOPATHY, LACTIC ACIDOSIS, AND 
SIDEROBLASTIC ANEMIA  
PVRL1 Mendelian autosomal recessive 7 Uac, S 
CLEFT LIP/PALATE-ECTODERMAL 
DYSPLASIA SYNDROME 
PYCR1 Mendelian autosomal recessive 5 A, S, (L), (B), U 
CUTIS LAXA, AUTOSOMAL 
RECESSIVE 
PYCR1 Mendelian autosomal recessive 5 A, S, T, U 
CUTIS LAXA, AUTOSOMAL 
RECESSIVE 
PIGV Mendelian autosomal recessive 1 M, Ua, (E ) 
HYPERPHOSPHATASIA WITH MENTAL 
RETARDATION SYNDROME 
RAB27A Mendelian autosomal recessive 8a H, R, J, S, C GRISCELLI SYNDROME 
RAB3GAP1 Mendelian autosomal recessive 1 B, T, L, H WARBURG MICRO SYNDROME  
RAB3GAP2 Mendelian autosomal recessive 4 B, T, W, H MARTSOLF SYNDROME 
RAB3GAP2 Mendelian autosomal recessive 1 T, H, B, L, X WARBURG MICRO SYNDROME  
RAB39B Mendelian X-linked not sure 6 (E), (P), (F) MENTAL RETARDATION, X-LINKED 
RAF1 Mendelian autosomal dominant 7 A, V, R, T, Q NOONAN SYNDROME 
RAF1 Mendelian autosomal dominant 7 A, V, R, T, Q LEOPARD SYNDROME 
RAI1 Mendelian autosomal dominant 5 P, H, J SMITH-MAGENIS SYNDROME 
RBM28 Mendelian autosomal recessive 2 K, S, H, G 
ALOPECIA, NEUROLOGIC DEFECTS, 
AND ENDOCRINOPATHY SYNDROME 
RELN Mendelian autosomal recessive 1 L, E, H LISSENCEPHALY 
RFT1 Mendelian autosomal recessive 2 H, E, B, M 
CONGENITAL DISORDER OF 
GLYCOSYLATION 
RMRP Mendelian autosomal recessive 8a AA, B, U ANAUXETIC DYSPLASIA 
RNASEH2A Mendelian autosomal recessive 2 
H, E, L, S, G, C, 
B AICARDI-GOUTIERES SYNDROME 
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RNASEH2B Mendelian autosomal recessive 2 H, E, L, S, G, B AICARDI-GOUTIERES SYNDROME  
RNASEH2
C Mendelian autosomal recessive 2 
H, E, L, S, G, C, 
B AICARDI-GOUTIERES SYNDROME 
RPGRIP1L Mendelian autosomal recessive 4 H, L, O, W, T, Ua JOUBERT SYNDROME  
RPGRIP1L Mendelian autosomal recessive 4 H, L, O, W, T COACH SYNDROME 
RPL10 Mendelian X-linked not sure 6 P AUTISM, SUSCEPTIBILITY TO  
RPS6KA3 Mendelian X-linked not sure 2 A, B, Ub, (H), (C) COFFIN-LOWRY SYNDROME 
RPS6KA3 Mendelian X-linked not sure 6 MENTAL RETARDATION, X-LINKED 
SALL1 Mendelian autosomal dominant 7 X, Ua, V, W TOWNES-BROCKS SYNDROME 
SATB2 Mendelian autosomal dominant 1 E, Uc CLEFT PALATE, ISOLATED 
SC5DL Mendelian autosomal recessive 4 M, B, Ua, L LATHOSTEROLOSIS 
SCO2 Mendelian autosomal recessive 8b M, L, H, G, C, Q 
CARDIOENCEPHALOMYOPATHY, 
FATAL INFANTILE, DUE TO 
CYTOCHROME c OXIDASE 
DEFICIENCY 
SDHA Mendelian autosomal recessive 8b 
M, L, E, H, G, C, 
Q LEIGH SYNDROME 
SDHA Mendelian autosomal recessive 8b 
M, L, E, H, G, C, 
Q 
MITOCHONDRIAL COMPLEX II 
DEFICIENCY 
SETBP1 Mendelian autosomal dominant 1 U, V, W, I, X, C 
SCHINZEL-GIEDION MIDFACE 
RETRACTION SYNDROME 
SETBP1 Mendelian autosomal dominant 5 (P) unspecific moderate ID 
SHANK2 Mendelian autosomal dominant 6 P AUTISM, SUSCEPTIBILITY TO 
SHANK3 Mendelian autosomal dominant 6 P 
CHROMOSOME 22q13.3 DELETION 
SYNDROME 
SHH Mendelian autosomal dominant 4 L, Uc, C HOLOPROSENCEPHALY  
SHH Mendelian autosomal dominant 4 L SCHIZENCEPHALY 
SHOC2 Mendelian autosomal dominant 4 A, S, V, (Q) 
NOONAN SYNDROME-LIKE DISORDER 
WITH LOOSE ANAGEN HAIR 
SHROOM4 Mendelian X-linked recessive 2 A, U 
STOCCO DOS SANTOS X-LINKED 
MENTAL RETARDATION SYNDROME 
SIL1 Mendelian autosomal recessive 5 H, L, Q, T, A, Ub MARINESCO-SJOGREN SYNDROME 
SIX3 Mendelian autosomal dominant 4 L, C HOLOPROSENCEPHALY  
SIX3 Mendelian autosomal dominant 4 L, C SCHIZENCEPHALY 
SLC12A6 Mendelian autosomal recessive 4 L, G, H, Ub, P 
AGENESIS OF THE CORPUS 
CALLOSUM WITH PERIPHERAL 
NEUROPATHY 
SLC16A2 Mendelian X-linked not sure 2 
K, H, Q, P, E, L, 
(A), (B) 
ALLAN-HERNDON-DUDLEY 
SYNDROME 
SLC17A5 Mendelian autosomal recessive 8b M, H, G, E, C, L 
INFANTILE SIALIC ACID STORAGE 
DISORDER 
SLC17A5 Mendelian autosomal recessive 8b M, H, G, E, L SIALURIA 
SLC25A15 Mendelian autosomal recessive 5 M, H, E 
HYPERORNITHINEMIA-
HYPERAMMONEMIA-
HOMOCITRULLINURIA SYNDROME 
SLC25A22 Mendelian autosomal recessive 2 E, B, H, L 
EPILEPTIC ENCEPHALOPATHY, 
EARLY INFANTILE 
SLC2A1 Mendelian autosomal dominant 5 M, E, H GLUT1 DEFICIENCY SYNDROME 
SLC2A1 Mendelian autosomal dominant 5 M, E, H, B GLUT1 DEFICIENCY SYNDROME 
SLC2A1 Mendelian autosomal dominant 5 M, E, H DYSTONIA  
SLC35C1 Mendelian autosomal recessive 2 M, A, B, H, J 
CONGENITAL DISORDER OF 
GLYCOSYLATION 
SLC4A4 Mendelian autosomal recessive 5 A, T, W 
RENAL TUBULAR ACIDOSIS, 
PROXIMAL, WITH OCULAR 
ABNORMALITIES AND MENTAL 
RETARDATION 
SLC6A8 Mendelian X-linked not sure 5 M, H, E, P CREATINE DEFICIENCY SYNDROME 
SMC1A Mendelian X-linked not sure 1 A, B, V, E, X CORNELIA DE LANGE SYNDROME  
SMC3 Mendelian autosomal dominant 5 ORNELIA DE LANGE SYNDROME  
SMPD1 Mendelian autosomal recessive 8b M, C, G, H, J, T NIEMANN-PICK DISEASE 
SMPD1 Mendelian autosomal recessive 5 M, A, C, H, J, T NIEMANN-PICK DISEASE 
SMS Mendelian X-linked recessive 5 Ub, H, E 
MENTAL RETARDATION, X-LINKED, 
SYNDROMIC 
SNAP29 Mendelian autosomal recessive 2 B, H, L, S 
CEREBRAL DYSGENESIS, 
NEUROPATHY, ICHTHYOSIS, AND 
PALMOPLANTAR KERATODERMA 
SYNDROME 
SOS1 Mendelian autosomal dominant 7 V, T NOONAN SYNDROME 
SOX10 Mendelian autosomal dominant 5 S, X, (L), H WAARDENBURG SYNDROME 
SOX10 Mendelian autosomal dominant 5 S, X, L, H 
PERIPHERAL DEMYELINATING 
NEUROPATHY, CENTRAL 
DYSMYELINATION, WAARDENBURG 
SYNDROME, AND HIRSCHSPRUNG 
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DISEASE 
SOX2 Mendelian autosomal dominant 4 L, T, A, W, X MICROPHTHALMIA, SYNDROMIC 
SOX3 Mendelian X-linked not sure 5 A, K 
MENTAL RETARDATION, X-LINKED, 
WITH PANHYPOPITUITARISM 
SPRED1 Mendelian autosomal dominant 8a S, (P) LEGIUS SYNDROME 
SRPX2 Mendelian X-linked not sure 5 E, H 
ROLANDIC EPILEPSY, MENTAL 
RETARDATION, AND SPEECH 
DYSPRAXIA, X-LINKED 
ST3GAL3 Mendelian autosomal recessive 6  
MENTAL RETARDATION, AUTOSOMAL 
RECESSIVE 
ST3GAL3 Mendelian autosomal recessive 2 E, H 
EPILEPTIC ENCEPHALOPATHY, 
EARLY INFANTILE 
STIL Mendelian autosomal recessive 5 B 
MICROCEPHALY, PRIMARY, 
AUTOSOMAL RECESSIVE 
STRA6 Mendelian autosomal recessive 1 C, T, V, X MICROPHTHALMIA, SYNDROMIC 
SUOX Mendelian autosomal recessive 5 T, H, M, (G), (C) SULFOCYSTEINURIA 
SURF1 Mendelian autosomal recessive 8b M, L, E, H, G, Q LEIGH SYNDROME 
SYN1 Mendelian X-linked recessive 8a E, P 
EPILEPSY, X-LINKED, WITH VARIABLE 
LEARNING DISABILITIES AND 
BEHAVIOR DISORDERS 
SYNGAP1 Mendelian autosomal dominant 3 E 
MENTAL RETARDATION, AUTOSOMAL 
DOMINANT  
SYP Mendelian X-linked not sure 6 (E ) MENTAL RETARDATION, X-LINKED 
TAT Mendelian autosomal recessive 8a M, S, T TYROSINEMIA 
TBCE Mendelian autosomal recessive 5 A, K, U 
HYPOPARATHYROIDISM-
RETARDATION-DYSMORPHISM 
SYNDROME 
TBCE Mendelian autosomal recessive 5 A, K, U, J KENNY-CAFFEY SYNDROME 
TCF4 Mendelian autosomal dominant 2 E, O, T, B PITT-HOPKINS SYNDROME 
TGFBR1 Mendelian autosomal dominant 7 Ub, Uc, (S) LOEYS-DIETZ SYNDROME 
TGFBR2 Mendelian autosomal dominant 7 Ub, Uc, (S) LOEYS-DIETZ SYNDROME 
TGIF1 Mendelian autosomal dominant 4 L, Uc, C, X HOLOPROSENCEPHALY 
THRB Mendelian autosomal dominant 8a K, (A) 
THYROID HORMONE RESISTANCE, 
GENERALIZED, AUTOSOMAL 
DOMINANT 
TIMM8A Mendelian X-linked recessive 8b H, G, T, P MOHR-TRANEBJAERG SYNDROME 
TMEM67 Mendelian autosomal recessive 4 H, L, W, T JOUBERT SYNDROME  
TMEM67 Mendelian autosomal recessive 4 H, L, W, T COACH SYNDROME 
TPI1 Mendelian autosomal recessive 8a M, R, H, C "TPI deficiency" 
TREX1 Mendelian autosomal recessive 2 
H, E, L, S, G, C, 
B AICARDI-GOUTIERES SYNDROME 
TRIM32 Mendelian autosomal recessive 4 N, T, Ua, W, K, P Bardet-Biedl syndrome 
TSC1 Mendelian autosomal dominant 5 E, I, L, S, W TUBEROUS SCLEROSIS  
TSC1 Mendelian autosomal dominant 5 E, L 
FOCAL CORTICAL DYSPLASIA OF 
TAYLOR 
TSC2 Mendelian autosomal dominant 5 E, I, L, S, W TUBEROUS SCLEROSIS 
TSPAN7 Mendelian X-linked recessive 6 MENTAL RETARDATION, X-LINKED  
TTC8 Mendelian autosomal recessive 4 N, T, Ua, W, K, P Bardet-Biedl syndrome 
TUBA1A Mendelian autosomal dominant 1 L, B, H, E LISSENCEPHALY  
TUBB2B Mendelian autosomal dominant 1 L, E, H POLYMICROGYRIA 
TUSC3 Mendelian autosomal recessive 3 
MENTAL RETARDATION, AUTOSOMAL 
RECESSIVE 
UBE2A Mendelian X-linked recessive 2 F, W, E 
MENTAL RETARDATION, X-LINKED, 
SYNDROMIC 
UBE3A Mendelian autosomal dominant 2 E, B, H, P ANGELMAN SYNDROME 
UBR1 Mendelian autosomal recessive 4 
X, K, S, (W), (A), 
(B) JOHANSON-BLIZZARD SYNDROME 
UPB1 Mendelian autosomal recessive 5 M, H 
BETA-UREIDOPROPIONASE 
DEFICIENCY 
UPF3B Mendelian X-linked recessive 5 P, Q 
MENTAL RETARDATION, X-LINKED, 
SYNDROMIC  
VLDLR Mendelian autosomal recessive 2 E, H, L, (T), (A) 
CEREBELLAR ATAXIA, MENTAL 
RETARDATION, AND 
DYSEQUILIBRIUM SYNDROME  
VPS13B Mendelian autosomal recessive 2 B, N, T, I, R, A, K COHEN SYNDROME 
XPA Mendelian autosomal recessive 8a, 8b 
B, H, G, S, T, I, 
(C) XERODERMA PIGMENTOSUM 
ZC3H14 Mendelian autosomal recessive 6  non syndromic autosomal recessive ID 
ZDHHC9 Mendelian X-linked recessive 2 (U) 
MENTAL RETARDATION, X-LINKED, 
SYNDROMIC 
ZEB2 Mendelian autosomal dominant 1 
B, E, V, W, X, A, 
L MOWAT-WILSON SYNDROME 
ZFYVE26 Mendelian autosomal recessive 5 H, G, (L) SPASTIC PARAPLEGIA, AUTOSOMAL 
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RECESSIVE 
ZIC2 Mendelian autosomal dominant 4 L, B HOLOPROSENCEPHALY  
ZNF41 Mendelian X-linked not sure 6 P MENTAL RETARDATION, X-LINKED  
ZNF674 Mendelian X-linked recessive 3 MENTAL RETARDATION, X-LINKED 
ZNF711 Mendelian X-linked not sure 6 MENTAL RETARDATION, X-LINKED  
ZNF81 Mendelian X-linked not sure 6 (A) MENTAL RETARDATION, X-LINKED  
List of 388 ID genes (status 2010) that was used for the enrichment analyses. This short 
version of the original catalog contains data on inheritance mode, associated ID-disorders, 
main class and additional phenotypes. 
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In this thesis haploinsufficiency of TCF4 as the underlying cause for Pitt-Hopkins syndrome 
was identified (chapter 2). Subsequently, recessive defects in NRXN1 and CNTNAP2 were 
detected in patients with a similar clinical phenotype (chapter 3). These findings and the 
associated molecular and functional studies helped to delineate the clinical phenotype on the 
one hand (chapters 2-5) and to provide inside into the (interconnected) molecular 
mechanisms on the other hand (chapters 2 and 4). Furthermore, with the comprehensive 
catalogue of all currently known ID genes and their associated phenotypes (chapter 6), a 
resource for future systematic studies in this field was generated, and first global insights 
were obtained. 
 
7.1. From phenotype to genotype and back 
For decades genetic diagnosis and assignment to particular syndromes was based on 
evaluation and description of the clinical phenotype. Only when the underlying genetic 
defects were identified, these clinical groups could be confirmed or not. The increasing 
molecular possibilities resulted in a fusion of phenotypic analysis with molecular biology and 
a new lumping and splitting strategy, taking full advantage of  both disciplines.330 This study 
is an example how close phenotypic and molecular findings can interact and complement 
each other.  
Pitt-Hopkins syndrome (PTHS) was initially described in 1978 in two unrelated 
patients with a supposedly distinct phenotype of severe ID, hyperbreathing and recognizable 
facial gestalt with a beaked nose.227 However, in the following nearly 30 years only a few 
single case reports described patients with a possibly identical disorder.228-231 Only after the 
identification of TCF4 haploinsufficiency by us and others as the underlying cause of Pitt-
Hopkins syndrome (chapter 2),247,250 the number of clinically identified and subsequently 
molecularly confirmed patients increased rapidly (chapter 3).260,261,331-333 Now the diagnosis 
could be confirmed or disproved in some of the previously described patients. This helped to 
delineate the clinical hallmarks of a distinct and recognizable clinical phenotype that 
apparently had been under-recognized for decades (chapter 2). The improved phenotypic 
delineation and the opportunity to perform confirmative molecular testing extensively raised 
the awareness for this syndrome amongst clinical geneticists and established it as a 
differential diagnosis in the field of severe ID together with Angelman- and Rett syndromes 
(chapter 3). To facilitate diagnosis even for less experienced clinicians, several groups 
recently attempted to establish clinical scores for Pitt-Hopkins syndrome.331,333 
For a long time, gene identification in ID was mainly limited to familial cases, allowing 
linkage analysis or homozygosity mapping.39,55,57 Identifying genes for sporadic ID disorders 
mostly relied on the random detection of chromosomal aberrations.68,150 With the 
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development of molecular karyotyping by arrayCGH or SNP array a new tool to identify more 
and smaller of such chromosomal aberrations became available. By detecting small 
deletions in one patient and by subsequently identifying mutations in one of the deleted 
genes in other patients with the same disorder but without chromosomal anomalies, the 
underlying cause for several disorders could be identified.36,73 Also in this study, molecular 
karyotyping confirmed its usefulness in disease gene identification by contributing to the 
identification of three underlying genetic causes for ID. De novo defects in TCF4 were 
identified in Pitt-Hopkins syndrome, and recessive defects in NRXN1 or CNTNAP2 were 
identified in patients with clinically overlapping disorders and no history of parental 
consanguinity (chapter 2 and 4). However, it also demonstrated, how valuable accurate 
clinical characterization is, as only identification of a de novo mutation in a second patient 
proved the deletion of TCF4 being the specific underlying cause in the first patient (chapter 
2). Both patients had previously been described with a clinical diagnosis of Pitt-Hopkins 
syndrome.229 In contrast, screening the gene in a larger group of patients with idiopathic ID 
but only mild phenotypic overlap did not lead to the identification of a second confirmatory 
patient.250  
The approach to systematically perform molecular karyotyping in a larger group of 
clinically homogenous patients - all referred with suspected Pitt-Hopkins syndrome but 
without TCF4 defect - lead to the identification of homozygous or compound heterozygous 
defects in CNTNAP2 in a pair of siblings and a sporadic patient and in NRXN1 in a sporadic 
patient. Their phenotype has been described as Pitt-Hopkins-like ID (chapter 4). 
Interestingly, a homozygous stop mutation in CNTNAP2 had previously been reported in 
patients with a cortical dysplasia focal epilepsy syndrome (CDFE), characterized by early 
onset of epilepsy and severe ID, following an initially normal development and subsequent 
regression.184 The patients with recessive defects in CNTNAP2 in our study also had early 
onset of epilepsy and normal or only mildly delayed early motor development. However, 
speech development was lacking from the beginning (chapter 4). While our patients had 
initially been diagnosed with Pitt-Hopkins syndrome due to severe ID with accompanying 
epilepsy, the patients published by Strauss et al.184 had been diagnosed with an epilepsy 
syndrome. Common genotypes can therefore bring together phenotypes that were previously 
considered as distinct disorders, probably rather due to clinical bias than due to a reliable 
genotype-phenotype correlation. 
Of note, all patients with recessive defects in CNTNAP2 showed severe speech 
impairment. Interestingly, a molecular link between CNTNAP2 and FOXP2, a member of the 
forkhead transcription factor family had previously been shown.281 Mutations in FOXP2 are 
known to cause speech and language disorders.334,335 
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Identification of further patients with Pitt-Hopkins syndrome did not only result in a better 
delineation of the phenotype but also of the genotype (chapter 2 and 3). The spectrum of 
aberrations in TCF4 comprises deletions, truncating mutations, and missense mutations 
which are located in exons coding for the bHLH domain of TCF4. The fact that all of these 
defects resulted in a similar and recognizable phenotype indicated haploinsufficiency as the 
underlying mechanism. With an in vitro transcriptional reporter assay after co-transfection of 
wild type or mutant TCF4 with an ASCL1 expression construct it could be shown that the 
missense mutations in the DNA- and protein-binding bHLH domain of TCF4 resulted in loss 
of the transactivating capacities, thus validating TCF4 haploinsufficiency as the underlying 
mechanism (chapter 2).  
ASCL1 is a tissue specific HLH transcription factor, knowing to interact with TCF4236 
and being part of the RET-signaling pathway. This additionally includes the PHOX2, RET 
and TH genes that are responsible for the development of transient or permanent 
noradrenergic derivatives.237 Mutations in ASCL1 and PHOX2 can cause the congenital 
central hypoventilation syndrome (CCHS)237,336 and mutations in RET are implicated in 
Hirschsprung disease.337,338 Therefore, interaction of TCF4 with ASCL1 and the reduced 
transactivation capacities upon TCF4 mutations might explain some of the PTHS specific 
phenotypic aspects such as the breathing anomalies and severe constipation. The findings 
from the cell-based luciferase assay were confirmed later by a similar experiment in a 
neuronal cell line.260 
Two recent studies investigated the consequences of different TCF4 missense 
mutations in various in vitro assays, finding evidence for a range of effects from hypomorphic 
to dominant-negative, thus contributing to the understanding of clinical variability in 
PTHS.316,339 However, these effects are based on single assays, thus possibly explaining 
some of the clinical variability but not contradicting TCF4 haploinsufficiency as the general 
underlying mechanism. 
 
7.2. From human to fly and back 
During the screening of Pitt-Hopkins syndrome-like patients without TCF4 mutation, 
recessive defects in CNTNAP2 in a pair of siblings and an isolated patient as well as 
recessive defects in NRXN1 in an isolated patient were detected (chapter 4). This was quite 
exciting as NRXN1 and CNTNAP2 belong to the same superfamily of neurexins, though no 
common molecular functions were known so far (see below). A potential common molecular 
basis and maybe even a link to TCF4 could therefore provide an explanation for the similar 
phenotype in the patients. However, neither NRXN1 nor CNTNAP2 is expressed in 
appreciable levels in blood, and other tissues are difficult to obtain from living patients. 
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Therefore Drosophila melanogaster was utilized as a model organism for further functional 
studies as all three genes do have orthologs in the fly: daughterless (TCF4), Nrx-I (NRXN1), 
and Nrx-IV (CNTNP2). 
Our first straightforward hypothesis was that TCF4 as a transcription factor could 
regulate the expression levels of NRXN1 and/or CNTNAP2. Ubiquitous knockdown of the 
TCF4 ortholog daughterless in the fly did not reveal conclusive data on altered expression 
levels of Nrx-I or Nrx-IV, the NRXN1 and CNTNAP2 orthologs, respectively, in the used 
system (chapter 4). However, recently another group reported a possible regulation of 
NRXN1 and CNTNAP2 through TCF4 in terms of a possible transactivation effect in cell 
system based promoter studies.316  
NRXN1/Nrx-I has been known to be one of the key synapse organizing molecules by 
forming bridges over the synaptic cleft with its postsynaptic binding partners, the 
neuroligins.287 Vertebrate CNTNAP2, also termed CASPR2 has been mainly known for its 
role in regulating neuron-glia contact and for colocalizing with K+- channels in the 
juxtaparanodal areas of Ranvier nodes in myelinated axons of both the central and 
peripheral nervous system.294,295 When this study was initiated, fly Nrx-IV was reported to be 
almost exclusively expressed in glia-cells and to regulate glia-glia contact.293,296 
The executed Drosophila experiments in this study brought several new insights 
(chapter 4) regarding NRXN1/Nrx-I and CNTNAP2/Nrx-IV and their possible interaction. 
 1) Nrx-IV was shown to play a role in neurons as neuronal knockdown lead to 
embryonic lethality. Previously, Nrx-IV was only considered to be expressed in glia cells in 
the fly.296 In parallel, two groups reported on neuronal Nrx-IV isoforms,264,268 thus supporting 
our conclusion that Nrx-IV plays a crucial role in neurons. 
2) Nrx-IV is present at synapses. Previously, only a report on detection of Caspr2 in 
fractionated rat synaptic plasma had pointed to a possible synaptic presence.266 
3) Nrx-I and Nrx-IV converge on synaptic active zone protein bruchpilot (brp) as a 
common target. Adding to the observation of decreased brp levels in Nrx-I mutants,270 our 
work showed that both Nrx-I or Nrx-IV levels determine brp levels bidirectionally and that 
either Nrx-I or Nrx-IV overexpression induces identical changes in synaptic morphology.  
Bruchpilot is a peripheral membrane protein being located at the presynaptic active 
zones, the location of neurotransmitter release into the synaptic cleft. Through its PDZ 
domain binding site it is involved in a large complex with other active zone proteins.298 Of 
note, also Nrx-I and Nrx-IV contain C-terminal PDZ-domain binding sites, therefore raising 
the possibilty that all three proteins are assembled into one synaptic complex or 
macromolecular network. Brp shows high sequence and functional homology to the 
vertebrate family of ELKS/CAST proteins,298 corresponding to the human synaptic proteins 
ERC1 and ERC2. 
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Summarizing, these findings in Drosophila helped to gain more insight into function of 
Nrx-I and Nrx-IV in the nervous system and particularly implicated Nrx-IV in synapse biology. 
It also helped to establish a functional link between Nrx-I and Nrx-IV as a possible 
explanation for the similar human phenotypes. Furthermore, with brp orthologs ERC1 and 
ERC2 it produced promising candidate genes to go back to humans and screen these genes 
for mutations in patients with a PTHS-like phenotype. 
Therefore, in this study Drosophila proved to be a valuable model organism for 
functional testing in ID. However, it is important to know what to expect from an animal model 
like Drosophila. It is no equivalent to human patients, but the same is applicable for all other 
animal models or in vitro assays. It cannot provide final evidence for the pathogenicity of 
particular mutations, but it can provide functional support for the role of particular genes in 
cognitive and behavioral function and dysfunction. As successfully demonstrated in this 
thesis, it can help to establish molecular networks. This is in particularly interesting as the 
theme of overlapping phenotypes being caused by genes that are linked to each other in 
molecular networks178 gets more and more evident and attractive. 
Drosophila is not the answer to all our questions but it is an extremely suitable and 
valuable tool to efficiently add pieces to the puzzle that has been keeping and will keep 
scientists with an interest in ID - geneticists, and neurobiologists - busy for a long time. 
 
7.3. From mono- to oligogenic and back? 
A common synaptic link between NRXN1 and CNTNAP2 and possibly TCF4 might result in 
the implication of all three encoding genes in disorders across diagnostic boundaries, severe 
intellectual disability at one end of the spectrum184,247,248,285,308,340,341 and neuropsychiatric 
disorders with no or only mild cognitive impairment at the other end.266,272-278,280-283,299-307,342,343  
Biallelic defects in NRXN1 or CNTNAP2 were observed in patients with severe 
cognitive disorders (chapter 4).184,285,340 Heterozygous copy number variants (CNVs) and 
single nucleotide changes in either gene at that time had been found in patients with 
neuropsychiatric disorders and no or only mild cognitive impairment.266,272-283,286,299-307 The 
apparent influence of gene-dosage on the phenotypic severity has been also perfectly 
mirrored in a published family. The index patient harboring a compound heterozygous 
deletion and splice site mutation in NRXN1 has severe ID with epilepsy and little social 
interaction, while some of his family members carrying only one of the NRXN1 aberrations 
have schizophrenia, psychotic disorders or sub-diagnostic autistic traits.344 
The observation of heterozygous variants as risk factors for low penetrant 
neuropsychiatric disorders and of biallelic defects in the same gene as causative for fully 
penetrant severe ID has not been reported for other genes so far. Only recently, a 
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homozygous mutation in the ANK3 gene was reported in a consanguineous family with 
moderate ID and severe behavioral anomalies.345 De novo, heterozygous mutations in ANK3 
had previously been implicated in ASD, and polymorphisms had been implicated as 
susceptibility factors for psychiatric disorders. However, in this study a correlation between 
severity and degree of inactivation due to the mutation was discussed rather than dosage 
sensitivity.345 
We continued to screen NRXN1 and CNTNAP2 in a larger cohort of patients with Pitt-
Hopkins like syndrome with severe ID and accepted samples from external patients with 
severe ID and a heterozygous CNV in NRXN1 or CNTNAP2 for mutational screening of the 
second allele. In this group we expected to identify more patients with biallelic defects in 
either gene and therefore to further delineate the associated clinical phenotype (chapter 5). 
However, surprisingly, in none of seven patients with severe ID and a heterozygous 
CNTNAP2 defect and in none of four patients with severe ID and a heterozygous NRXN1 
defect we could identify a mutation on the respective second allele. In most of the patients, 
the heterozygous defect was inherited from a healthy parent, therefore a second defect on 
the other allele would have been expected in order to explain the severe phenotype. 
Prompted by the molecular link between NRXN1 and CNTNAP2/CASPR2 fly orthologs 
(chapter 4) and considering a possible digenic pathomechanism, screening of the respective 
other gene was performed in these patients but without resulting in the detection of 
mutations.  
Of course the second mutation in either gene might have remained undetected due to 
localization in a non-coding regulatory element or in a non-tested alternative isoform, or the 
finding of the NRXN1 or CNTNAP2 defect might have been just coincidence without 
pathogenic relevance to the severe phenotype of these patients. This might be true for the 
patient with a splice site variant in CNTNAP2 and additionally a clearly pathogenic mutation 
in MEF2C.346 However, the large number of such severely affected patients, further raised by 
recent reports at least for NRXN1,347-349 might indicate the presence of a second and maybe 
third contributing factor somewhere else in the genome in terms of a digenic or oligogenic 
cause.  
While mild forms of ID are assumed to represent the lower end of normal IQ 
distribution and to result from the interaction of various genetic and other factors, for severe 
ID mainly a single genetic cause is assumed.2 This is confirmed by recent exome sequencing 
studies identifying de novo mutations in a large proportion of patients with unspecific severe 
ID.34,35,42 For a small subset of developmental disorders that are frequently associated with 
mild cognitive impairment, such as autism or dyslexia, polygenic effects are discussed.314,350 
However, in contrast to the multifactorial “common disease, common variant” model, 
suggesting many genetic and non-genetic factors (epigenetic and environmental) with small 
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effect in individual patients,351 the picture now rather points to single events of large effect. 
Recent studies on common neurodevelopmental disorders like autism spectrum 
disorders47,116,350,352,353 or schizophrenia354,355 revealed a large number of de novo mutations. 
One study on autism spectrum disorders estimated a 5- to 20-fold increased risk by 
spontaneous coding mutations in any of a large number of genes.350 The concurrent finding 
of de novo defects in SHANK2 with other inherited CNVs known to be risk factors for 
neuropsychiatric disorders would be in line with a multiple hit model for autism spectrum 
disorders.46 This is also supported by the finding of a de novo frameshift mutation in FOXP1 
in combination with an inherited mutation in CNTNAP2 in a patient with severe language 
delay, moderate ID and regression.352 Before, FOXP1 defects were found in patients with 
mild to moderate ID and language defects.356,357 Therefore, a combination of FOXP1 
haploinsufficiency with increased CNTNAP2 expression might contribute to the more severe 
phenotype in this patient.352 Interestingly, for FOXP2, another member of the forkhead 
transcription factor family and implicated in language disorders, a molecular link to 
CNTNAP2 had previously been shown.281 
While monogenic or single chromosomal defects might still be responsible for the 
majority of severe ID, there are already a few examples for disorders with digenic inheritance 
or a two hit model. For some cases of Bardet-Biedl syndrome, a di- or even trigenic 
inheritance has been reported.48 Regarding a recurrent 16p12.1 microdeletion, second hits 
were shown to be necessary to evoke the full, severe phenotype.45  
Only recently, two patients with heterozygous NRXN1 deletions and additionally a 
NRXN3 or a 16p11.2 deletion, respectively, were reported.349 As defects in NRXN3 as well 
the common 16p11.2 deletion have already been implicated in autism spectrum 
disorders,342,358,359 these findings support the presence and absence of additional genetic 
lesions as contributory to the variable expressivity and incomplete penetrance in carriers of a 
NRXN1 heterozygous exonic deletion.349 By comparing the de novo rate of mutations and the 
burden of “second hits” in individuals with NRXN1 deletions and carriers of known recurrent 
“susceptibility CNVs” the authors place NRXN1 exonic deletions somewhere in the spectrum 
between 15q13.3 and 16p12.1 deletions.349 In some of our patients with heterozygous 
CNTNAP2 or NRXN1 aberrations (chapter 5) additional unknown CNVs were observed by 
molecular karyotyping. However, an interpretation regarding a possible contributory effect of 
these CNVs is currently not yet possible.  
The advances in NGS during the next years will hopefully help to understand how 
many cases of ID can indeed be explained by monogenic causes and how many will be due 
to a combination of multiple de novo and/or inherited defects. 
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7.4. From single genes to functional modules and back 
Intellectual disability is clinically and genetically highly heterogeneous. The underlying genes 
are only incompletely identified so far, and even for the majority of known ID genes their 
individual function as well as their role in larger networks and pathways is only poorly 
understood.  
Linking ID genes in common molecular or functional pathways indicates a general 
regulatory role of these networks in cognitive function and dysfunction2,318‐321 and supports the 
idea that similar phenotypes are caused by defects in functionally related genes.178 By linking 
CNTNAP2 and NRXN1 via a common synaptic target, this thesis (chapter 4) contributed to 
this theme. To cope with the arising challenges resulting from NGS technologies and to 
further identify and delineate the complex networks of cognitive function and dysfunction, a 
systematic, large-scale and collaborative interdisciplinary approach is required.  
Though several attempts were undertaken to create catalogs of ID genes, none of 
them was either highly reliable or complete.96,257,325 We therefore established such an ID 
gene collection and introduced it into a database that is supplemented with many other 
datasets (chapter 6). We furthermore established a classification system of ID genes, based 
on the clinical manifestation and severity of the associated disorders. This resulted in nine 
individual classes that could be summarized in six overlapping higher-order groups (SWSM: 
syndromic with structural malformations, SWOSM, syndromic without structural 
malformations, NS: non-syndromic; CS: classic severe, CM: classic mild to moderate or 
variable, NC: non-classic). First analyses showed several interesting enrichment and 
expression patterns (chapter 6):  
1) Genes from the postsynaptic density of the human neocortex322 are significantly 
enriched in the non-syndromic group (NS). This goes in hand with significantly increased 
expression levels for NS genes in fetal brain and several brain regions. Enrichment of X-
linked inheritance in the NS group might indicate a high proportion of ID genes with synaptic 
function on the X-chromosome, as was also discussed previously.329  
2) The highest enrichment of haploinsufficiency (HI) genes is found in the SWSM 
group. This goes in hand with significant enrichment of autosomal dominant inheritance (in 
terms of de novo mutations) in the SWSM group. These observations indicate the role of HI 
genes in disorders that affect the development of the brain and many other organs and 
systems.  
3) Autosomal-recessive inheritance is significantly enriched in the SWOSM group 
while it is significantly depleted in the SWSM and the NS groups. This indicates that 
mutations in autosomal recessive genes cause syndromic ID but without structural 
malformations which might be true for most of the metabolic genes.  
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4) CS genes show increased expression in various brain regions, while CM genes 
show no significant expression pattern, and NC genes shows a heterogeneous pattern for 
organs, brain tissues and blood and immune cells. Thus, the high and specific expression of 
CS genes in brain is correlating with the severity of ID.  
These analyses are only our first steps towards a comprehensive systems biology-
like approach. They already demonstrated that both molecular as well as phenotypic 
“grouping” can be used to detect patterns. These might be helpful both for ID disease gene 
prediction as well as for prediction of protein function and modularity. 
 
7.5. Back to the future 
The growing impact and progression in NGS technology and data interpretation will rapidly 
increase the identification of new disease genes and of disease causing mutations in known 
genes in the next few years. This might reduce the importance of good clinical 
characterization prior to molecular testing, but it will raise the need for good clinical 
phenotyping afterwards. As NGS will result in the detection of various mutations in various 
genes, a good interaction between clinical and molecular findings will be the prerequisite to 
accurately delineate genotype-phenotype correlations.   
Only recently, approaches like multiplex targeting sequences (MIB) were developed 
for cost-efficient resequencing of candidate genes in large cohorts of patients with ID or 
epilepsy.360,361 Nevertheless, due to the extreme heterogeneity in ID, it has to be assumed 
that not for all patients or families with a mutation in a convincing candidate gene 
confirmation for its pathogenicity can be obtained by detecting other patients or families with 
mutations in the same gene easily. This will be particularly relevant for missense variants, for 
which a deleterious effect is less obvious than for truncating mutations. For some cases, 
functional analyses will be and remain necessary to support a pathogenic relevance of 
particular genetic defects. 
It can also be safely assumed that not all ID disorders will be due to single defects in 
a single gene, but that there will be certain proportion of oligogenic or even multifactorial 
causes of ID, particularly in the milder spectrum. Large clinical variability in some monogenic 
ID disorders - sometimes even resulting from an identical mutation - is assumed to result 
from additional, modifying genetic, epigenetic and environmental factors. To delineate at 
least the former will require large bioinformatics and statistical approaches on a massive 
amount of data. It will also require a thorough functional characterization of genes and 
variants in order to map them to common pathways and complexes and to explain their 
influence on each other. 
                                                                                                                     General Discussion  
149 
 
Understanding the molecular and functional basis of ID and to connect single genes 
and proteins in functional networks and pathways is the prerequisite to get back to clinics 
and establish therapeutic approaches. This is one of the big challenges for the years and 
decades to come.  
Taken together, bringing together clinics, molecular diagnostics, basic research, 
bioinformatics and pharmacology for the ultimate goal of unraveling and treating ID is both a 
challenge and a promise for the future of human genetics and medical genomics. 
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Summary 
Intellectual disability (ID) affects 2-3% of the population and therefore has a major social and 
economic impact on both families and society. The genetic causes for ID are very 
heterogeneous and so far, the underlying cause can only be identified in about half of the 
affected individuals. During the last years the development of first molecular karyotyping in 
order to detect small chromosomal aberrations and then Next-Generation-Sequencing to 
detect sequence variants provided potent new technologies to identify known and novel 
genetic causes of ID. Diagnosing the underlying genetic defect in a particular family helps to 
provide proper counseling regarding prognosis, potential complications, comorbidities, and 
recurrence risks on one hand. On the other hand, identification of novel genes and 
connecting them in functional networks provides the basis for the long-term development of 
therapeutic approaches. For this, a detailed understanding of the molecular and functional 
basis of ID is necessary as well as connecting single genes and proteins in functional 
networks and pathways. This requires a tight collaboration of different disciplines such as 
clinics, molecular diagnostics, basic research, and bioinformatics. 
The aim of this thesis was to contribute to the genetic, clinical and functional 
characterization of ID disorders, with a particular focus on Pitt-Hopkins (PTHS) and Pitt-
Hopkins-like syndromes. 
 
Chapter 1 provides an introduction on intellectual disability. It discusses the genetic 
and clinical heterogeneity, the underlying molecular defects, methods for disease gene 
identification, and functional testing with different approaches. 
Chapter 2 describes the detection of a TCF4 deletion by molecular karyotyping in a 
patient with Pitt-Hopkins syndrome. This disorder is characterized by severe ID, breathing 
anomalies and typical facial dysmorphism. Subsequent identification of mutations in this 
gene in further patients with a similar clinical phenotype identified TCF4 haploinsufficiency as 
the underlying cause for PTHS and contributed to the delineation of the distinct, but until then 
under-recognized, phenotype. Impaired transcriptional interaction with ASCL1 from the 
ASCL1-PHOX2B-Ret pathway upon TCF4 mutations was demonstrated with a transcriptional 
reporter assay and might explain some of the characteristic PTHS symptoms. 
In chapter 3, a larger number of patients with PTHS and TCF4 mutations were 
collected in order to further delineate the clinical and genetic characteristics of this syndrome. 
This helped to increase the awareness of clinicians towards this disorder and to establish it 
as an important differential diagnosis to Rett- and Angelman syndromes, widely known and 
intensely studied severe ID disorders. 
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As only in a subset of patients referred with suspected PTHS mutations in TCF4 could be 
identified, chapter 4 describes the continuing screening for small aberrations with molecular 
karyotyping in the remaining patients. This revealed a homozygous deletion within CNTNAP2 
in a pair of siblings, and a further sporadic patient with a compound heterozygous deletion 
and mutation in this gene. Additionally, a compound heterozygous deletion and mutation in 
the NRXN1 gene was identified in a sporadic patient with a similar phenotype. Drosophila 
melanogaster as a model organism allowed to demonstrate a possible interaction between 
Nrx-IV (CNTNAP2) and Nrx-I (NRXN1) by converging on a common target, the presynaptic 
protein bruchpilot. 
Chapter 5 describes how heterozygous defects in CTNAP2 and NRXN1 but no 
second mutation were found in patients with severe ID and one of their healthy parents, 
respectively. This expanded the clinical spectrum associated with heterozygous defects in 
any of the two genes to the severe end by including severe ID. This observation suggested 
the existence of additionally contributing genetic factors, thus pointing to a possible di- or 
oligogenic cause for the severe ID in these patients 
The work described in chapter 6 aims at a more global understanding of the 
molecular pathology of ID disorders by establishing a systematic inventory of all ID-related 
genes and their associated phenotypes. By creating a clinical classification system based on 
the manifestation of ID as well as on accompanying phenotypic features this study attempted 
to establish correlations between clinical and molecular/functional aspects. 
A general discussion of the findings in this thesis and their implications in the broader 
field of ID genetics as well as future perspectives are provided in chapter 7. Understanding 
the molecular and functional basis of ID by connecting single genes and proteins in 
functional networks and pathways is the prerequisite to begin to unravel and treat ID in the 
coming years. 
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List of abbreviations 
AD autosomal dominant 
AR 
ASD 
ATP 
autosomal recessive 
autism spectrum disorder 
Adenosine-5'-triphosphate 
BAC bacterial artificial chromosome 
Bp 
ca. 
ChIP 
base pair 
circa 
chromatin immunoprecipitation 
arrayCGH microarray-based comparative genomic hybridization 
CM classic mild to severe or variable  
CNV copy number variant 
Ct threshold cycles 
CS classic severe 
dbSNP database of single nucleotide polymorphisms 
DECIPHER database of chromosomal imbalance and phenotype in humans 
using ensemble resources 
DNA deoxyribonucleic acid 
EBV Epstein-Barr virus 
EEG electroencephalogram 
e.g. 
etc. 
for example 
et cetera 
FISH fluorescence in situ hybridisation 
GNF Genomics Institute of the Novartis Research Foundation 
HI haploinsufficiency 
hPSD post-synaptic density from human neocortex 
i.e. 
iPS cells 
that is 
induced pluripotent stem cells 
ID intellectual disability 
IQ Intelligence quotient 
kb kilobase (thousand base pairs) 
LD linkage disequilibrium 
LOD logarithm of odds 
Mb megabase (million base pairs) 
MLPA multiplex ligation dependent probe amplification 
MR mental retardation 
MRI magnetic resonance imaging 
mRNA messenger ribonucleic acid 
NC non-classic 
NCBI national center for biotechnology information 
NGS next generation sequencing 
NMD nonsense-mediated mRNA decay 
NMJ neuromuscular junction 
NS non-syndromic 
OFC occipitofrontal head circumference 
OMIM online mendelian inheritance in man database 
ORF open reading frame 
PCR polymerase chain reaction 
qPCR quantitative polymerase chain reaction 
RNA ribonucleic acid 
RNAi inducible RNA interference 
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RT-PCR real time polymerase chain reaction or reverse transcriptase 
polymerase chain reaction 
SD 
shRNA 
siRNA 
standard deviation 
short hairpin RNA 
short interference RNA 
SNP single nucleotide polymorphism 
SWSM syndromic with structural malformations 
SWOSM syndromic without structural malformations 
UAS upstream activating sequence 
UCSC University of California, Santa Cruz 
UTR untranslated region 
WT wild type 
  
 
